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METHODS OF INHIBITING ALU RNA AND 
THERAPEUTIC USES THEREOF 
RELATED APPLICATIONS 
This application is a divisional of U.S. patent application 
Ser. No. 13/701,450, now allowed, which is a 371 applica-
tion of International Patent Application No. PCT/US2011/ 
038753, filed Jun. 1, 2011, which claims priority from U.S. 
Provisional Application Ser. No. 61/396,747, filed on Jun. 1, 
2010; U.S. Provisional Application Ser. No. 61/432,110, 
filed Jan. 12, 2011; and U.S. Provisional Application Ser. 
No. 61/432,948, filed Jan. 14, 2011. The entire disclosures of 
these applications are incorporated herein by this reference. 
TECHNICAL FIELD 
The presently-disclosed subject matter relates to uses of 
DICER overexpression and the inhibition of Alu RNA. 
INTRODUCTION 
Geographic atrophy, an advanced form of age-related 
macular degeneration that causes blindness in millions of 
people worldwide and for which there is no approved 
treatment, results from death of retinal pigmented epithe-
lium (RPE) cells. As described herein the present inventors 
show that expression of DICER, an enzyme involved in 
microRNA (miRNA) biogenesis, is reduced in the RPE of 
human eyes with geographic atrophy, and that conditional 
ablation of Dicerl induces RPE degeneration in mice. Sur-
prisingly, ablation of seven other enzymes responsible for 
miRNA biogenesis or function does not induce such pathol-
ogy. Instead, knockdown of DICER1 leads to accumulation 
of Alu repeat RNA in human RPE cells and of B1 and B2 
(Alu-like elements) repeat RNAs in the RPE of mice. 
2 
SUMMARY 
The presently-disclosed subject matter meets some or all 
of the needs identified herein, as will become evident to 
those of ordinary skill in the art after a study of information 
provided in this document. 
This Summary describes several embodiments of the 
presently-disclosed subject matter, and in many cases lists 
variations and permutations of these embodiments. This 
10 Summary is merely exemplary of the numerous and varied 
embodiments. Mention of one or more representative 
features of a given embodiment is likewise exemplary. Such 
an embodiment can typically exist with or without the 
feature(s) mentioned; likewise, those features can be applied 
15 to other embodiments of the presently-disclosed subject 
matter, whether listed in this Summary or not. To avoid 
excessive repetition, this Summary does not list or suggest 
all possible combinations of such features. 
In some embodiments, the presently-disclosed subject 
20 matter includes a method of identifying an Alu RNA inhibi-
tor. The method can include providing a cell in culture 
wherein Alu RNA is upregulated; contacting the cell with a 
candidate compound; and determining whether the candi-
date compound results in a change in the Alu RNA. In some 
25 embodiments, the cell is an RPE cell. In some embodiments, 
the Alu RNA can be upregulated by decreasing native levels 
of DICER polypeptides in the cell. In some embodiments, 
the Alu RNA can be upregulated using heat shock stress. In 
some embodiments, the change in the Alu RNA is a mea-
30 surable decrease in Alu RNA, said change being an indica-
tion that the candidate compound is an Alu RNA inhibitor. 
In some embodiments, the presently-disclosed subject 
matter includes a method of treating geographic atrophy, 
including inhibiting Alu RNA associated with an RPE cell. 
35 In some embodiments, the presently-disclosed subject mat-
ter includes a method of protecting an RPE cell, including 
inhibiting Alu RNA associated with the RPE cell. In some 
embodiments, the RPE cell is of a subject having age-related 
Alu RNA is dramatically increased in the RPE of human 
eyes with geographic atrophy, and introduction of this 
40 
pathological RNA induces death of human RPE cells and 
RPE degeneration in mice. 
macular degeneration. 
In some embodiments, the presently-disclosed subject 
matter includes a method of treating a condition of interest, 
including inhibiting Alu RNA associated with a cell of a 
subject. In some embodiments, the condition of interest is 
selected from: geographic atrophy, dry age-related macular 
Antisense oligonucleotides targeting Alu/B1/B2 RNAs 
inhibit DICER1 depletion-induced RPE degeneration 
despite persistence of global miRNA downregulation. 
DICER1 degrades Alu RNA, and Alu RNA loses the ability 
to induce RPE degeneration in mice when digested by 
DICERl. These findings reveal a novel miRNA-indepen-
dent cell survival function for DICER1 via degradation of 
retrotransposon transcripts, introduce the concept that Alu 
RNA can directly cause human pathology, and identifY new 
molecular targets for treating a major cause of blindness. 
Age-related macular degeneration (AMD), which is as 
prevalent as cancer in industrialized countries, is a leading 
cause of blindness worldwide. In contrast to the neovascular 
form of AMD, for which many approved treatments exise, 
the far more common atrophic form of AMD remains poorly 
understood and without effective clinical intervention2 . 
Extensive atrophy of the retinal pigment epithelium (RPE) 
leads to severe vision loss and is termed geographic atrophy, 
the pathogenesis of which is unclear. As described herein, 
the present inventors identifY dysregulation of the RNase 
DICER1 3 and the resulting accumulation of transcripts of 
Alu elements, the most common small interspersed repeti-
tive elements in the human genome4 , as a cause of geo-
graphic atrophy, and describe treatment strategies to inhibit 
this pathology in vivo. 
45 degeneration, thallasemia, familial hypercholesterolemia, 
Dent's disease, acute intermittent porphyria, anterior pitu-
itary aplasia, A pert syndrome, Hemophilia A, Hemophilia B, 
glycerol kinase deficiency, autoimmune lymphoproliferative 
syndrome, X-linked agammaglobulinemia, X-linked severe 
50 combined immunodeficiency, adrenoleukodystrophy, Men-
kes disease, hyper-immunoglobulin M syndrome, retinal 
blinding, Type 1 anti-thrombin deficiency, Muckle-Wells 
syndrome, hypocalciuric hypercalcemia and hyperparathy-
roidism, cholinesterase deficiency, hereditary desmoid dis-
55 ease, chronic hemolytic anemia, cystic fibrosis, branchio-
oto-renal syndrome, lipoprotein lipase deficiency, CHARGE 
syndrome, Walker Warburg syndrome, Complement defi-
ciency, Mucolipidosis type II, Breast cancer, ovarian cancer, 
prostate cancer, von Hippe! Lindau disease, Hereditary 
60 non-polyposis colorectal cancer, multiple endocrine neopla-
sia type 1, hereditary diffuse gastric cancer, hepatoma, 
neurofibromatosis type 1, acute myeloid leukemia, T-acute 
lymphoblastic leukemia, and Ewing sarcoma. 
In some embodiments of the methods of the presently 
65 disclosed subject matter including inhibiting Alu RNA asso-
ciated with a cell, the inhibiting Alu RNA comprises increas-
ing levels of a DICER polypeptide in the cell. In some 
US 9,464,289 B2 
3 
embodiments, increasing levels of a DICER polypeptide 
comprises overexpressing the DICER polypeptide in the 
cells. In some embodiments, increasing levels of a DICER 
polypeptide comprises using a vector comprising a nucleo-
tide encoding the DICER polypeptide. In some embodi- 5 
ments, the vector is a viral vector. In some embodiments, the 
virus is selected from an adena-associated virus, a lentivirus, 
and an adenovirus. In some embodiments, the vector is a 
plasmid vector. In some embodiments, the nucleotide encod-
ing the DICER polypeptide is selected from SEQ ID NO: 7 10 
and SEQ ID NO: S. In some embodiments, the DICER 
polypeptide is selected from SEQ ID NO: 9, 10, 11, 12, 13, 
14, 15, 16, IS, and 20. In some embodiments, the DICER 
polypeptide comprises a functional fragment of the sequence 
of SEQ ID NO: 9, IS, or 20. In some embodiments, the 15 
DICER polypeptide comprises the following amino acid 
residues of the polypeptide of SEQ ID NO: 9: 605-1922, 
605-1912, 1666-1922, 1666-1912, 605-17S6 and lS00-
1922, 605-17S6 and lS00-1912, 1666-17S6 and lS00-1922, 
1666-17S6 and lS00-1912, 1276-1922, 1276-1912, 1276- 20 
17S6 and lS00-1922, 1276-17S6, S00-1912, 1275-1S24, or 
1276-1S24. 
4 
was not significantly different (P>O.ll by Mann Whitney U 
test) in human eyes with geographic atrophy and control 
eyes. Transcript abundance quantified by real-time RT-PCR 
and normalized to ISS rRNA and to control eye levels. 
n=l0-11. b, Relative quantification of DICERl protein 
abundance, relative to Vinculin, assessed by Western blot-
ting (Supplementary FIG. 1), was lower in the RPE of 
human eyes with geographic atrophy (GA; n=4) compared 
to the RPE of normal human eyes without GA (n=4). 
P=0.003 by Student t test. c, Immunohistochemistry for 
DICERl (blue) showed reduced protein abundance in the 
RPE of human eyes with GA compared to normal eyes 
without GA. d, Fundus photographs show extensive RPE 
degeneration in BEST! Cre; Dicer]flf mice but not in litter-
mate control mice. e, Toluidine blue-stained sections show 
marked RPE degeneration in BEST! Cre; Dicer]flf mice 
compared to normal RPE architecture in control mice. 
Arrowheads point to basal surface of RPE. f, Flat mounts of 
the RPE and choroid stained with antibodies against zonula 
occludens-1 (Z0-1; red) show marked disruption of the RPE 
monolayer architecture in BEST! Cre; Dicerf mice com-
pared to the uniformly tesselated RPE layer in littermate 
control mice. g, Fundus photographs show RPE degenera-
In some embodiments of the methods of the presently 
disclosed subject matter including inhibiting Alu RNA asso-
ciated with a cell, the inhibiting Alu RNA comprises increas-
ing levels of a DICER polypeptide comprises using DICER 
mRNA or a functional fragment thereof. In some embodi-
ments, the DICER mRNA has the sequence of SEQ ID NO: 
17, 19, or 21. In some embodiments, the DICER mRNA 
encodes a DICER polypeptide, for example, the DICER 
polypeptide of SEQ ID NO: 9, IS, or 20, or a functional 
fragment thereof. 
25 tion in Dicer]flf mice following subretinal injection of 
AAVl-BESTl-Cre but notAAVl-BESTl-GFP. h, Toluidine 
blue-stained sections show marked degeneration ofRPE and 
photoreceptor outer segments in Dicer]flf mice following 
subretinal injection of AAVl-BESTl-Cre but not AAVl-
In some embodiments of the methods of the presently 
disclosed subject matter including inhibiting Alu RNA asso-
ciated with a cell, the inhibiting Alu RNA comprises admin-
istering an oligonucleotide targeting Alu RNA. In some 
embodiments, the oligonucleotide has a sequence including 
30 BESTl-GFP. i, Flat mounts show marked increase in RPE 
cell size and distortion of RPE cell shape in Dicer]flf mice 
following subretinal injection of AAVl-BESTl-Cre but not 
AAVl-BESTl-GFP. RPE cell borders outlined by Z0-1 
staining (red). Nuclei stained blue with Hoechst 33342. 
35 Representative images shown. n=16-32 (d-f); 10-12 (g-i). 
a sequence selected from SEQ ID NO: 22, 23, 24, 25, and 
26. In some embodiments, at least two oligonucleotides are 
administered. The presently-disclosed subject matter further 40 
includes an isolated oligonucleotide that inhibits the expres-
sion of Alu RNA, including a sequence selected from SEQ 
ID NO: 22, 23, 24, 25, and 26 and including about 29 to 100 
nucleotides. 
In some embodiments of the methods of the presently 45 
disclosed subject matter including inhibiting Alu RNA asso-
ciated with a cell, the inhibiting Alu RNA comprises admin-
istering an siRNA targeting Alu RNA. In some embodi-
ments, the siRNA includes a first strand having a sequence 
selected from SEQ ID NO: 1, 2, 3, 4, 5, and 6. The 50 
presently-disclosed subject matter further includes an iso-
lated double-stranded RNA molecule that inhibits expres-
sion of Alu RNA, wherein a first strand of the double-
stranded RNA comprises a sequence selected from SEQ ID 
NO: 1, 2, 3, 4, 5, and 6 and including about 19 to 25 55 
nucleotides. 
BRIEF DESCRIPTION OF THE DRAWINGS 
Scale bars, (c,e,h), 10 f.tm; (f,i) 20 f.tm. j, Transfection of 
adenoviral vector coding for Cre recombinase (Ad-Cre) in 
RPE cells isolated from Dicer]flf mice resulted in loss of cell 
viability, as monitored by MTS assay at 7 days, compared to 
transfection with Ad-Null or untreated (no Tx) cells. k, 
Transfection of antisense oligonucleotide (as) targeting 
DICERl into human RPE cells resulted in increasing loss of 
cell viability over time compared to scrambled sequence 
antisense (Ctrl as )-treated cells. n=6-S. 
FIG. 2 Alu RNA accumulation in geographic atrophy 
triggered by DICER reduction. a, Immunohistochemistry 
with anti-double stranded RNA (dsRNA) antibody (J2) 
shows abundant accumulation of dsRNA (blue staining) in 
the retinal pigmented epithelium (RPE) of a human eye with 
geographic atrophy. b, Lack of immunolabeling with an 
isotype antibody in the same eye with geographic atrophy 
confirms specificity of dsRNA staining c,d, dsRNA is immu-
nolocalized (blue staining) in the RPE and sub-RPE deposits 
(drusen) of a human eye with geographic atrophy (c) but not 
in the RPE of a normal (control) eye (d). Scale bars, (a-d), 
10 fllll· n=lO (a-d) e, PCR amplification of dsRNA immu-
noprecipitated by 12 antibody from RPE isolates from 
human eyes with geographic atrophy and normal eyes 
yielded amplicons with sequence homology to Alu 
FIG. 1 DICERl deficit in geographic atrophy induces 
RPE degeneration. a, DICERl mRNAabundance, relative to 
ISS rRNA, monitored by real-time RT-PCR, was lower in 
the retinal pigmented epithelium (RPE) of human eyes with 
geographic atrophy (GA; n=lO) compared to the RPE of 
normal human eyes without GA (n=ll). P=0.004 by Mann 
Whitney U test. The abundance of DR OSHA, DGCRS, and 
EIF2C2 (encoding AG02) mRNA transcripts in the RPE 
60 sequences (Supplementary FIG. S7) in eyes with geographic 
atrophy but not in normal eyes. Water negative control (-) 
showed no amplification and positive control ( +) recombi-
nant dsRNA showed predicted amplicon. f, Alu RNA abun-
dance, relative to ISS rRNA, monitored by real-time RT-
65 PCR, was higher in the RPE of human eyes with geographic 
atrophy compared to the RPE of normal human eyes without 
GA (n=7). P<0.05 by Student t test. There was no significant 
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difference in Alu RNA abundance in the neural retina of 
these two patient groups. Values normalized to relative 
abundance in normal eyes. 
6 
induced loss of cell viability of Dicer]flf mouse RPE cells. 
This was rescued by transfection of antisense oligonucle-
otide targeting Bl and B2 RNAs but not by control (Ctrl) 
FIG. 3 DICERl degrades Alu RNA. a, Transfection of 
antisense oligonucleotide (as) targeting DICERl into human 5 
RPE cells induced a time-dependent increase in the abun-
dance of Alu RNA transcripts. b, c, Transfection of adena-
viral vector coding for Cre recombinase (Ad-Cre) into 
mouse RPE cells isolated from Dicer]flf mice increased, in 
the nucleus (b) and the cytoplasm (c), the abundance ofBl 10 
and B2 RNAs, the Alu-like repetitive elements in the mouse, 
compared to cells transfected with adenoviral vector coding 
for green fluorescent protein (Ad-GFP). d, DICERl as 
treatment of human RPE cells upregulated Alu RNA levels 
antisense oligonucleotide. Levels normalized to untreated 
cells (no Tx). d, Bl/B2 RNA as inhibited accumulation of 
Bl and B2 RNAs induced by Ad-Cre-induced Dicerl deple-
tion. *P<0.05 by Student t test. n=4-6 (a-d). d, Subretinal 
AAV-BESTl-Cre administration induced RPE degeneration 
(blue arrowheads in fundus photograph on top row and 
marked increase in RPE cell size and distortion of RPE cell 
shape in Z0-1 stained (red) RPE flat mounts (bottom row) 
in Dicer]flf mice 20 days after injection. Subretinal admin-
istration of cholesterol-conjugated Bl/B2 as, but not Ctrl as, 
10 days after AAV-BESTl-Cre injection inhibited RPE 
degeneration (e) and abundance ofB1/B2 RNAs in the RPE 
of these mice, as monitored by real-time RT-PCR at 10 days 
in both the nucleus (Nuc) and cytoplasm (Cyt). e, Alu RNA 15 
isolated and cloned from the RPE of human eye with 
geographic atrophy was degraded by recombinant DICERl 
digestion ( +) as visualized by agarose gel electrophoresis. 
Digestion with heat denatured DICERl did not degrade Alu 
RNA. Image representative of 6 experiments. f, The 20 
increased abundance of Alu RNA in human RPE cells 
after as injection, normalized to ISS rRNA levels, and 
normalized to levels in eyes treated with cholesterol-conju-
gated Ctrl as (f). n=S (e,f). Scale bar, 20 f.tm. (e). g, DICERl 
as treatment of human RPE cells led to global reduction of 
miRNA expression at 2 days compared to Ctrl as. There was 
transfected with plasmid coding for Alu (pAlu) compared to 
pNull or no treatment (no Tx) at 24 h was reduced by 
co-transfection with pDICERl. *P<0.05. n=4-S (a-d, f). 
RNA abundance was quantified by real-time RT-PCR, nor-
malized to ISS rRNA levels, and normalized to levels in 
control as-treated (for Alu) or Ad-GFP-infected cells (forB 
elements). 
FIG. 4 DICERl protects RPE cells from Alu RNA cyto-
toxicity. a, Transfection of mouse or human retinal pig-
mented epithelium cells (mRPE or hRPE) with plasmid 
coding for Alu RNA (pAlu) compromised cell viability. b, 
Subretinal administration of pAlu induced RPE degenera-
tion in wild-type mice whereas pNull did not do so. Fundus 
photograph (top row) shows area of degeneration in pAlu 
injected eye compared to the normal appearance in pNull. 
Flat mount preparations stained with anti-zonula 
occludens-1 antibody (Z0-1, red, bottom row) show marked 
distortion of RPE cell shape and size compared to pNull-
injected eye. c, Alu RNA induced dose-dependent increase 
in cell death of human RPE cells. d, Cell death of human 
RPE cells induced by transfection of pAlu was inhibited by 
co-transfection with pDICERl but not pNull. (a,c,d) Cell 
viability monitored by MTS assay at 2 days. Values nor-
malized to null plasmid (pNull) transfected or vehicle 
treated cells. *P<0.05 by Student t test. n=4-6. e, Subretinal 
co-administration of pDICERl, but not of pNull, inhibited 
pAlu induced RPE degeneration in wild-type mice. f, Sub-
retinal administration of Alu RNA isolated and cloned from 
the RPE of a human eye with geographic atrophy (GA) 
induced RPE degeneration in wild-type mice whereas sub-
retinal injection of vehicle did not. g, Subretinal injection of 
this Alu RNA, when subjected to cleavage by DICERl, did 
not induce RPE degeneration in wild-type mice whereas Alu 
RNA subjected to mock cleavage by DICERl did do so, as 
evident on fundus photography (top row) or flat mount 
preparation (bottom row). Area of degeneration outlined by 
blue arrowheads in fundus photographs (b, e-g). Scale bars 
(20 f.tm). n=l0-15 (b, e-g). 
FIG. 5 DICERl dyregulation induces RPE cell death via 
Alu RNA accumulation. a, Loss of human RPE cell viability, 
as monitored by MTS assay, induced by transfection of 
antisense oligonucleotide (as) targeting DICERl was res-
cued by co-transfection of Alu RNA as. Levels normalized 
or compared to transfection with control (Ctrl) antisense 
oligonucleotide. b, Alu RNA as inhibited accumulation of 
Alu RNA induced by DICERl as. c, Ad-Cre but not Ad-Null 
no significant difference in miRNA abundance between Alu 
as and Ctrl as-treated DICERl depleted cells. n=3. 
FIG. 6 DICERl levels in RPE are reduced in geographic 
25 atrophy. Western blots of macular RPE lysates from indi-
vidual human donor eyes show that DICERl protein abun-
dance, normalized to the levels of the housekeeping protein 
Vinculin, are reduced in geographic atrophy (GA) compared 
to age-similar control human eyes without age-related macu-
30 lar degeneration. 
FIG. 7 DICERl levels in neural retina are unchanged in 
geographic atrophy. a, DICERl mRNA abundance in the 
neural retina, as monitored by real-time RT-PCR, was not 
significantly different (P>0.05 by Maun Whitney U test) 
35 between normal human retinas and those with geographic 
atrophy. Levels normalized to ISS rRNA abundance and to 
normal retinas. n=7. b-e, DICERl protein immunolocaliza-
tion in the neural retina was not different between human 
eyes with geographic atrophy (b) and normal (d) eyes. 
40 Specificity ofDICERl staining was confirmed by absence of 
reaction production with isotype control antibody ( c,e ). 
Representative images shown. n=S. Scale bars (20 f.tm, b-e). 
FIG. 8 DICERl is not generically downregulated in 
retinal diseases. Immunolocalization studies revealed abun-
45 dant DICERl protein expression (blue, left column) in the 
RPE in the eye of an S5-year-old man with Best disease 
(vitelliform macular dystrophy), a 6S-year-old man with 
retinal detachment secondary to choroidal melanoma, and a 
72-year-old woman with retinitis pigmentosa. Specificity of 
50 DICERl staining was confirmed by absence of reaction 
production with isotype control antibody (right column). 
Representative images shown. n=13. Scale bars (10 f.tm). 
Dicerl mRNA expression in the RPE was not significantly 
(NS) different in Ccl2_1_ Ccr2_1_ mice or Cp_1_ Heph_1_ mice 
55 compared to their background strains. Transcript abundance 
quantified by real-time RT-PCR and normalized to ISS 
rRNA and to control eye levels. n=6. NS, not significant. 
FIG. 9 Cre recombinase expression does not induce 
retinal pigmented epithelium (RPE) degeneration. Subreti-
60 nal administration of adena-associated viral vector coding 
for Cre recombinase directed by the BEST! promoter 
(AAVl-BESTl-Cre) in wild-typemice did not induce retinal 
toxicity that was evident on fundus photography (top left) 
and did not disrupt the tiling pattern of the RPE monolayer 
65 (top right). Circular flash artifact is seen in the centre of the 
fundus photograph. RPE cell borders delineated by staining 
with anti-Z0-1 antibody (red) and nuclei stained by Hoechst 
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in an immuno-dot blot format. 12 antibody did not recognize 
rRNA or tRNA (negative controls), but did recognize RNA 
duplexes of325-bp or 1-kbp in length (positive controls). b, 
Immunofluorescent imaging of human RPE cells transfected 
33342 (blue). RPE flat mounts show successful Cre recom-
binase expression (red) following subretinal injection of 
AAVI-BESTl-Cre in wild-type (bottom left) and Dicer]flf 
(bottom right) mouse eyes. Representative images shown. 
n=S-10. Scale bar (20 f.tm). 
FIG. 10 Retinal pigmented epithelium (RPE) cell dys-
morphology in human age-related macular degeneration eye 
with atrophy. In contrast to the well tessellated RPE cell 
monolayer observed in a normal human eye (right), marked 
changes in RPE cell size and shape are observed in the 
human eye with geographic atrophy (left). These changes 
resemble those observed in eyes of mice wherein Dicerl has 
been depleted in the RPE. RPE cell borders delineated by 
staining with anti-Z0-1 antibody (green) and nuclei stained 
5 with pAlu shows that 12 recognizes Alu expressed in these 
cells (left panel). Specificity of staining confirmed by 
absence of staining with isotype control antibody (middle 
panel) and by the absence of immunodetection following 
transfection with pNull (right panel). Representative images 
10 shown. n=3. Scale bar (20 f.tm). 
by propidium iodide (red). Representative image shown. 15 
n=S. Scale bar, 50 f.tm. 
FIG. 11 Conditional ablation of Drosha, Dgcr8, or Ago2 
in the retinal pigmented epithelium (RPE) does not induce 
degeneration as seen in Dicerl-ablated mice. Fundus pho-
tographs (left colunm) show no significant degeneration 20 
following subretinal injection of AAV-BESTl-Cre in mice 
"foxed" for Drosha, DGCRS, or Ago2. Circular flash arti-
facts are seen near the centre of the fundus photographs. 
Injection site wound appears white in the fundus photograph 
of the Ago:Y"f eye. RPE flat mounts (middle colunm) stained 25 
with anti-Z0-1 antibody (red) and Hoechst 33342 (blue) 
show normal tiling pattern of RPE with no gross disturbance 
of cell size or shape. RPE flat mounts (right colunm) stained 
with anti-Cre recombinase antibody (red) and Hoechst 
33342 (blue) shows successful Cre expression in these mice 30 
eyes. Representative images shown. n=S-12. Scale bar (20 
f.tm). 
FIG. 12 Deficiency of Ago I, Ago3, Ago4, or Tarbp2 does 
not induce RPE degeneration. Mice deficient inAgol Ago3 
Ago4, or Tarbp2 have normal retinal appearance on fundus 35 
photography (top row) and normal RPE monolayer archi-
tecture on Z0-1 stained (red) flat mounts (bottom row). 
Circular flash artifact is seen in the centre of the fundus 
photographs. Scale bar, 20 f.tm. 
FIG. 13 DICERI mutant cells impaired in miRNA bio- 40 
genesis do not have compromised cell viability. There was 
FIG. 16 Confirmation of lack of DNA contamination in 
Alu RNA PCR. The relative abundance of Alu RNA in the 
RPE of human eyes with human geographic eyes was 
presented in FIG. 2f Shown above is the detection of the 
PCR product band for a sample of human geographic 
atrophy RPE that underwent reverse transcription (RT +).No 
amplification was detected in the negative controls where 
reverse transcriptase (RT-) was omitted or where water 
alone was analyzed. These data demonstrate the absence of 
DNA contamination in the sample. 
FIG. 17 Validation of DICERI knockdown. Transfection 
ofDICERI antisense oligonucleotides (as) into human RPE 
cells knocks down DICERI protein abundance, as moni-
tored by Western blot analysis, over 2 days. Efficiency of 
protein loading is monitored by blotting for the housekeep-
ing Vinculin protein. Representative of 3 experiments. 
FIG. 18 DICERI is expressed in nucleus and cytoplasm. 
a, Western blot shows expression of DICERI in both the 
nuclear and cytoplasmic fractions of human RPE cells. 
Blotting of the same protein sample reveals the presence of 
Tubulin in the cytoplasmic fraction and not in the nuclear 
fraction. b, Merged images (bottom row) ofDICERI immu-
nofluorescence (red, top row) and nuclear DAPI fluores-
cence (middle row) confirm expression of DICERI in both 
the nucleus and the cytoplasm of human RPE cells. Repre-
sentative images shown. Scale bar, I 0 f.tm. 
FIG. 19 Retrotransposons and repetitive RNAs are not 
generically activated in geographic atrophy or by DICERI 
depletion. In the RPE of human eyes with geographic 
atrophy (GA, n=7), there was no significant increase in the 
abundance of RNAs coded by LINE L1.3, a long inter-
spersed repetitive element, human endogenous retrovirus-W 
envelope (HERV-WEI), a long terminal repeat retrotrans-
poson, or h Y3, a repetitive small cytoplasmic Ro RNA 
no difference in baseline cell viability between HCT-
DICERI exs cells, which are impaired in miRNA biogenesis1 , 
and parent HCT116 cells over 3 days of analysis of cell 
proliferation. n=3. NS, not significant. 
FIG. 14 Human geographic atrophy eye retinal pigmented 
epithelia contain Alu RNA sequences. a, Top: Typical Alu 
element with conserved structural regions (adapted from ref. 
45 compared to normal human eyes (top, n=S). These RNAs 
also were not upregulated by DICERI antisense (as) knock-
down, compared to control (Ctrl) as treatment, in human 
RPE cells (bottom). n=3. Transcript abundance monitored 
2). The left arm consists of RNA polymerase III binding sites 
(Box A and Box B). The right arm occasionally contains a 50 
terminal poly A tail that may be interspersed with non-A 
bases. The 5' and 3' regions of the Alu element are linked by 
a mid-stretch A-rich sequence. Bottom: Representative Alu 
eDNA (Sequence 1). The conserved regions mentioned 
above are highlighted and correspond to the coloured boxes 55 
in the top figure. b, Aligument of Alu eDNA Sequences I 
and 2 isolated from human eyes with geographic atrophy to 
Alu Sq consensus sequence. These sequences contain the 
highly conserved 5' Alu consensus elements (5' character-
istic Alu region-blue; RNA polymerase III promoter B 60 
box-red), with extensive heterogeneity located 3' to the 
mid-sequence poly-A stretch that have been reported to exist 
in Alu sequences3 •4 . 
FIG. 15 12 anti-dsRNA antibody recognizes Alu RNA. a, 
Alu RNA duplex isolated and cloned from the retinal 65 
pigmented epithelium (RPE) of a human eye with geo-
graphic atrophy was recognized by 12 anti-dsRNA antibody 
by real-time RT-PCR and normalized to ISS rRNA levels. 
FIG. 20 Alu RNA induced by DICERI depletion is RNA 
Pol III derived. a, The upregulation of Alu RNA in RPE cells 
treated with antisense (as) oligonucleotides targeting 
DICERI, compared to control (Ctrl), is inhibited by treat-
ment with the Pol III inhibitor tagetitoxin (tagetin), but not 
by the Pol II inhibitor a-amanitin. *, P<0.05, NS, not 
significant, compared to treatment with DICERI as treat-
ment alone. b, Northern blot (NB) shows that the abundance 
of Alu RNA species in the RPE of a human eye with 
geographic atrophy (GA) is greater than in normal human 
eye RPE, and is principally approximately 300 nucleotides 
long, consistent with the length of a non-embedded Pol III 
derived transcript. Reprobing these samples with a probe 
corresponding to the "S region" of the 7SL RNA gene that 
is not present in Alu elements shows that 7SL RNA abun-
dance is not different between the RPE of normal and GA 
human eyes. Abundance ofU6 RNA in GA and normal eyes 
shows loading efficiency. c, Northern blot shows that Alu 
US 9,464,289 B2 
9 
probe detects in vitro transcribedAlu RNA but not 7SL RNA 
in mouse liver (which lacks primate-specific Alu), and 
reprobing these samples confirms specificity of the 7SL 
probe. d, DICERI knockdown by antisense (as) oligonucle-
otides in human RPE cells does not, compared to control 5 
(Ctrl) as treatment, induce upregulation of several Pol II-
transcribed genes (ADAR2, NICN, NLRP, SLFN II) that 
contain embedded Alu sequences in their exons. n=3. 
FIG. 21 7SL RNA is not regulated in geographic atrophy 
or by inhibition of DICERI or Alu. a, 7SL RNA abundance 10 
was not different in the RPE of human eyes with geographic 
atrophy (GA) compared to the RPE of normal human eyes 
without GA (n=S). b, 7SL RNA abundance was not different 
in human RPE cells transfected with antisense oligonucle-
15 
otide (as) targeting DICERI from those transfected with 
control (Ctrl) as. n=3. c, 7SL RNA abundance was not 
different in human RPE cells transfected with antisense 
oligonucleotide (as) targeting Alu from those transfected 
with control (Ctrl) as. n=3. 7SL RNA abundance, relative to 20 
ISS rRNA, was monitored by real-time RT-PCR. NS, not 
significant by Student t test. 
FIG. 22 Overexpression of Bl or B2 RNA induces RPE 
degeneration. Sub retinal transfection of pB I or pB2 RNAs, 
but not of pNull, induces RPE degeneration in wild-type 25 
mice. Top row shows fundus photographs demonstrating 
areas of degeneration outlined by blue arrowheads. Bottom 
row shows Z0-1 stained (red) RPE flat mounts demon-
strated marked degeneration and disarray of the RPE cells in 
mice overexpressing Bl or B2 RNAs. Circular flash artifact 30 
is seen in the centre of the fundus photographs. n=4. 
Representative images shown. Scale bar, 20 f.tm. 
FIG. 23 Alu RNA enters retinal pigmented epithelium 
(RPE) cells in vivo. Subretinal administration of Alu RNA 
in wild-type mice achieved RPE cell delivery at S h after 35 
injection as monitored by real-time RT-PCR in isolated cell 
lysates (n=3). 
10 
eration in Tlr3-/- mice where pNull transfection did not do 
so. Representative images shown. n=4. Scale bar, 20 fllll· 
FIG. 27 DICERI reduction or Alu RNA augmentation 
induces caspase-3 activation. a, Immunolocalization of acti-
vated caspase-3 (red) in the RPE of human eyes with 
geographic atrophy (left panel). Specificity of immunola-
beling revealed by absence of staining with isotype control 
antibody (middle panel) and in control eyes stained with 
antibody against cleaved caspase-3 (right panel). Autofluo-
rescence of RPE and choroid seen in green channel. Nuclei 
stained by DAPI (blue). b, Flat mounts of BEST! Cre; 
Dicer]flf mice show evidence of caspase-3 activation (red 
staining, top left panel). Specificity of immunolabeling 
revealed by absence of staining with isotype control anti-
body (top right panel). No caspase-3 activation was detect-
able in the RPE oflittermate control BEST! Cre or Dicer]flf 
mice (bottom panels). c, Human RPE cells transfected with 
pAlu showed evidence of caspase-3 activation (red staining, 
top left panel). DAPI (blue staining) and merged images are 
also shown. Scale bars (20 f.tm, a,b; 10 f.tm, c). Representa-
tive images shown. n=4-6. d, Exposure of human RPE cells 
to Alu RNA induced dose-dependent increase in caspase-3 
activation, as monitored by fluorometric plate assay. n=3, 
*P<0.05 compared to vehicle by Student t test. e, Transfec-
tion of human RPE cells with pAlu induced increase in 
caspase-3 activation. n=3, *P=0.47 by Student t test. 
FIG. 28 Alu RNA cleavage fragments do not modulate 
RPE degeneration. a, Transfection of pAlu induced cell 
death in human RPE cells. Cotransfection of DICERI-
cleaved Alu RNA fragments did not change the degree of 
cell death. n=3. b, Subretinal transfection of DICERI-
cleavedAlu RNA fragments (Frag) in wild-type mice did not 
cause RPE degeneration as seen by fundus photography (top 
left) or Z0-1-stained (red) RPE flat mounts (bottom left). 
Cotransfections of these fragments did not prevent the RPE 
degeneration induced by pAlu in wild-type mice (right 
panels). n=4. Representative images shown. Scale bar, 20 
40 f.tm. 
FIG. 24 Human GA Alu dsRNA does not induce RPE 
degeneration when cleaved by DICERl. a, Subretinal 
administration of a fully complementary synthetic Alu RNA 
(dsRNA) corresponding to the sequence of an Alu RNA 
isolated from a human eye with geographic atrophy (GA) 
induces RPE degeneration in wild-type mice. Vehicle 
administration does not damage the retina. Top panels show 
fundus photographs with the area of RPE degeneration 45 
outlined by blue arrowheads. Circular flash artifact is seen in 
the centre of the fundus photographs. Bottom panels show 
Z0-1 stained (red) RPE flat mounts that are well arrayed in 
vehicle (bottom) but disorganized in Alu dsRNA (top). b, 
This Alu dsRNA did not induce RPE degeneration when it 50 
was first subjected to cleavage by recombinant DICERI. 
However, when subjected to mock cleavage by DICERI, 
this Alu dsRNA did induce RPE degeneration. n=4. Repre-
sentative images shown. Scale bar, 20 f.tm. 
FIG. 25 RPE degeneration does not occur in response to 55 
a variety of structured RNAs. Subretinal transfection of 
transfer RNA (tRNA) or of plasmids coding for 7SL RNA, 
pri-miRNA-29bl or pri-miRNA26a2 in wild-type mice did 
not induce retinal toxicity that was evident on fundus 
photography. Circular flash artifact is seen in the centre of 60 
the fundus photographs. N=4. Representative images 
shown. 
FIG. 26 Alu RNA does not cause RPE degeneration via 
TLR3. a, Western blot shows that transfection of pAlu or 
pNull does not induce TLR3 phosphorylation, relative to the 65 
levels of the housekeeping protein Vinculin, in human RPE 
cells. b, Subretinal transfection of pAlu induced RPE degen-
FIG. 29 Impaired DICERI processing of microRNAs 
does not increase Alu RNA abundance or modulate Alu 
RNA cytotoxicity. a, There was no significant difference 
(P>0.05) in Alu RNA transcript abundance between 
HCT116 parent cells and HCT mutant cells carrying a 
mutation in exon 5 (ex5) of DICERI which renders it 
incapable of processing microRNAs. b, Transfection of 
anti-sense oligonucleotide (as) targeting DICERI into 
HCT116 cells increased the abundance of Alu RNA tran-
scripts compared to control anti-sense oligonucleotide (Ctrl 
as) at 4S h. Transcript abundance monitored by real-time 
RT-PCR and normalized to ISS rRNA levels. c, Alu RNA 
induced similar levels of cell death in HCT116 parent and 
HCT-DICERI exs cells. *P<0.05 by Student t test. n=4-6. 
FIG. 30 Oxidative stress downregulates DICERI in 
human RPE cells. Human retinal pigmented epithelium 
(RPE) cells exposed to varying concentrations of hydrogen 
peroxide (H20 2 ) display a dose- and time-dependent reduc-
tion in DICERI mRNA abundance, as monitored by real-
time RT-PCR and normalized to ISS rRNA levels. n=3. 
BRIEF DESCRIPTION OF THE SEQUENCE 
LISTING 
SEQ ID NO: I is an embodiment of a first strand of an 
siRNA provided in accordance with the presently-disclosed 
subject matter. 
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SEQ ID NO: 2 is an embodiment of a first strand of an 
siRNA provided in accordance with the presently-disclosed 
subject matter. 
SEQ ID NO: 3 is an embodiment of a first strand of an 
siRNA provided in accordance with the presently-disclosed 5 
subject matter. 
SEQ ID NO: 4 is an embodiment of a first strand of an 
siRNA provided in accordance with the presently-disclosed 
subject matter. 
SEQ ID NO: 5 is an embodiment of a first strand of an 10 
siRNA provided in accordance with the presently-disclosed 
subject matter. 
SEQ ID NO: 6 is an embodiment of a first strand of an 




SEQ ID NO: 26 is an embodiment of an antisense 
oligonucleotide sequence provided in accordance with the 
presently-disclosed subject matter. 
DESCRIPTION OF EXEMPLARY 
EMBODIMENTS 
The presently-disclosed subject matter includes methods 
for identifYing Alu RNA inhibitors, and methods and com-
positions for inhibiting Alu RNA and therapeutic uses 
thereof. 
As disclosed herein, Alu RNA (including Alu repeat RNA 
in human cells and B1 and B2, Alu-like element repeat 
RNAs) increases are associated with cells that are associated 
with certain conditions of interest. For example, Alu RNA 
increase is associated with the retinal pigment epithelium 
(RPE) cells of eyes with geographic atrophy. This increase 
of Alu RNA induces the death of RPE cells. Methods and 
SEQ ID NO: 7 is nucleotide sequence encoding a human 
DICER polypeptide, including all untranslated regions 
(GenBank Accession Number NM_177438). 
SEQ ID NO: 8 is a eDNA sequence encoding a human 
DICER polypeptide. 
compositions disclosed herein can protect a cell from Alu 
20 RNA-triggered cell death, thereby treating conditions asso-
ciated with such cell death. 
SEQ ID NO: 9 is a polypeptide sequence for a human 
DICER polypeptide. 
SEQ ID NO: 10 is a polypeptide sequence for a human 
DICER polypeptide, including residues 1276-1922 of SEQ 25 
ID NO: 9. 
SEQ ID NO: 11 is a polypeptide sequence for a human 
DICER polypeptide, including residues 605-1922 of SEQ 
ID NO: 9. 
SEQ ID NO: 12 is a polypeptide sequence for a human 30 
DICER polypeptide, including residues 1666-1922 of SEQ 
ID NO: 9. 
SEQ ID NO: 13 is a polypeptide sequence for a human 
DICER polypeptide, including residues 1666-1912 of SEQ 
35 
ID NO: 9. 
SEQ ID NO: 14 is a polypeptide sequence for a human 
DICER polypeptide, including residues 1666-1786 and 
1800-1912 of SEQ ID NO: 9. 
The presently-disclosed subject matter further includes 
methods useful for identifying an Alu RNA inhibitor and 
uses of such inhibitors, including therapeutic and protective 
uses. In some embodiments, the method makes use of a 
cultured cell wherein Alu RNA is upregulated. Candidate 
compounds can be screened using the cultured cell to 
determine efficacy as antagonists of Alu RNA. Candidate 
compounds include, for example, small molecules, biolog-
ics, and combinations thereof, such as compositions includ-
ing multiple compounds. The term small molecules is inclu-
sive of traditional pharmaceutical compounds. The term 
biologics is inclusive of polypeptides and nucleotides. 
In some embodiments, the screening method includes 
providing a cell in culture wherein Alu RNA is upregulated; 
and contacting a candidate compound with the cell. The 
method can further include identifying a change in Alu 
RNA. For example, a measurable change in Alu RNA levels 
can be indicative of efficacy associated with the candidate 
SEQ ID NO: 15 is a polypeptide sequence for a human 
DICER polypeptide, including residues 1275-1824 of SEQ 
ID NO: 9. 
SEQ ID NO: 16 is a polypeptide sequence for a human 
DICER polypeptide, including residues 1276-1824 of SEQ 
ID NO: 9. 
40 compound. In some embodiments, wherein the change in the 
Alu RNA is a measurable decrease in Alu RNA, the change 
is an indication that the candidate compound is an Alu RNA 
inhibitor. Such Alu RNA inhibitors can have utility for 
SEQ ID NO: 17 is an mRNA sequence encoding a human 
DICER polypeptide. 
SEQ ID NO: 18 is a polypeptide sequence for a Schi-
zosaccharomyces pombe DICER polypeptide. 
45 
therapeutic applications as disclosed herein. 
In some embodiments, the Alu RNA can be upregulated 
by decreasing native levels of DICER polypeptides in the 
cell using methods known to those skilled in the art. In some 
embodiments, the Alu RNA associated with cultured cell can 
be upregulated by using heat shock stress using methods 
SEQ ID NO: 19 is an mRNA sequence encoding a 
Schizosaccharomyces pombe DICER polypeptide. 
50 known to those skilled in the art. In some embodiments, the 
cultured cell is an RPE cell. 
SEQ ID NO: 20 is a polypeptide sequence for a Giardia 
Iamblia DICER polypeptide. 
Methods and compositions of the presently-disclosed 
subject matter for treating a condition of interest include 
inhibiting Alu RNA associated with a cell, such as a cell of SEQ ID NO: 21 is an mRNA sequence encoding a 
Giardia Iamblia DICER polypeptide. 
SEQ ID NO: 22 is an embodiment of an antisense 
oligonucleotide sequence provided in accordance with the 
presently-disclosed subject matter. 
55 a subject in need of treatment. Examples of conditions of 
interest include, but are not limited to: geographic atrophy, 
dry age-related macular degeneration, thallasemia, familial 
hypercholesterolemia, Dent's disease, acute intermittent 
SEQ ID NO: 23 is an embodiment of an antisense 
oligonucleotide sequence provided in accordance with the 60 
presently-disclosed subject matter. 
SEQ ID NO: 24 is an embodiment of an antisense 
oligonucleotide sequence provided in accordance with the 
presently-disclosed subject matter. 
SEQ ID NO: 25 is an embodiment of an antisense 65 
oligonucleotide sequence provided in accordance with the 
presently-disclosed subject matter. 
porphyria, anterior pituitary aplasia, Apert syndrome, 
Hemophilia A, Hemophilia B, glycerol kinase deficiency, 
autoimmune lymphoproliferative syndrome, X-linked 
agammaglobulinemia, X-linked severe combined immuno-
deficiency, adrenoleukodystrophy, Menkes disease, hyper-
immunoglobulin M syndrome, retinal blinding, Type 1 anti-
thrombin deficiency, Muckle-Wells syndrome, 
hypocalciuric hypercalcemia and hyperparathyroidism, cho-
linesterase deficiency, hereditary desmoid disease, chronic 
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hemolytic anemia, cystic fibrosis, branchio-oto-renal syn-
drome, lipoprotein lipase deficiency, CHARGE syndrome, 
Walker Warburg syndrome, Complement deficiency, Muco-
lipidosis type II, Breast cancer, ovarian cancer, prostate 
cancer, von Hippe! Lindau disease, Hereditary non-polypo-
sis colorectal cancer, multiple endocrine neoplasia type 1, 
hereditary diffuse gastric cancer, hepatoma, neurofibroma-
tosis type 1, acute myeloid leukemia, T-acute lymphoblastic 
leukemia, and Ewing sarcoma. 
14 
The terms "polypeptide", "protein", and "peptide", which 
are used interchangeably herein, refer to a polymer of the 20 
protein amino acids, or amino acid analogs, regardless of its 
size. The terms "polypeptide fragment" or "fragment", when 
used in reference to a reference polypeptide, refers to a 
polypeptide in which amino acid residues are deleted as 
compared to the reference polypeptide itself, but where the 
remaining amino acid sequence is usually identical to the 
corresponding positions in the reference polypeptide. Such 
As used herein, the terms treatment or treating relate to 
any treatment of a condition of interest, including but not 
limited to prophylactic treatment and therapeutic treatment. 
As such, the terms treatment or treating include, but are not 
limited to: preventing a condition of interest or the devel-
opment of a condition of interest; inhibiting the progression 
10 deletions can occur at the amino-terminus (e.g., removing 
residues 1-604, 1-1274, 1-1275, or 1-1665 of SEQ ID NO: 
9) or carboxy-terminus of the reference polypeptide (e.g., 
removing residues 1825-1922, or 1913-1922 of SEQ ID NO: 
9), from interal portions of the reference polypeptide (e.g., 
15 removing residues 1787-1799 of SEQ ID NO: 9), or a 
combination thereof. of a condition of interest; arresting or preventing the devel-
opment of a condition of interest; reducing the severity of a 
condition of interest; ameliorating or relieving symptoms 
associated with a condition of interest; and causing a regres-
sion of the condition of interest or one or more of the 20 
symptoms associated with the condition of interest. 
As used herein, the term "subject" refers to a target of 
treatment. The subject of the herein disclosed methods can 
be a vertebrate, such as a mammal, a fish, a bird, a reptile, 
or an amphibian. Thus, the subject of the herein disclosed 25 
methods can be a human or non human. Thus, veterinary 
therapeutic uses are provided in accordance with the pres-
ently disclosed subject matter. 
In some embodiments, the condition of interest is geo-
graphic atrophy and the cell is an RPE cell. In this regard, 30 
a subject having age-related macular degeneration can be 
treated using methods and compositions as disclosed herein. 
As will be understood by those skilled in the art upon 
studying this application, inhibition of Alu RNA associated 
a cell can be achieved in a number of manners. For example, 35 
in some embodiments, inhibiting Alu RNA associated with 
a cell comprises increasing levels of a DICER polypeptide 
in the cell, for example, by overexpressing the DICER 
polypeptide in the cell. For another example, a DICER 
mRNA could be used. For another example, in some 40 
embodiments, inhibiting Alu RNA associated with a cell 
comprises administering an oligonucleotide or a small RNA 
molecule targeting the Alu RNA. As used herein, inhibiting 
Alu RNA associated with a cell refers to a reduction in the 
levels of Alu RNA inside and/or outside the cell in the 45 
extracellular space. 
A fragment can also be a "functional fragment," in which 
case the fragment retains some or all of the activity of the 
reference polypeptide as described herein. For example, in 
some embodiments, a functional fragment of the polypep-
tide of SEQ ID NO: 9 can retain some or all of the ability 
of the polypeptide of SEQ ID NO: 9 to degrade Alu RNA. 
Examples of functional fragments of the polypeptide of SEQ 
ID NO: 9 include the polypeptides of SEQ ID NOS: 10-16. 
Additional examples include, but are not limited to, the 
polypeptide of SEQ ID NO: 9, including the following 
residues: 605-1922, 605-1912, 1666-1922, 1666-1912, 605-
1786 and 1800-1922, 605-1786 and 1800-1912, 1666-1786 
and 1800-1922, 1666-1786 and 1800-1912, 1276-1922, 
1276-1912, 1276-1786 and 1800-1922, 1276-1786 and 
1800-1912, 1275-1824, or 1276-1824. 
The terms "modified amino acid", "modified polypep-
tide", and "variant" refer to an amino acid sequence that is 
different from the reference polypeptide by one or more 
amino acids, e.g., one or more amino acid substitutions. A 
variant of a reference polypeptide also refers to a variant of 
a fragment of the reference polypeptide, for example, a 
fragment wherein one or more amino acid substitutions have 
been made relative to the reference polypeptide. A variant 
can also be a "functional variant," in which the variant 
retains some or all of the activity of the reference protein as 
described herein. The term functional variant includes a 
functional variant of a functional fragment of a reference 
polypeptide. 
In some embodiments, the DICER Polypeptide can be 
overexpressed in the cell using a vector comprising a 
nucleotide encoding the DICER polypeptide, for example, 
the nucleotide of SEQ ID NOS: 7 or 8, or appropriate 
fragment thereof, or a nucleotide encoding a DICER Poly-
The term DICER Polypeptide refers to polypeptides 
known to those of ordinary skill in the art as DICER, 
including, but not limited to polypeptides comprising the 
sequences of SEQ ID NO: 9, 18, and 20, and functional 
fragments or functional variants thereof. 
It is noted that one of ordinary skill in the art will be able 
50 peptide, for example, a nucleotide encoding SEQ ID NOS: 
9, 10, 11, 12, 13, 14, 15, 16, 18, or 20. As will be recognized 
by those skilled in the art, the vector can be a plasmid vector 
or a viral vector (e.g., adena-associated virus, lentivirus, 
adenovirus. 
to readily obtain publicly-available information related to 
DICER, including relevant nucleotide and polypeptide 
sequences included in publicly-accessible databases, such as 55 
GENBANK®. Some of the sequences disclosed herein are 
cross-referenced to GENBANK® accession numbers, e.g., 
GenBank Accession Number NM_177438. The sequences 
cross-referenced in the GENBANK® database are expressly 
incorporated by reference as are equivalent and related 
sequences present in GENBANK® or other public data-
bases. Also expressly incorporated herein by reference are 
all annotations present in the GENBANK® database asso-
ciated with the sequences disclosed herein. Unless otherwise 
indicated or apparent, the references to the GENBANK® 
database are references to the most recent version of the 
database as of the filing date of this application. 
As noted above, in some embodiments, inhibiting Alu 
RNA comprises use of a DICER mRNA. In some embodi-
ments, a functional fragment of a DICER mRNA could be 
used. In some embodiments, a DICER mRNA having the 
sequence of SEQ ID NOS: 17, 19, or 21, or a functional 
60 fragment thereof could be used. In some embodiments an 
mRNA encoding a DICER Polypeptide could be used, for 
example, an mRNA encoding SEQ ID NOS: 9, 10, 11, 12, 
13, 14, 15, 16, 18, or 20. 
As noted above, in some embodiments, inhibiting Alu 
65 RNA comprises administering an oligonucleotide or a small 
RNA molecule targeting the Alu RNA. Such nucleotides can 
target and degrade Alu RNA. 
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As such, in some embodiments, a method is provided 
including administering an oligonucleotide targeting Alu 
RNA. Examples of oligonucleotides targeting Alu RNA 
include those set forth in SEQ ID NOS: 22-26. In some 
embodiments, more than one oligonucleotide is adminis-
tered. 
In some embodiments, a method is provided including 
administering an siRNA targeting Alu RNA. Examples of 
siRNAs for targeting Alu RNA include those set forth in 
SEQ ID NOS: 1-6. 10 
The details of one or more embodiments of the presently-
disclosed subject matter are set forth in this document. 
Modifications to embodiments described in this document, 
and other embodiments, will be evident to those of ordinary 
skill in the art after a study of the information provided in 15 
this document. The information provided in this document, 
and particularly the specific details of the described exem-
plary embodiments, is provided primarily for clearness of 
understanding and no unnecessary limitations are to be 
understood therefrom. In case of conflict, the specification of 20 
this document, including definitions, will control. 
While the terms used herein are believed to be well 
understood by one of ordinary skill in the art, definitions are 
16 
The following examples may include compilations of data 
that are representative of data gathered at various times 
during the course of development and experimentation 
related to the present invention. 
EXAMPLES 
DICERl Reduction in Geographic Atrophy 
In human donor eyes with geographic atrophy (n=l 0), the 
present inventors found using real-time RT-PCR that 
DICERl mRNAabundance was reduced in the macular RPE 
by 65±3% (mean±SEM; P=0.0036; Marm-Whitney U test) 
compared to age-similar human eyes without geographic 
atrophy (n=ll) (FIG. la). Because the best understood 
function of DICERl is miRNA generation3 , the present 
inventors measured the expression of other enzymes 
involved in miRNA biogenesis. The abundance of the genes 
encoding DROSHA or the double stranded RNA (dsRNA) 
binding protein DGCRS, which form a complex that pro-
cesses pri-miRNAs into pre-miRNAs5 , was not reduced in 
the RPE of human eyes with geographic atrophy. There was 
also no reduction in the expression of the gene encoding 
Argonaute 2 (AG02, encoded by EIF2C2), the core com-set forth to facilitate explanation of the presently-disclosed 
subject matter. 
Unless defined otherwise, all technical and scientific 
terms used herein have the same meaning as commonly 
understood by one of ordinary skill in the art to which the 
presently-disclosed subject matter belongs. Although any 
methods, devices, and materials similar or equivalent to 
those described herein can be used in the practice or testing 
of the presently-disclosed subject matter, representative 
methods, devices, and materials are now described. 
25 ponent of the miRNA effector complex6 .7, in the RPE of 
human eyes with geographic atrophy. Corroborating the 
mRNA data, the present inventors observed a marked reduc-
tion of DICERl protein expression in the RPE layer of 
human eyes with geographic atrophy compared to controls 
Following long-standing patent law convention, the terms 
"a", "an", and "the" refer to "one or more" when used in this 
application, including the claims. Thus, for example, refer-
ence to "a cell" includes a plurality of such cells, and so 
forth. 
30 in Western blot (FIG. lb and FIG. 6) and immunohisto-
chemistry analyses (FIG.lc). Interestingly, DICERl mRNA 
and protein abundance in the adjacent neural retina was 
similar between the two groups (FIG. 7). 
Because DICERl downregulation is observed in some 
35 cell types in culture conditions in response to various 
chemical stresses8 , the present inventors wondered whether 
DICERl reduction in geographic atrophy might be a com-
mon downstream pathway in dying retina. DICERl protein 
levels were not reduced in the RPE of human eyes with Unless otherwise indicated, all numbers expressing quan-
tities of ingredients, properties such as reaction conditions, 
and so forth used in the specification and claims are to be 
understood as being modified in all instances by the term 
"about". Accordingly, unless indicated to the contrary, the 
numerical parameters set forth in this specification and 
claims are approximations that can vary depending upon the 45 
desired properties sought to be obtained by the presently-
disclosed subject matter. 
40 several other retinal disorders such as vitelliform macular 
dystrophy, retinitis pigmentosa, or retinal detachment (FIG. 
8). Also, Dicerl mRNA abundance in the RPE in two animal 
models of retinal degeneration---Ccl2_1_ Ccr2_1_ (refs. 9,10) 
and Cp_;_ Heph_;_ mice11-was unchanged compared to 
their background strains (FIG. 8). Gene expression studies in 
numerous other mouse models of retinal degeneration also 
have not reported modulation of Dicerl (Supplemental 
Notes). These data argue that DICERl depletion in the RPE 
of eyes with geographic atrophy is not a generic response of 
damaged or dying retinal cells in vivo. 
DICERl Depletion Induces RPE Degeneration 
To determine the functional consequence of reduced 
DICERl levels, the present inventors conditionally ablated 
Dicerl in mouse RPE cells by interbreeding "foxed" Dicerl 
As used herein, the term "about," when referring to a 
value or to an amount of mass, weight, time, volume, 
concentration or percentage is meant to encompass varia- 50 
tions of in some embodiments ±20%, in some embodiments 
±10%, in some embodiments ±5%, in some embodiments 
±1%, in some embodiments ±0.5%, and in some embodi-
ments ±0.1% from the specified amount, as such variations 
are appropriate to perform the disclosed method. 55 mice12 (Dicer]flf) with BEST! Cre mice13 , which express 
Cre recombinase under the control of the RPE cell-specific 
BEST! promoter. BEST! Cre; Dicer]flf mice uniformly 
exhibited dramatic RPE cell degeneration (FIG. ld-j) that 
was evident by the time of weaning. None of the littermate 
As used herein, ranges can be expressed as from "about" 
one particular value, and/or to "about" another particular 
value. It is also understood that there are a number of values 
disclosed herein, and that each value is also herein disclosed 
as "about" that particular value in addition to the value itself. 
For example, if the value "10" is disclosed, then "about 10" 
is also disclosed. It is also understood that each unit between 
two particular units are also disclosed. For example, if 10 
and 15 are disclosed, then 11, 12, 13, and 14 are also 
disclosed. 
The presently-disclosed subject matter is further illus-
trated by the following specific but non-limiting examples. 
60 controls exhibited similar pathology. The present inventors 
also deleted Dicerl in adult mouse RPE by subretinal 
injection of an adena-associated viral vector coding for Cre 
recombinase under the control of the BEST! promoter14 
(AAVl-BESTl-Cre) in Dicer]flf mice (FIG. 9). These eyes 
65 uniformly displayed RPE cell degeneration at 28 days after 
injection similar to that observed in mice depleted ofDicerl 
expression during development (FIG. lg-i; FIG. 9). In 
US 9,464,289 B2 
17 18 
eyes without geographic atrophy (n=10; FIG. 2d). To iden-
tify this dsRNA species, the present inventors immunopre-
cipitated RPE lysates with 12 antibody and then sequenced 
contrast, neither the contralateral eyes of Dicerlflf mice that 
underwent subretinal injection of AAV1-BEST1-GFP nor 
the eyes of wild-type mice injected with subretinal AAV1-
BEST1-Cre developed RPE cell degeneration (FIG. 1g-i and 
FIG. 9). The RPE cell dysmorphology in mice depleted of 5 
Dicerl expression resembled that observed in the eyes of 
humans with RPE atrophy due to AMD (FIG. 10). When 
cultured RPE cells isolated from Dicerlflf mice were 
infected with an adenoviral vector coding for Cre recombi-
nase (Ad-Cre ), the present inventors observed a reduction of 
cell viability compared to infection with Ad-Null (FIG. 1}). 
Similarly, antisense oligonucleotide mediated knockdown of 
DICER1 in human RPE cells resulted in increasing cell 
death over time (FIG. 1k). Collectively, these data support 
the hypothesis that DICER1 dysregulation is involved in the 
pathogenesis of geographic atrophy. 
the dsRNA using a T4 RNA ligase-aided, adaptor-based 
PCR amplification strategy. Interestingly, approximately 
300-nt long dsRNA species were found in the macular RPE 
of human eyes with geographic atrophy (12/12) but not in 
eyes without geographic atrophy (0/18) (P=1.2x10-8 by 
Fisher's exact test) (FIG. 2e). 
10 The present inventors recovered clones from 8 of the 12 
geographic atrophy eyes and identified two distinct 
sequences with high homology (E=3.3x10- 103 ; 1.1x10-76) 
to Alu repeat RNAs (FIG. 14). These sequences showed 
15 
homology to the Alu Sq subfamily consensus sequence. 
DICER1 Depletion Phenotype not Due to miRNA Dys-
regulation 
Apart from mitochondrial RNAs that were occasionally 
found in the RPE of both geographic atrophy and normal 
eyes, Alu RNAs were the only dsRNA transcripts identified 
specifically in the geographic atrophy samples. The present 
20 inventors confirmed that the 12 monoclonal antibody rec-
ognized Alu RNA both in immunoblotting and in immuno-
fluorescence assays (FIG. 15). The present inventors also 
detected a greater than 40-fold increase in the abundance of 
Alu RNAs in the RPE of human eyes with geographic 
The present inventors tested whether depletion of other 
enzymes involved in miRNA biogenesis also would induce 
RPE degeneration. Subretinal injection of AAV1-BEST1-
Cre in DroshJif (ref. 13), Dgcrsftf (refs. 15,16), or 10Ago:Y"f 
mice17 did not result in the dramatic RPE cell damage that 
was evident in similarly treated Dicer"'f mice (FIG. 11). 
These data suggest that miRNA imbalances are not respon-
sible for RPE degeneration induced by DICER1 depletion. 
However, the present inventors and others have reported18•19 
that a small subset (approximately 7%) of mammalian 
miRNAs is generated by Dicerl independent of Drosha and 
Dgcr8. There is also debate as to whether Ago2 is essential 
for miRNA function: Ago2 deficiency leads to global reduc-
tion of miRNA expression uncompensated by other three 
Ago proteins in mice17•20 and in mouse embryonic fibro-
blasts and oocytes21 •22, yet functional redundancy among 
Argonaute proteins has been reported in mouse embryonic 35 
stem cells23 . The present inventors found no RPE degen-
eration in mice deficient inAgo1, Ago3, or Ago4 (FIG. 12). 
TRBP (the human immunodeficiency virus transactivating 
response RNA-binding protein encoded by Tarbp2) recruits 
DICER1 to the four Argonaute proteins to enable miRNA 40 
processing and RNA silencing (ref 24 and R. Shiekhattar, 
personal communication); Tarbp2_1_ mice too had no RPE 
degeneration (FIG. 12). These data suggest that RPE degen-
eration induced by Dicerl ablation involves a mechanism 
specific to Dicerl and not to miRNA machinery in general. 45 
25 atrophy compared to control eyes (n=7), but no significant 
difference in Alu RNA abundance was detected in the 
adjacent neural retina between the two groups (FIG. 2/, FIG. 
16). The present inventors did not identifY exact matches to 
these Alu sequences in the reference human genome. This 
30 could be attributed to genetic variations or regions not 
represented in the reference genome or to chimeric Alu 
formation. Further studies are needed to elucidate the 
genomic origin of and regulatory factors involved in tran-
scription of these Alu RNAs. 
DICER1 Depletion Induces Alu RNA Accumulation 
The present inventors tested whether Alu RNA accumu-
lation in the RPE of geographic atrophy was the result of 
deficient DICER1 processing activity. DICER1 knockdown 
in human RPE cells using antisense oligonucleotides 
resulted in increasing Alu RNA accumulation over time 
(FIG. 3a, FIG. 17). Similarly, Ad-Cre infection of RPE cells 
isolated from Dicer1flf mice resulted in accumulation of B1 
and B2 repeat RNAs (FIG. 3b, c), which are Alu-like short 
interspersed repetitive elements in the mouse. Interestingly, 
DICER1 was expressed in both the nucleus and cytoplasm 
of RPE cells and its depletion led to accumulation of 
Alu/B1/B2 RNA in both cellular compartments (FIG. 3b-d, 
FIG. 18). In addition, recombinant DICER1 degraded Alu 
RNA, and the biological specificity of this cleavage was 
confirmed by the inability of heat-denatured DICER1 to 
degrade Alu RNA (FIG. 3e). Enforced expression of 
DICER1 in human RPE cells reduced Alu RNA abundance 
following enforced expression of Alu RNA (FIG. 3j), con-
sistent with degradation of these repetitive transcripts by 
DICER1 in vivo. Collectively these data confirm that 
DICER1 dysregulation can trigger Alu/B1/B2 RNA accu-
mulation. 
Because cell stresses such as heat shock or viral infection 
To further investigate whether miRNA imbalances might 
contribute to the phenotype observed in the setting of 
DICER1 depletion, the present inventors studied human 
HCT116 colon cancer cells in which the helicase domain in 
exon 5 ofDICER1 was disrupted. Despite the impairment of 50 
miRNA biogenesis in these HCT-DICER1 exs cells25 , there 
was no difference between HCT-DICER1 exs and parent 
HCT116 cells in baseline cell viability (FIG. 13). Collec-
tively, these findings suggest that the principal biological 
effect ofDICER1 deficit contributing to the development of 55 
geographic atrophy is not miRNA dysregulation. The find-
ings do not, however, exclude the possibility that miRNA 
dysregulation could promote geographic atrophy through 
other pathways. can induce generalized retrotransposon activation, the pres-
60 ent inventors wondered whether Alu RNA accumulation in Alu RNA Accumulation in Geographic Atrophy 
Because miRNA perturbations could not be implicated, 
the present inventors speculated that impaired processing of 
other dsRNAs might be involved. Using an antibody26 •27 
that recognizes long dsRNA (12), the present inventors 
detected abundant dsRNA immunoreactivity in the macular 65 
RPE of human eyes with geographic atrophy (n=10; FIG. 
2a-c ). In contrast, no 12 immunoreactivity was observed in 
geographic atrophy might be a generic response in dying 
retina. However, in the RPE of human eyes with geographic 
atrophy and in DICER1-depleted human RPE cells, there 
was no increase in the abundance of RNAs coded by L1.3 
(a long interspersed repetitive element), human endogenous 
retrovirus-W envelope (a long terminal repeat retrotranspo-
son), or hY3 (a repetitive small cytoplasmic Ro RNA) (FIG. 
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19). These data demonstrate that Alu RNA accumulation is 
a biologically specific response to DICER1 depletion. 
20 
To determine whether Alu RNA accumulation was 
derived from RNA polymerase II (Pol II) or Pol III tran-
scription, the present inventors performed experiments using 5 
a-amanitin (a Pol II inhibitor) and tagetitoxin (a Pol III 
inhibitor). Alu RNA upregulation induced by DICER1 
knockdown was inhibited by tagetitoxin but not a-amanitin 
(FIG. 20). The present inventors also found using Northern 
blotting that Alu RNA from the RPE of human eyes with 10 
geographic atrophy was approximately 300 nucleotides in 
length, consistent with the length of non-embedded Pol III 
Alu transcripts. Because homology between Alu RNA and 
7SL RNA, the evolutionary precursor of Alu, can complicate 
interpretation of northern blot analysis, the present inventors 15 
reprobed these samples using a probe that specifically 
detects the non-Alu "S domain" of7SL RNA. In contrast to 
the increased amounts of RNA species detected by the 
Alu-targeting probe in geographic atrophy RPE, there was 
DICER1 did not induce RPE degeneration in wild-type mice 
(FIG. 4g, FIG. 24). When theseA!u RNAs were subjected to 
mock DICER1 digestion, they retained their ability to 
induce RPE degeneration, suggesting a role for DICER1 in 
protecting against Alu RNA-induced degeneration. 
The present inventors tested whether other structured 
RNAs of similar length as Alu would damage the retina. 
Subretinal transfection of transfer RNA or plasmids coding 
for 7SL RNA or two different primary miRNAs did not 
induce RPE degeneration in wild-type mice (FIG. 25). The 
present inventors reported that chemically synthesized dsR-
NAs that mimic viral dsRNA can induce RPE degeneration 
by activating toll like receptor-3 (TLR3)29, a pattern recep-
tor that generically recognizes dsRNA. However, transfec-
tion of a plasmid coding for Alu RNA did not induce TLR3 
phosphorylation in human RPE cells and did induce RPE 
degeneration in Tlr3_1_ mice (FIG. 26). These results indi-
cate that the ability of Alu RNA to induce RPE degeneration 
cannot be attributed solely to its repetitive or double 
no difference in 7SL RNA abundance. The present inventors 
also confirmed that the Alu probe did not detect endogenous 
7SL RNA under the stringent conditions the present inven-
tors employed. Corroborating these data, real-time RT-PCR 
analysis showed that 7SL RNA was not dysregulated in the 
RPE of human eyes with geographic atrophy or in DICER1-
depleted human RPE cells (FIG. 21). 
DICER1 knockdown also did not induce upregulation of 
several Pol II-transcribed genes (ADAR2, NICN, NLRP, 
SLFN 11) that contain embedded Alu sequences in their 
exons. Collectively, these data suggest that Alu RNA 
detected in the RPE of human eyes with geographic atrophy 
are primary Alu transcripts and not passenger or bystander 
sequences embedded in other RNAs. Conclusive assigument 
of these Alu sequences as Pol III transcripts must await 
precise determination of their transcription start site. 
Alu RNA Induces RPE Degeneration 
Next the present inventors tested whether accumulation of 
Alu RNA might promote the development of geographic 
atrophy. Transfecting human or wild-type mouse RPE cells 
with a plasmid coding for Alu (pA!u) reduced cell viability 
(FIG. 4a ). Subretinal transfection of plasmids coding for two 
different Alu RNAs or for B1 or B2 RNAs induced RPE 
degeneration in wild-type mice (FIG. 4b, FIG. 22, and data 
not shown). Treatment of human RPE cells with a recom-
binant 281 nucleotide (nt)-long Alu RNA that is identical to 
a Pol III derived Alu RNA isolated from a human embryonal 
carcinoma cell line, i.e., a single RNA strand that folds into 
a defined secondary structure, resulted in a dose-dependent 
increase in cell death (FIG. 4c). These findings suggest that 
endogenous DICER1 can degrade small amounts of Alu 
RNA but are overwhelmed by high levels. Consistent with 
this concept, overexpression of DICER1 blocked pAin-
induced cell death in human RPE cells (FIG. 4d) and RPE 
degeneration in wild-type mice (FIG. 4e). 
The present inventors verified that subretinal injection of 
Alu RNA resulted in its delivery to RPE cells in wild-type 
mice (FIG. 23), consistent with the ability of long RNAs 
with duplex motifs to enter cells28 . The present inventors 
then cloned a 302-nt long Alu RNA isolated from the RPE 
20 stranded nature, as it exerted effects distinct from other 
structured dsRNAs of similar length. 
The mechanism of RPE cell death in geographic atrophy 
has not been previously defined. DNA fragmentation has 
been identified in RPE cells in human eyes with geographic 
25 atrophy30, and Dicerl knockdown has been associated with 
induction of apoptosis in diverse tissues12•31 . The present 
inventors now provide evidence of caspase-3 cleavage in 
regions ofRPE degeneration in human eyes with geographic 
atrophy (FIG. 27). Caspase-3 cleavage was also observed in 
30 the RPE cells of BESTlCre; Dicer]flf mice and in Alu 
RNA-stimulated or -overexpressing human RPE cells. 
These data suggest a role for Alu RNA-induced RPE cell 
apoptosis triggered by DICER1 dysregulation in geographic 
35 
atrophy. 
Although the present inventors show that Alu RNA 
induces RPE degeneration, the presented observations could 
be consistent with the idea that an imbalance in small RNA 
species produced from long Alu RNAs could contribute to 
the RPE degeneration phenotype. To study this question, the 
40 present inventors exposed human RPE cells or wild-type 
mice to DICER1 cleavage fragments of Alu RNA. Subreti-
nal transfection of these fragments alone in wild-type mice 
had no detectable effect on RPE cell morphology, and 
co-administering these fragments did not prevent RPE cell 
45 degeneration induced by subretinal transfection of a plasmid 
coding for Alu RNA (FIG. 28). Similarly, these fragments 
did not prevent human RPE cell death induced by overex-
pression of Alu RNA. These data suggest that upregulation 
oflong Alu RNA rather than imbalance in Alu RNA-derived 
50 small RNA fragments is responsible for RPE degeneration 
induced by DICER1 reduction. 
As these experiments were performed with in vitro cleav-
age fragments the present inventors cannot be certain 
whether in vivo cleavage fragments would function simi-
55 larly. However, Alu RNAs with varying sequences induced 
RPE degeneration in vivo. Because the cleavage fragments 
of these different Alu RNAs would not be identical it is 
unlikely that they all execute identical biological functions, 
of a human eye with geographic atrophy and transcribed it 60 
in vitro to generate partially and completely annealed struc-
tures that mimic Alu RNAs transcribed by Pol III and Pol II, 
respectively. Subretinal injection of either of these Alu 
RNAs resulted in RPE degeneration in wild-type mice (FIG. 
particularly if they functioned as miRNAs. Another line of 
evidence that Alu RNA, and not its cleavage fragments, is 
responsible for RPE degeneration comes from functional 
rescue experiments (see below) wherein antisense-mediated 
inhibition of Alu RNA blocks human RPE cell death induced 
by DICER1 knockdown and inhibition of B1/B2 RNA 
blocks RPE degeneration in Dicerl-depleted mice and 
mouse RPE cells. Because these antisense treatments would 
4{, FIG. 24), supporting the assignment of disease causality 65 
in accord with the molecular Koch's postulates. In contrast, 
subretinal injection of these Alu RNAs digested with not be expected to alter the reduced levels of DICER1-
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cleaved Alu/B1/B2 RNA fragments, the imbalance in these 
fragments is unlikely to have induced RPE degeneration. 
Nevertheless, subtle functions of these small RNAs in 
modulating Alu RNA induced pathology cannot be 
excluded. 
To dissect the contribution of Alu RNA accumulation 
versus that of miRNA dysregulation to RPE degeneration in 
the context of reduced DICER1 expression, the present 
inventors re-examined HCT-DICER1 exs cells in which 
miRNA biogenesis is impaired but long dsRNA cleavage is 
preserved due to the intact RNase III domains. The present 
inventors found no significant difference in Alu RNA levels 
between HCT-DICER1 exs and parent HCT116 cells (FIG. 
29). In contrast, when DICER1 was knocked down by 
antisense oligonucleotides in HCT116 cells, increased Alu 
RNA accumulation was observed. Also, Alu RNA induces 
similar levels of cytotoxicity in HCT-DICER1 exs and parent 
HCT116 cells, suggesting that coexisting miRNA expres-
sion deficits do not augment Alu RNA induced RPE degen-
eration. In conjunction with the discordance in the RPE 
degeneration phenotype between ablation of Dicerl and that 
of various other small RNA biogenesis pathway genes in 
mice, the findings suggest that Alu RNA accumulation is 
critical to cytotoxicity induced by DICER1 reduction. 
RPE Degeneration Blocked by Alu RNA Inhibition 
The present inventors then tested whether the cytotoxic 
effects of DICER1 reduction could be attributed to Alu RNA 
accumulation. DICER1 knockdown in human RPE cells by 
antisense oligonucleotides reduced cell viability (FIG. Sa). 
This cytotoxic effect of DICER1 reduction was inhibited by 
antisense oligonucleotides targeting Alu RNA sequences but 
not by a scrambled antisense control (FIG. Sa, b and FIG. 
21). Ad-Cre infection of RPE cells isolated from Dicer]flf 
mice resulted in reduced cell viability, and this was blocked 
by antisense oligonucleotides targeting both B1 and B2 
repeat RNAs but not by a scrambled antisense control (FIG. 
Sc, d). Subretinal administration of antisense oligonucle-
otides that reduced accumulation of B1 and B2 RNAs also 
inhibited RPE degeneration in Dicer]flf mice treated with 
AAV1-BEST1-Cre (FIG. Se, f), providing evidence of in 
vivo functional rescue. 
The present inventors tested whether Alu inhibition also 
rescued miRNA expression deficits as a potential explana-
tion for the functional rescue of RPE degeneration induced 
22 
observations have direct relevance for clinical strategies to 
prevent and treat geographic atrophy. 
Discussion 
The findings elucidate a critical cell survival function for 
5 DICER1 by functional silencing of toxic Alu transcripts. 
This unexpected function suggests that RNAi-independent 
mechanisms should be considered in interpreting the phe-
notypes of systems in which Dicerl is dysregulated. For 
example, it would be interesting to test the speculation that 
10 Dicerl ablation induced cell death in mouse neural retina32 
and heart33 might also involve B1/B2 RNA accumulation. 
More broadly, recognition of DICER1 's hitherto unidenti-
fied function as an important controller of transcripts derived 
from the most abundant repetitive elements in the human 
15 and mouse genomes can illuminate new functions for 
RNases in cytoprotective surveillance. DICER1 expression 
is reduced in geographic atrophy and partial loss of DICER 
promotes RPE degeneration; thus the present inventors 
could speculate that loss of heterozygosity in DICER1 may 
20 underlie the development of geographic atrophy, similar to 
its function as a haploinsufficient tumor suppressor34-36 . 
This also is, to our knowledge, the first example of how 
Alu could cause a human disease via direct RNA cytotox-
icity rather than by inducing chromosomal DNA rearrange-
25 ments or insertional mutagenesis through retrotransposition, 
which have been implicated in diseases such as a-thalas-
semia37, colon cancer38, hypercholesterolemia39•40, and 
neurofibromatosis41 . Future studies can be employed to 
determine the precise chromosomal locus of the Alu RNA 
30 elements that accumulate in geographic atrophy and the 
nature of transcriptional and post-transcriptional machinery 
that enable their biogenesis. 
In addition to processing miRNAs3, DICER1 has been 
implicated in heterochromatin assembly42•43 · Since Alu 
35 repeat elements are abundant within heterochromatin44, it 
would be interesting to investigate whether perturbations in 
centromeric silencing also underlie the pathogenesis of 
geographic atrophy. Indeed, the finding that chromatin 
remodelling at Alu repeats can regulate miRNA expression45 
40 raises the intriguing possibility of other types of regulatory 
intersections between DICER1 andAlu. It also remains to be 
by DICER1 depletion. As expected, DICER1 knockdown in 45 
human RPE cells reduced the abundance of numerous 
investigated whether centromeric satellite repeats that have 
been described to accumulate in Dicerl-null mouse embry-
onic stem cells46•47 might be involved in the pathogenesis of 
geographic atrophy. 
In the mouse germline, Dicerl has been implicated in the 
generation of endogenous small interfering RNAs ( endo-
siRNAs) from repeat elements48•49 . If this process is con-
served in mammalian somatic tissues, it would be interesting 
miRNAs including let-7a, which is ubiquitously expressed, 
miR-184, miR-204/211, and miR-221/222, which are 
enriched in the RPE, and miR-320a, and miR-484 and 
miR-877, which are DROSHA/DGCR8-independent and 
DICER1-dependent (FIG. Sg). However, inhibition of Alu 
RNA did not lead to recovery of miRNA expression in these 
DICER1-depleted cells. Thus the rescue ofRPE cell viabil-
ity by Alu RNA inhibition despite the persistence of global 
miRNA expression deficits argues that RPE degeneration 
induced by DICER1 deficit is due to Alu RNA accumulation 
and not miRNA dysregulation. 
These data, taken together, support a model in which 
primary Alu transcripts are responsible for the observed RPE 
degeneration. Whether similar pathology can also result 
from upregulation of as yet undefined Pol II transcripts with 
embedded Alu sequences is an intriguing possibility that 
may be addressed in future studies. Importantly, the present 
inventors show here that primary Alu transcripts are elevated 
in human disease, that Alu transcripts recapitulate disease in 
relevant experimental models, and that targeted suppression 
of Alu transcripts successfully inhibits this pathology. These 
50 to learn whether endo-siRNAs serve a homeostatic function 
in preventing the development of geographic atrophy. A 
recent study in nematodes demonstrated that caspases can 
cleave Dicerl and convert it into a DNase that promotes 
apoptosis50. The finding that Alu RNA can induce caspase 
55 activation therefore introduces the possibility of bidirec-
tional regulation between DICER1 and Alu that could trig-
ger feed-forward loops that further amplifY the disease state. 
The inciting events that trigger an RPE-specific reduction 
ofDICER1 in patients with geographic atrophy remain to be 
60 determined. Potential culprit could include oxidative stress, 
which is postulated to underlie AMD pathogenesis2, as the 
present inventors found that exposure to hydrogen peroxide 
downregulates DICER1 in human RPE cells (FIG. 30). 
While the upstream triggers of DICER1 dysregulation and 
65 the possible role of other DICER-dependent, DROSHA/ 
DGCR8-independent small RNAs in geographic atrophy 
await clarification, the ability of Alu RNA antisense oligo-
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nucleotides to inhibit RPE cell death induced by DICERl 
depletion provides a rationale to investigate Alu RNA inhi-




antibodies against human zonula occludens-1 (1:100, Invit-
rogen), Cre recombinase (1:1000, EMD4Biosciences), or 
human cleaved caspase-3 (1 :200, Cell Signaling) and visu-
alized with Alexa594- or Cy5-conjugated secondary anti-
5 bodies. Both antibodies are cross-reactive against the mouse 
homologues. Primary human RPE cells were grown to 
70-80% confluency in chamber slides (Lab-Tek). After 24 h 
of transfection with pAlu or pUC19, cells were fixed in 
Dicerl mRNA levels are not modulated in multiple mouse 
models of retinal degeneration including light damage53 •54, 
hyperoxia, 55retinal detachment53 •56, Crx_1_ mice57 , Rslh_1_ 
mice58 , rdl mice59•60 , cpfll mice61 , or Mitf mice62 . Dicerl 
abundance also is not reduced in mouse models of cellular 10 
acetone for 10 min at -20° C. Cells were blocked with 
PBS-3% BSA and incubated with mouse antibody against 
dsRNA (1:500, clone J2) overnight at 4° C. and visualized 
with Alexa Fluor 488-conjugated secondary antibodies. For 
DICERl staining, cells were fixed in methanol/acetone (7 :3) 
stress in the retina including exposure to advanced glycation 
endproducts63 or retinal detachment64 . Therefore, Dicerl 
downregulation is not a generic late-stage stress response in 
the retina. 
Materials and Methods 
Animals 
All animal experiments were approved by institutional 
review committees and the Association for Research in 
Vision and Ophthalmology. C57Bl/6J and Dicer]flf mice 
were purchased from The Jackson Laboratory. Transgenic 
mice that express Cre recombinase in the retinal pigmented 
epithelium under the control of the human bestrophin-1 
promoter (BEST! Cre mice), DGCRsft--'; Droshafl--'; 
Tarbp2_1_, Ccl2_1_ Ccr2_1_, and Cp_1_ Heph_1_ mice have 
15 
for 30 min on ice, blocked with PBS-3% BSA-5% FBS, 
incubated with rabbit antibody against human DICERl 
(1: 100, Santa Cruz Biotechnology) overnight at 4 o C., and 
visualized with goat-anti-rabbit Alexa Fluor 594-conjugated 
secondary antibodies. After DAPI counterstaining, slides 
20 were cover slipped in Vectashield (Vector Laboratories). 
Images were obtained using the Leica SP-5 or Zeiss Axio 
Observer Zl microscopes. 
Histology. 
Mouse eyes were fixed with 4% paraformaldehyde and 
25 3.5% glutaraldehyde, postfixed in 2% osmium tetroxide, and 
dehydrated in ethanol and embedded. Semi-thin (1 f.tm) 
sections were cut and stained with toluidine blue. Bright 
field images were obtained using the Zeiss Axio Observer 
been previously described65 -71 . Ago:Y"f mice 72 and mice 
deficient in Ago!, Ago3, or Ago4 (ref. 73) were generously 
provided by A. Tarakhovsky. For all procedures, anaesthesia 
was achieved by intraperitoneal injection of 50 mg/kg 
ketamine hydrochloride (Ft. Dodge Animal Health) and 10 
mg/kg xylazine (Phoenix Scientific), and pupils were dilated 30 
with topical 1% tropicamide (Alcon Laboratories). 
Zl microscope. 
Subretinal Injection. 
Subretinal injections (1 f.LL) in mice were performed using 
a Pica-Injector (PLI-100, Harvard Apparatus). In vivo trans-
fection of plasmids coding for DICERl (ref. 74), Alu Ya5 
(ref. 75), Alu Yb9 (ref. 76), 7SL RNA (ref. 77), pri-miR29bl 
Fundus Photography. 
Retinal photographs of dilated mouse eyes were taken 
with a TRC-50 IX camera (Topcon) linked to a digital 
imaging system (Sony). 
Human Tissue. 
Donor eyes or ocular tissues from patients with geo-
graphic atrophy due to AMD or patients without AMD were 
obtained from various eye banks in Australia and the United 
States of America. These diagnoses were confirmed by 
dilated ophthalmic examination prior to acquisition of the 
tissues or eyes or upon examination of the eye globes post 
mortem. The study followed the guidelines of the Declara-
tion of Helsinki Institutional review boards granted approval 
for allocation and histological analysis of specimens. 
Immunolabeling. 
Human eyes fixed in 2-4% paraformaldehyde were pre-
pared as eyecups, cryoprotected in 30% sucrose, embedded 
in optimal cutting temperature compound (Tissue-Tek OCT; 
Sakura Finetek), and cryosectioned into 10 f.Ull sections. 
Depigmentation was achieved using 0.25% potassium per-
manganate and 0.5% oxalic acid. Immunohistochemical 
staining was performed with the mouse antibody against 
dsRNA (1: 1,000, clone 12, English & Scientific Consulting) 
35 (Addgene), or pri-miR26a2 (Addgene) and bovine tRNA 
(Sigma-Aldrich) (0.5 mg/mL) was achieved using 10% 
Neuroporter (Genlantis). AAV1-BEST1-Cre78 or AAVl-
BESTl-GFP were injected at l.Oxl011 pfu/mL and recom-
binantAlu RNAs (1: a single RNA strand of281 nucleotides 
40 whose sequence is that of the eDNA clone TS 103 (ref 51) 
and folds into a defined secondary structure identical to a Pol 
III derived transcript; 2: a single RNA strand of302 nucleo-
tides whose sequence is identical to that of a clone isolated 
from the RPE of a human eye with geographic atrophy that 
45 folds into a defined secondary structure identical to a Pol III 
derived transcript; or 3: a fully complementary dsRNA 
version of this 302 nucleotide long sequence that mimics a 
Pol II derived transcript) was injected at 0.3 mg/mL. Cell-
permeating cholesterol conjugated-Bl/B2 antisense oligo-
50 nucleotides (as) (5'-TCAGATCTCGTTACGGATGGTT-
GTGA-3') or cholesterol conjugated-control as (5'-
TTGGTACGCATACGTGTTGACTGTGA-3') (both from 
Integrated DNA Technologies) were injected (2 flg in 1 f.LL) 
10 days after AAVl-BESTl-Cre was injected in Dicer]flf 
55 m1ce. or rabbit antibody against human DICERl (1: 100, Santa 
Cruz Biotechnology). Isotype IgG was substituted for the 
primary antibody to assess the specificity of the staining 
Bound antibody was detected with biotin-conjugated sec-
ondary antibodies (Vector Laboratories). Slides were further 
incubated in alkaline phosphatase-streptavidin solution (In- 60 
vitrogen) and the enzyme complex was visualized by Vector 
Blue (Vector Laboratories). Levamisole (Vector Laborato-
ries) was used to block endogenous alkaline phosphatase 
activity. Slides were washed in PBS, rinsed with deionized 
water, air-dried, and then mounted in Clear Mount (EMS). 65 
Mouse RPE/choroid flat mounts were fixed with 4% para-
formaldehyde or 100% methanol and stained with rabbit 
Isolation of dsRNA. 
Human eyes were stored in RNAlater (Ambion). Tissue 
extracts were prepared by lysis in buffer containing 50 mM 
Tris-HCl, pH 8, 150 mM NaCl, 1% Nonidet P-40, protease 
and phosphatase inhibitors (complete mini EDTA-free, pro-
tease inhibitor and phosphatase inhibitor cocktail tablets, 
Roche), and RNase inhibitor (SUPERase-In, Ambion). After 
homogenization using bullet blender (Nextadvance) and 
centrifugation, immunoprecipitations were performed by 
adding 40 flg of mouse antibody against dsRNA (clone J2) 
for 16 h at 4° C. Immunocomplexes were collected on 
protein A/G agarose (Thermo scientific) and dsRNA species 
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were separated and isolated using Trizol (Invitrogen) 
according to the manufacturer's instructions. 
Ligation of dsRNA and Anchor Primer. 
An anchor primer (PC3-T7 loop, 5'-p-GGATC-
CCGGGAATTCGGTAATACGACTCACTATATTTT-
TATAGTGAGTCGTATTA-OH-3', 200-400 ng, IDTf9 •80 
was ligated to dsRNA (200-400 ng) in 50 mM HEPES/ 
NaOH, pHS (vWR), IS mM MgC12 (Invitrogen), 0.01% 
BSA (Fisher Scientific), I mM ATP (Roche), 3 mM DTT 
(Fluka), 10% DMSO (Finnzymes), 20% PEG 6000 (Alfa 
Aesar), and 30U T4 RNA ligase (Ambion). Ligation was 
26 
transcript) of the 302 nt hnman geographic atrophy Alu 
using linearized PCRII TOPO plasmid templates using T7 or 
SP6 RNA polymerases (MegaScript, Ambion) according to 
the manufacturer's recommendations. After purification, 
5 equal molar amount of each transcript were combined and 
heated at 95° C. for I min, cooled and then annealed at room 
temperature for 24 h. The Alu dsRNA was precipitated, 
suspended in water and analyzed on 1.4% non-denaturing 
agarose gel using the single-stranded complementary 
10 strands as controls. 
Real-Time PCR. 
performed at 37° C. for 16 h, and ligated dsRNA was Total RNA was extracted from tissues or cells using Trizol 
purified by MinElute Gel extraction colunms (Qiagen). reagent (Invitrogen) according to manufacturer's recom-
Sequence-Independent eDNA Synthesis. mendations and were treated with RNase free DNase (Am-
After denaturation, ligated dsRNA was reverse tran- 15 bion). Total RNA (I flg) was reverse transcribed as previ-
scribed in aRT reaction containing 50 mM Tris-HCl, pH S.3, ously described70 using qScript eDNA SuperMix (Quanta 
10 mM MgC12, 70 mM KCl, 30 mM ~-mercaptoethanol, I Biosciences). The RT products (eDNA) were amplified by 
mM dNTPs and 15U cloned AMV reverse transcriptase real-time quantitative PCR (Applied Biosystems 7900 HT 
(Invitrogen). The mixture was incubated in a thermal cycler Fast Real-Time PCR system) with Power SYBR green 
(Eppendorf) at 42° C. for 45 min followed by 55° C. for 15 20 Master Mix. Oligonucleotide primers specific for DICERI 
mm. (forward 5'-CCCGGCTGAGAGAACTTACG-3' and 
Polymerase Chain Reaction (PCR) Amplification. reverse 5'-CTGTAACTTCGACCAACACCTTTAAA-3'), 
Amplification of eDNA was performed using primer PC2 DR OSHA (forward 5'-GAACAGTTCAACCCCGATGTG-
(5'-p-CCGAATTCCCGGGATCC-3', IDT) in a reaction buf- 3' and reverse 5'-CTCAACTGTGCAGGGCGTATC-3'), 
fer containing 5 f.LL eDNA and 40 f.LL Platinum PCR Super- 25 DGCRS (forward 5'-TCTGCTCCTTAGCCCTGTCAGT-3' 
Mix (Invitrogen). The PCR cycling parameters consisted of and reverse 5'-CCAACACTCCCGCCAAAG-3'), EIF2C2 
one step of no C. for I min to fill incomplete eDNA ends (forward 5'-GCACGGAAGTCCATCTGAAGTC-3' and 
and produce intact DNA, followed by one step of initial reverse 5'-CCGGCGTCTCTCGAGATCT-3'), human ISS 
denaturation (94 o C., 2 min), 39 cycles of94 o C. for 30 s, 53° rRNA (forward 5'-CGCAGCTAGGAATAATGGAATAGG-
C. for 30 s, and no C. for I min, and a final extension step 30 3' and reverse 5'-GCCTCAGTTCCGAAAACCAA-3'), Alu 
of no C. for 10 min. In vitro transcribed dsRNAs of varying (forward 5'-CAACATAGTGAAACCCCGTCTCT-3' and 
lengths (325 bp, I and 2 kb) were used as positive controls. reverse 5'-GCCTCAGCCTCCCGAGTAG-3'), LINE L1.3 
Cloning and Sequencing. (ORF2) (forward 5'-CGGTGATTTCTGCATTTCCA-3' and 
The amplified eDNA products were incubated with IU reverse 5'-TGTCTGGCACTCCCTAGTGAGA-3'), HERV-
calf intestinal alkaline phosphatase (Invitrogen) at 37° C. for 35 WEI (forward 5'-GCCGCTGTATGACCAGTAGCT-3' and 
5 min to remove the 5'-phosphate group, separated on a reverse 5'-GGGACGCTGCATTCTCCAT-3'), human Ro-
low-melting point agarose gel (I%) and purified using associated Y3 (hY3) (forward 5'-CCGAGTGCAGTGGT-
Qiaquick gel extraction kit (Qiagen). The purified dephos- GTTTACA-3' and reverse 5'-GGAGTGGA-
phorylated eDNA fragments were cloned in PCRII TOPO GAAGGAACAAAGAAATC-3'), 7SL (forward 
vector (Invitrogen) and sequenced using Ml3 forward ( -20) 40 5'-CGGCATCAATATGGTGACCT-3' and reverse 5'-CT-
and Ml3 reverse primers at the University of Kentucky GATCAGCACGGGAGTTTT-3'), Bl (forward 5'-TGC-
Advanced Genetic Technologies Center using multi-colour CTTTAATCCCAGCACTT-3' and reverse 5'-GCTGCTCA-
fluorescence based DNA sequencer (ABI 3730xl). CACAAGGTTGAA-3'), B2 (forward 
Sequences were assembled using ContigExpress from vee- 5'-GAGTTCAAATCCCAGCAACCA-3' and reverse 
tor NTI Advance. The homology of the isolated eDNA 45 5'-AAGAGGGTCTCAGATCTTGTTACAGA-3'), cyto-
sequences to known Alu consensus sequences was deter- plasmic B2 (forward 5'-GCCCTGTTACAATTGGCTTT-3' 
mined using the CENSOR server81 (a WU-BLAST-powered and reverse 5'-GTGGTTGCTGGGATTTGAAC-3'), 
database of repetitive elements (http://www.girinst.org/cen- Dicerl (forward 5'-CCCACCGAGGTGCATGTT-3' and 
sor). For each eDNA sequence, the homologous region of reverse 5'-TAGTGGTAGGAGGCGTGTGTAAAA-3'), 
the query was aligned to the consensus Alu sequence using 50 mouse ISS rRNA (forward 5'-TTCGTATTGCGC-
BLASTn82 (http://www.ncbi.nlm.nih.gov/BLAST). Mul- CGCTAGA-3' and reverse 5'-CTTTCGCTCTGGTC-
tiple sequence alignment was performed using ClustalW2 CGTCTT-3') were used. The QPCR cycling conditions were 
(http://www.ebi.ac.uk/Tools/clustalw2). The consensus 50° C. for 2 min, 95° C. for 10 min followed by 40 cycles 
sequences have been deposited in GenBank under the acces- of a two-step amplification program (95° C. for 15 sand 5S 0 
sian nnmbers HNI765S4 and HNI765S5. 55 C. for I min). At the end of the amplification, melting curve 
Alu RNA Synthesis. analysis was applied using the dissociation protocol from the 
The present inventors synthesized two Alu RNAs: a 2SI Sequence Detection system to exclude contamination with 
nt Alu sequence originating from the eDNA clone TS I 03 unspecific PCR products. The PCR products were also 
which is known to be expressed in hnman cells 5 1 and a 302 confirmed by agarose gel and showed only one specific band 
nt Alu sequence isolated from the RPE of a human eye with 60 of the predicted size. For negative controls, no RT products 
geographic atrophy. Both of these Alu RNAs were synthe- were used as templates in the QPCR and verified by the 
sized using a RNA polymerase T7 promoter and runoff absence of gel-detected bands. Relative expressions of target 
transcription followed by gel purification as previously genes were determined by the 2-Mct method. 
described83 . This yields single stranded RNAs that fold into miRNA PCR. 
a defined secondary structure identical to Pol III derived 65 miRNA abundance was quantified using the All-in-One™ 
transcripts. The present inventors also synthesized a fully miRNA qRT-PCR Detection Kit (GeneCopoeia). Briefly, 
complementary dsRNA form (resembling a Pol II derived total RNA was polyadenylated and reverse transcribed using 
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a poly dT-adaptor primer. Quantitative RT-PCR was carried 
out using a miRNA-specific forward primer and universal 
reverse primer. PCR products were subjected to dissociation 
curve and gel electrophoresis analyses to ensure that single, 
mature miRNA products were amplified. Data were normal- 5 
ized to ACTB levels. The forward primers for the miRNAs 
were as follows: miR-184 (5'-TGGACGGAGAACTGA-
TAAGGGT-3'); miR-221/222 (5'-AGCTACATCTGGC-
TACTGGGT-3'); miR-204/211 (5'-TTCCCTTTGTCATC-




TGAGGTAGTAGGTTGTATAGTT-3'). The reverse 
15 
primers were proprietary (Genecopoeia). The primers for 
ACTB were forward (5'-TGGATCAGCAAGCAGGAG-
TATG-3') and reverse (5'-GCATTTGCGGTGGACGAT-3'). 
Dot Blot (Immuno-Dot Binding). 
Increasing amounts of Alu RNA were spotted onto 20 
hybond-N+ positively charged nylon membrane (Amer-
sham) and UV cross-linked. After blocking, the membranes 
were incubated with mouse antibody against dsRNA (1: 1, 
000, clone J2) for 1 hat RT. The peroxidase-conjugated goat 
anti-mouse secondary antibody (1:5,000, Sigma) was used 25 
for 1 h at RT. After several washes, the signals were 
visualized by enhanced chemiluminescence (ECL plus, 
Amersham). In vitro transcribed dsRNAs of different length 
were used as positive controls. Transfer and ribosomal 




Tissues were homogenized in lysis buffer (1 0 mM Tris 
base, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 
1% Triton X-100, 0.5% NP-40, protease and phosphatase 
inhibitor cocktail (Roche)). Protein concentrations were 
determined using a Bradford assay kit (Bio-Rad) with 
bovine serum albumin as a standard. Proteins ( 40-100 flg) 
were run on 4-12% Novex Bis-Tris gels (Invitrogen). The 
transferred membranes were blocked for 1 h at RT and 
incubated with antibodies against DICERl (1:1,000, ref. 85; 
or 1:200, Santa Cruz Biotechnology) at 4° C. overnight. 
Protein loading was assessed by immunoblotting using an 
anti-Tubulin antibody (1: 1,000; Sigma-Aldrich). The sec-
ondary antibodies were used (1:5,000) for 1 h at RT. The 
signal was visualized by enhanced chemiluminescence 
(ECL Plus) and captured by VisionWorksLS Image Acqui-
sition and Analysis software (Version 6.7.2, UVP, LLC). 
Densitometry analysis was performed using ImageJ (NIH). 
The value of 1 was arbitrarily assigned for normal eye 
samples. 
DICERl Cleavage. 
The ability of DICERl to cleave Alu RNA was tested 
using Recombinant Human Dicer Enzyme Kit (Genlantis) 
according the manufacturer's instructions. The products of 
the digestion were purified for the in vivo injection using 
RNA Purification Colunm (Genlantis). 
Cell Culture. 
All cell lines were cultured at 37° C. and 5% C02 . 
Primary mouse RPE cells were isolated as previously 
described86 and grown in Dulbecco Modified Eagle Medium 
(DMEM) supplemented with 10% FBS and standard anti-
biotics concentrations. Primary human RPE cells were iso-
lated as previously described87 and maintained in DMEM 
supplemented with 20% FBS and antibiotics. Parental 
Total RNA from normal and diseased macular RPE was 
extracted as described above using Trizol. RNA integrity 
and quality was assessed using 1% agarose gel electropho-
resis and RNA concentrations and purity were determined 
for each sample by NanoDrop 1000 spectrophotometer V3.7 
(Thermo Fisher Scientific). dsRNA (2 flg) was separated on 
denaturing 15% PAGE-urea ready gel (Bio-Rad), and total 
RNA (10 flg) was separated by size on 1% agarose, 0.7M 
formaldehyde gels and visualized on an ultraviolet transil-
luminator to ensure consistent loading between different 
groups and to record the distance of migration of the ISS and 
28S rRNA bands. dsRNA ladder (21-500 bp, New England 
BioLabs) and RNA ladder (0.1-2 kb, Invitrogen) were used 
as markers. Gels were then transferred to a positively 
charged Nylon membrane (Hybond-N+, GE Healthcare Bio-
Sciences) by vacuum blotting apparatus (VacuGene XL 
Vacuum Blotting System, GE Healthcare Bio-Sciences ). 
The RNAs were crosslinked to the membranes by ultraviolet 
irradiation and baked at 80° C. for 20-30 min. Membranes 
were hybridized with (a-32P)-dCTP-labeled DNAAlu probe 
35 HCT116 and isogenic Dicerx5 cells25 were cultured m 
McCoy's SA medium supplemented with 10% FBS. 
at 42° C. overnight. On the following day, the membranes 
were rinsed twice with lxSSC, 0.1% SDS at 55° C. Each 
wash was for 20 min, and then membranes were subjected 
to storage in a phosphor autoradiography cassette. Hybrid-
ization signals were determined by using Typhoon phospho-
rimager (GE Healthcare Bio-Sciences). The 7SL probe was 
synthesized by PCR amplification of a 7SL RNA plasmid77 • 
Transient Transfection. 
Human and mouse RPE cells were transfected with 
pUC19, pAlu, pCDNA3.1/Dicerl-FLAG, pCDNA3.1, 
40 DICERl antisense oligonucleotide (as) (5'-GCUGAC-
CTTTTTGCTUCUCA-3'), Bl/B2 as (5'-TCAGATCTCGT-
TACGGATGGTTGTGA-3'), control (for DICERl and 
Bl/B2) as (5'-TTGGTACGCATACGTGTTGACTGTGA-
3'), Alu as (5'-CCCGGGTTCACGCCATTCTCCTGC-
45 CTCAGCCTCACGAGTAGCTGGGACTACAGGCGC 
CCGACACCACTCCCGGCTAATTTTTTGTATTTTT-3'), 
control (for Alu) as (5'-GCATGGCCAGTCCATTGATCT-
TGCACGCTTGCCTAGTACGCTCCTCAACCTATC-
CTCC TAGCCCGTTACTTGGTGCCACCGGCG-3') using 
50 Lipofectamine 2000 (Invitrogen) or Oligofectamine (Invit-
rogen) according to the manufacturer's instructions. 
Adenoviral Infection. 
Cells were plated at density of 15xl03/cm2 and after 16 h, 
at approximately 50% confluence, were infected withAdCre 
55 or AdNull (Vector Laboratories) with a multiplicity of 
infection of 1 ,000. 
RNA Polymerase Inhibition. 
84 with the following primers (forward 5'-ATCGGGTGTC- 60 
CGCACTAAG-3' and reverse 5'-ATCAG-
CACGGGAGTTTTGAC-3') designed to amplifY a 128-bp 
fragment within the S-region that is not contained in Alu. 
For visualization of U6, membranes were stripped and 
blotted again using the High Sensitive MiRNA Northern 65 
Blot Assay Kit (Signosis) according to the manufacturer's 
Human RPE cells were transfected with DICERl or 
control antisense oligonucleotides using Lipofectamine 
2000. After a change of medium at 6 h, the cells were 
incubated with 45 f.LM tagetitoxin (Epicentre Technologies, 
Tagetin) or 10 flg/ml a-amanitin (Sigma-Aldrich) and the 
total RNA was collected after 24 h. 
Cell Viability. 
MTS assays were performed using the CellTiter 96 A 
Queous One Solution Cell Proliferation Assay (Prom ega) in 
according to the manufacturer's instructions. instructions. 
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Caspase-3 Activity. 
Sub-confluent human RPE cells were treated with PBS or 
Alu RNA at different concentrations in 2% FBS medium for 
8 h. The caspase-3 activity was measured using Caspase-3 
Fluorimetric Assay (R&D Systems) according to the manu- 5 
facturer's instructions. 
Oxidative Stress. 
Confluent human RPE cells were exposed to hydrogen 
peroxide (0-2 mM, Fisher Scientific). 
Statistics. 
Results are expressed as mean±SEM, with P<0.05 con-
sidered statistically significant. Differences between groups 
were compared by using Mann-Whitney U test or Student t 
test, as appropriate, and 2-tailed P values are reported. 
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Throughout this document, various references are men- 15 
tioned. All such references are incorporated herein by ref-
erence, including the references set forth in the following 
list: 
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106, 498-502 (2009). 
17. O'Carroll, D. eta!. A Slicer-independent role for Argo-
naute 2 in hematopoiesis and the microRNA pathway. 
Genes Dev 21, 1999-2004 (2007). 
18. Chong, M. M. et a!. Canonical and alternate functions of 
the microRNA biogenesis machinery. Genes Dev 24, 
1951-1960 (2010). 
19. Babiarz, J. E., Ruby, J. G., Wang, Y., Bartel, D. P. & 
Blelloch, R. Mouse ES cells express endogenous shR-
NAs, siRNAs, and other Microprocessor-independent, 
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expressing neurons regulates cocaine addiction. J Exp 
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ctcagcctca cgagtagct 
<210> SEQ ID NO 2 
<211> LENGTH, 19 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
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<400> SEQUENCE, 2 
tgggactaca ggcgcccga 
<210> SEQ ID NO 3 
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gcctcagcct cacgagtagc t 
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<213> ORGANISM, Artificial Sequence 
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<223> OTHER INFORMATION, siRNA 
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<400> SEQUENCE, 4 
gctgggacta caggcgcccg a 21 
<210> SEQ ID NO 5 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, siRNA 
<400> SEQUENCE, 5 
gggactacag gcgcccgaca c 21 
<210> SEQ ID NO 6 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, siRNA 
<400> SEQUENCE, 
acaggcgccc gacaccactc c 21 
<210> SEQ ID NO 7 
<211> LENGTH, 10323 
<212> TYPE, DNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 7 
cggaggcgcg gcgcaggctg ctgcaggccc aggtgaatgg agtaacctga cagcggggac 60 
gaggcgacgg cgagcgcgag gaaatggcgg cgggggcggc ggcgccgggc ggctccggga 120 
ggcctgggct gtgacgcgcg cgccggagcg gggtccgatg gttctcgaag gcccgcggcg 180 
ccccgtgctg cagtaagctg tgctagaaca aaaatgcaat gaaagaaaca ctggatgaat 240 
gaaaagccct gctttgcaac ccctcagcat ggcaggcctg cagctcatga cccctgcttc 300 
ctcaccaatg ggtcctttct ttggactgcc atggcaacaa gaagcaattc atgataacat 360 
ttatacgcca agaaaatatc aggttgaact gcttgaagca gctctggatc ataataccat 420 
cgtctgttta aacactggct cagggaagac atttattgca gtactactca ctaaagagct 480 
gtcctatcag atcaggggag acttcagcag aaatggaaaa aggacggtgt tcttggtcaa 540 
ctctgcaaac caggttgctc aacaagtgtc agctgtcaga actcattcag atctcaaggt 600 
tggggaatac tcaaacctag aagtaaatgc atcttggaca aaagagagat ggaaccaaga 660 
gtttactaag caccaggttc tcattatgac ttgctatgtc gccttgaatg ttttgaaaaa 720 
tggttactta tcactgtcag acattaacct tttggtgttt gatgagtgtc atcttgcaat 780 
cctagaccac ccctatcgag aaattatgaa gctctgtgaa aattgtccat catgtcctcg 840 
cattttggga ctaactgctt ccattttaaa tgggaaatgt gatccagagg aattggaaga 900 
aaagattcag aaactagaga aaattcttaa gagtaatgct gaaactgcaa ctgacctggt 960 
ggtcttagac aggtatactt ctcagccatg tgagattgtg gtggattgtg gaccatttac 1020 
tgacagaagt gggctttatg aaagactgct gatggaatta gaagaagcac ttaattttat 1080 
caatgattgt aatatatctg tacattcaaa agaaagagat tctactttaa tttcgaaaca 1140 
gatactatca gactgtcgtg ccgtattggt agttctggga ccctggtgtg cagataaagt 1200 
agctggaatg atggtaagag aactacagaa atacatcaaa catgagcaag aggagctgca 1260 
caggaaattt ttattgttta cagacacttt cctaaggaaa atacatgcac tatgtgaaga 1320 
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gcacttctca cctgcctcac ttgacctgaa atttgtaact cctaaagtaa tcaaactgct 
cgaaatctta cgcaaatata aaccatatga gcgacagcag tttgaaagcg ttgagtggta 
taataataga aatcaggata attatgtgtc atggagtgat tctgaggatg atgatgagga 
tgaagaaatt gaagaaaaag agaagccaga gacaaatttt ccttctcctt ttaccaacat 
tttgtgcgga attatttttg tggaaagaag atacacagca gttgtcttaa acagattgat 
aaaggaagct ggcaaacaag atccagagct ggcttatatc agtagcaatt tcataactgg 
acatggcatt gggaagaatc agcctcgcaa caaacagatg gaagcagaat tcagaaaaca 
ggaagaggta cttaggaaat ttcgagcaca tgagaccaac ctgcttattg caacaagtat 
tgtagaagag ggtgttgata taccaaaatg caacttggtg gttcgttttg atttgcccac 
agaatatcga tcctatgttc aatctaaagg aagagcaagg gcacccatct ctaattatat 
aatgttagcg gatacagaca aaataaaaag ttttgaagaa gaccttaaaa cctacaaagc 
tattgaaaag atcttgagaa acaagtgttc caagtcggtt gatactggtg agactgacat 
tgatcctgtc atggatgatg atgacgtttt cccaccatat gtgttgaggc ctgacgatgg 
tggtccacga gtcacaatca acacggccat tggacacatc aatagatact gtgctagatt 
accaagtgat ccgtttactc atctagctcc taaatgcaga acccgagagt tgcctgatgg 
tacattttat tcaactcttt atctgccaat taactcacct cttcgagcct ccattgttgg 
tccaccaatg agctgtgtac gattggctga aagagttgta gctctcattt gctgtgagaa 
actgcacaaa attggcgaac tggatgacca tttgatgcca gttgggaaag agactgttaa 
atatgaagag gagcttgatt tgcatgatga agaagagacc agtgttccag gaagaccagg 
ttccacgaaa cgaaggcagt gctacccaaa agcaattcca gagtgtttga gggatagtta 
tcccagacct gatcagccct gttacctgta tgtgatagga atggttttaa ctacaccttt 
acctgatgaa ctcaacttta gaaggcggaa gctctatcct cctgaagata ccacaagatg 
ctttggaata ctgacggcca aacccatacc tcagattcca cactttcctg tgtacacacg 
ctctggagag gttaccatat ccattgagtt gaagaagtct ggtttcatgt tgtctctaca 
aatgcttgag ttgattacaa gacttcacca gtatatattc tcacatattc ttcggcttga 
aaaacctgca ctagaattta aacctacaga cgctgattca gcatactgtg ttctacctct 
taatgttgtt aatgactcca gcactttgga tattgacttt aaattcatgg aagatattga 
gaagtctgaa gctcgcatag gcattcccag tacaaagtat acaaaagaaa caccctttgt 
ttttaaatta gaagattacc aagatgccgt tatcattcca agatatcgca attttgatca 
gcctcatcga ttttatgtag ctgatgtgta cactgatctt accccactca gtaaatttcc 
ttcccctgag tatgaaactt ttgcagaata ttataaaaca aagtacaacc ttgacctaac 
caatctcaac cagccactgc tggatgtgga ccacacatct tcaagactta atcttttgac 
acctcgacat ttgaatcaga aggggaaagc gcttccttta agcagtgctg agaagaggaa 
agccaaatgg gaaagtctgc agaataaaca gatactggtt ccagaactct gtgctataca 
tccaattcca gcatcactgt ggagaaaagc tgtttgtctc cccagcatac tttatcgcct 
tcactgcctt ttgactgcag aggagctaag agcccagact gccagcgatg ctggcgtggg 
agtcagatca cttcctgcgg attttagata ccctaactta gacttcgggt ggaaaaaatc 
tattgacagc aaatctttca tctcaatttc taactcctct tcagctgaaa atgataatta 
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ctctctagaa aatcatgacc aaatgtctgt gaactgcaga acgttgctca gcgagtcccc 
tggtaagctc cacgttgaag tttcagcaga tcttacagca attaatggtc tttcttacaa 
tcaaaatctc gccaatggca gttatgattt agctaacaga gacttttgcc aaggaaatca 
gctaaattac tacaagcagg aaatacccgt gcaaccaact acctcatatt ccattcagaa 
tttatacagt tacgagaacc agccccagcc cagcgatgaa tgtactctcc tgagtaataa 
ataccttgat ggaaatgcta acaaatctac ctcagatgga agtcctgtga tggccgtaat 
gcctggtacg acagacacta ttcaagtgct caagggcagg atggattctg agcagagccc 
ttctattggg tactcctcaa ggactcttgg ccccaatcct ggacttattc ttcaggcttt 
gactctgtca aacgctagtg atggatttaa cctggagcgg cttgaaatgc ttggcgactc 
ctttttaaag catgccatca ccacatatct attttgcact taccctgatg cgcatgaggg 
ccgcctttca tatatgagaa gcaaaaaggt cagcaactgt aatctgtatc gccttggaaa 
aaagaaggga ctacccagcc gcatggtggt gtcaatattt gatccccctg tgaattggct 
tcctcctggt tatgtagtaa atcaagacaa aagcaacaca gataaatggg aaaaagatga 
aatgacaaaa gactgcatgc tggcgaatgg caaactggat gaggattacg aggaggagga 
tgaggaggag gagagcctga tgtggagggc tccgaaggaa gaggctgact atgaagatga 
tttcctggag tatgatcagg aacatatcag atttatagat aatatgttaa tggggtcagg 
agcttttgta aagaaaatct ctctttctcc tttttcaacc actgattctg catatgaatg 
gaaaatgccc aaaaaatcct ccttaggtag tatgccattt tcatcagatt ttgaggattt 
tgactacagc tcttgggatg caatgtgcta tctggatcct agcaaagctg ttgaagaaga 
tgactttgtg gtggggttct ggaatccatc agaagaaaac tgtggtgttg acacgggaaa 
gcagtccatt tcttacgact tgcacactga gcagtgtatt gctgacaaaa gcatagcgga 
ctgtgtggaa gccctgctgg gctgctattt aaccagctgt ggggagaggg ctgctcagct 
tttcctctgt tcactggggc tgaaggtgct cccggtaatt aaaaggactg atcgggaaaa 
ggccctgtgc cctactcggg agaatttcaa cagccaacaa aagaaccttt cagtgagctg 
tgctgctgct tctgtggcca gttcacgctc ttctgtattg aaagactcgg aatatggttg 
tttgaagatt ccaccaagat gtatgtttga tcatccagat gcagataaaa cactgaatca 
ccttatatcg gggtttgaaa attttgaaaa gaaaatcaac tacagattca agaataaggc 
ttaccttctc caggctttta cacatgcctc ctaccactac aatactatca ctgattgtta 
ccagcgctta gaattcctgg gagatgcgat tttggactac ctcataacca agcaccttta 
tgaagacccg cggcagcact ccccgggggt cctgacagac ctgcggtctg ccctggtcaa 
caacaccatc tttgcatcgc tggctgtaaa gtacgactac cacaagtact tcaaagctgt 
ctctcctgag ctcttccatg tcattgatga ctttgtgcag tttcagcttg agaagaatga 
aatgcaagga atggattctg agcttaggag atctgaggag gatgaagaga aagaagagga 
tattgaagtt ccaaaggcca tgggggatat ttttgagtcg cttgctggtg ccatttacat 
ggatagtggg atgtcactgg agacagtctg gcaggtgtac tatcccatga tgcggccact 
aatagaaaag ttttctgcaa atgtaccccg ttcccctgtg cgagaattgc ttgaaatgga 
accagaaact gccaaattta gcccggctga gagaacttac gacgggaagg tcagagtcac 
tgtggaagta gtaggaaagg ggaaatttaa aggtgttggt cgaagttaca ggattgccaa 
atctgcagca gcaagaagag ccctccgaag cctcaaagct aatcaacctc aggttcccaa 
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aattatttaa atcggaaagg aagacttaaa gttgttagtg agtggaatga attgaaggca 
gaatttaaag tttggttgat aacaggatag ataacagaat aaaacattta acatatgtat 
aaaattttgg aactaattgt agttttagtt ttttgcgcaa acacaatctt atcttctttc 
ctcacttctg ctttgtttaa atcacaagag tgctttaatg atgacattta gcaagtgctc 
aaaataattg acaggttttg tttttttttt tttgagttta tgtcagcttt gcttagtgtt 
agaaggccat ggagcttaaa cctccagcag tccctaggat gatgtagatt cttctccatc 
tctccgtgtg tgcagtagtg ccagtcctgc agtagttgat aagctgaata gaaagataag 
gttttcgaga ggagaagtgc gccaatgttg tcttttcttt ccacgttata ctgtgtaagg 
tgatgttccc ggtcgctgtt gcacctgata gtaagggaca gatttttaat gaacattggc 
tggcatgttg gtgaatcaca ttttagtttt ctgatgccac atagtcttgc ataaaaaagg 
gttcttgcct taaaagtgaa accttcatgg atagtcttta atctctgatc tttttggaac 
aaactgtttt acattccttt cattttatta tgcattagac gttgagacag cgtgatactt 
acaactcact agtatagttg taacttatta caggatcata ctaaaatttc tgtcatatgt 
atactgaaga cattttaaaa accagaatat gtagtctacg gatatttttt atcataaaaa 
tgatctttgg ctaaacaccc cattttacta aagtcctcct gccaggtagt tcccactgat 
ggaaatgttt atggcaaata attttgcctt ctaggctgtt gctctaacaa aataaacctt 
agacatatca cacctaaaat atgctgcaga ttttataatt gattggttac ttatttaaga 
agcaaaacac agcaccttta cccttagtct cctcacataa atttcttact atacttttca 
taatgttgca tgcatatttc acctaccaaa gctgtgctgt taatgccgtg aaagtttaac 
gtttgcgata aactgccgta attttgatac atctgtgatt taggtcatta atttagataa 
actagctcat tatttccatc tttggaaaag gaaaaaaaaa aaaacttctt taggcatttg 
cctaagtttc tttaattaga cttgtaggca ctcttcactt aaatacctca gttcttcttt 
tcttttgcat gcatttttcc cctgtttggt gctatgttta tgtattatgc ttgaaatttt 
aatttttttt tttttgcact gtaactataa tacctcttaa tttacctttt taaaagctgt 
gggtcagtct tgcactccca tcaacatacc agtagaggtt tgctgcaatt tgccccgtta 
attatgcttg aagtttaaga aagctgagca gaggtgtctc atatttccca gcacatgatt 
ctgaacttga tgcttcgtgg aatgctgcat ttatatgtaa gtgacatttg aatactgtcc 
ttcctgcttt atctgcatca tccacccaca gagaaatgcc tctgtgcgag tgcaccgaca 
gaaaactgtc agctctgctt tctaaggaac cctgagtgag gggggtatta agcttctcca 
gtgttttttg ttgtctccaa tcttaaactt aaattgagat ctaaattatt aaacgagttt 
ttgagcaaat taggtgactt gttttaaaaa tatttaattc cgatttggaa ccttagatgt 
ctatttgatt ttttaaaaaa ccttaatgta agatatgacc agttaaaaca aagcaattct 
tgaattatat aactgtaaaa gtgtgcagtt aacaaggctg gatgtgaatt ttattctgag 
ggtgatttgt gatcaagttt aatcacaaat ctcttaatat ttataaacta cctgatgcca 
ggagcttagg gctttgcatt gtgtctaata cattgatccc agtgttacgg gattctcttg 
attcctggca ccaaaatcag attgttttca cagttatgat tcccagtggg agaaaaatgc 
ctcaatatat ttgtaacctt aagaagagta tttttttgtt aatactaaga tgttcaaact 
tagacatgat taggtcatac attctcaggg gttcaaattt ccttctacca ttcaaatgtt 
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ttgactcaca gtttgaagca ttctgtgatc ccctggttac tgagttaaaa aataaaaaag 8460 
tacgagttag acatatgaaa tggttatgaa cgcttttgtg ctgctgattt ttaatgctgt 8520 
aaagttttcc tgtgtttagc ttgttgaaat gttttgcatc tgtcaattaa ggaaaaaaaa 8580 
aatcactcta tgttgcccca ctttagagcc ctgtgtgcca ccctgtgttc ctgtgattgc 8640 
aatgtgagac cgaatgtaat atggaaaacc taccagtggg gtgtggttgt gccctgagca 8700 
cgtgtgtaaa ggactgggga ggcgtgtctt gaaaaagcaa ctgcagaaat tccttatgat 8760 
gattgtgtgc aagttagtta acatgaacct tcatttgtaa attttttaaa atttctttta 8820 
taatatgctt tccgcagtcc taactatgct gcgttttata atagcttttt cccttctgtt 8880 
ctgttcatgt agcacagata agcattgcac ttggtaccat gctttacctc atttcaagaa 8940 
aatatgctta acagagagga aaaaaatgtg gtttggcctt gctgctgttt tgatttatgg 9000 
aatttgaaaa agataattat aatgcctgca atgtgtcata tactcgcaca acttaaatag 9060 
gtcatttttg tctgtggcat ttttactgtt tgtgaaagta tgaaacagat ttgttaactg 9120 
aactcttaat tatgttttta aaatgtttgt tatatttctt ttcttttttc ttttatatta 9180 
cgtgaagtga tgaaatttag aatgacctct aacactcctg taattgtctt ttaaaatact 9240 
gatattttta tttgttaata atactttgcc ctcagaaaga ttctgatacc ctgccttgac 9300 
aacatgaaac ttgaggctgc tttggttcat gaatccaggt gttcccccgg cagtcggctt 9360 
cttcagtcgc tccctggagg caggtgggca ctgcagagga tcactggaat ccagatcgag 9420 
cgcagttcat gcacaaggcc ccgttgattt aaaatattgg atcttgctct gttagggtgt 9480 
ctaatccctt tacacaagat tgaagccacc aaactgagac cttgatacct ttttttaact 9540 
gcatctgaaa ttatgttaag agtctttaac ccatttgcat tatctgcaga agagaaactc 9600 
atgtcatgtt tattacctat atggttgttt taattacatt tgaataatta tatttttcca 9660 
accactgatt acttttcagg aatttaatta tttccagata aatttcttta ttttatattg 9720 
tacatgaaaa gttttaaaga tatgtttaag accaagacta ttaaaatgat ttttaaagtt 9780 
gttggagacg ccaatagcaa tatctaggaa atttgcattg agaccattgt attttccact 9840 
agcagtgaaa atgatttttc acaactaact tgtaaatata ttttaatcat tacttctttt 9900 
tttctagtcc atttttattt ggacatcaac cacagacaat ttaaatttta tagatgcact 9960 
aagaattcac tgcagcagca ggttacatag caaaaatgca aaggtgaaca ggaagtaaat 10020 
ttctggcttt tctgctgtaa atagtgaagg aaaattacta aaatcaagta aaactaatgc 10080 
atattatttg attgacaata aaatatttac catcacatgc tgcagctgtt ttttaaggaa 10140 
catgatgtca ttcattcata cagtaatcat gctgcagaaa tttgcagtct gcaccttatg 10200 
gatcacaatt acctttagtt gttttttttg taataattgt agccaagtaa atctccaata 10260 
aagttatcgt ctgttcaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 10320 
aaa 10323 
<210> SEQ ID NO 8 
<211> LENGTH, 10220 
<212> TYPE, DNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 8 
ggaaactctg aaagaactta gaatcagcat tttgagagca gaagcttggg catgctgtga 60 
ttttccaata aactgctatc acaatgtcaa aatgcagttc agacaagagc aacacagaga 120 
tctcaaacat taaaacgtaa gctgtgctag aacaaaaatg caatgaaaga aacactggat 180 
44 
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gaatgaaaag ccctgctttg caacccctca gcatggcagg cctgcagctc atgacccctg 
cttcctcacc aatgggtcct ttctttggac tgccatggca acaagaagca attcatgata 
acatttatac gccaagaaaa tatcaggttg aactgcttga agcagctctg gatcataata 
ccatcgtctg tttaaacact ggctcaggga agacatttat tgcagtacta ctcactaaag 
agctgtccta tcagatcagg ggagacttca gcagaaatgg aaaaaggacg gtgttcttgg 
tcaactctgc aaaccaggtt gctcaacaag tgtcagctgt cagaactcat tcagatctca 
aggttgggga atactcaaac ctagaagtaa atgcatcttg gacaaaagag agatggaacc 
aagagtttac taagcaccag gttctcatta tgacttgcta tgtcgccttg aatgttttga 
aaaatggtta cttatcactg tcagacatta accttttggt gtttgatgag tgtcatcttg 
caatcctaga ccacccctat cgagaaatta tgaagctctg tgaaaattgt ccatcatgtc 
ctcgcatttt gggactaact gcttccattt taaatgggaa atgtgatcca gaggaattgg 
aagaaaagat tcagaaacta gagaaaattc ttaagagtaa tgctgaaact gcaactgacc 
tggtggtctt agacaggtat acttctcagc catgtgagat tgtggtggat tgtggaccat 
ttactgacag aagtgggctt tatgaaagac tgctgatgga attagaagaa gcacttaatt 
ttatcaatga ttgtaatata tctgtacatt caaaagaaag agattctact ttaatttcga 
aacagatact atcagactgt cgtgccgtat tggtagttct gggaccctgg tgtgcagata 
aagtagctgg aatgatggta agagaactac agaaatacat caaacatgag caagaggagc 
tgcacaggaa atttttattg tttacagaca ctttcctaag gaaaatacat gcactatgtg 
aagagcactt ctcacctgcc tcacttgacc tgaaatttgt aactcctaaa gtaatcaaac 
tgctcgaaat cttacgcaaa tataaaccat atgagcgaca gcagtttgaa agcgttgagt 
ggtataataa tagaaatcag gataattatg tgtcatggag tgattctgag gatgatgatg 
aggatgaaga aattgaagaa aaagagaagc cagagacaaa ttttccttct ccttttacca 
acattttgtg cggaattatt tttgtggaaa gaagatacac agcagttgtc ttaaacagat 
tgataaagga agctggcaaa caagatccag agctggctta tatcagtagc aatttcataa 
ctggacatgg cattgggaag aatcagcctc gcaacaaaca gatggaagca gaattcagaa 
aacaggaaga ggtacttagg aaatttcgag cacatgagac caacctgctt attgcaacaa 
gtattgtaga agagggtgtt gatataccaa aatgcaactt ggtggttcgt tttgatttgc 
ccacagaata tcgatcctat gttcaatcta aaggaagagc aagggcaccc atctctaatt 
atataatgtt agcggataca gacaaaataa aaagttttga agaagacctt aaaacctaca 
aagctattga aaagatcttg agaaacaagt gttccaagtc ggttgatact ggtgagactg 
acattgatcc tgtcatggat gatgatgacg ttttcccacc atatgtgttg aggcctgacg 
atggtggtcc acgagtcaca atcaacacgg ccattggaca catcaataga tactgtgcta 
gattaccaag tgatccgttt actcatctag ctcctaaatg cagaacccga gagttgcctg 
atggtacatt ttattcaact ctttatctgc caattaactc acctcttcga gcctccattg 
ttggtccacc aatgagctgt gtacgattgg ctgaaagagt tgtagctctc atttgctgtg 
agaaactgca caaaattggc gaactggatg accatttgat gccagttggg aaagagactg 
ttaaatatga agaggagctt gatttgcatg atgaagaaga gaccagtgtt ccaggaagac 
caggttccac gaaacgaagg cagtgctacc caaaagcaat tccagagtgt ttgagggata 
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ctttacctga tgaactcaac tttagaaggc ggaagctcta tcctcctgaa gataccacaa 
gatgctttgg aatactgacg gccaaaccca tacctcagat tccacacttt cctgtgtaca 
cacgctctgg agaggttacc atatccattg agttgaagaa gtctggtttc atgttgtctc 
tacaaatgct tgagttgatt acaagacttc accagtatat attctcacat attcttcggc 
ttgaaaaacc tgcactagaa tttaaaccta cagacgctga ttcagcatac tgtgttctac 
ctcttaatgt tgttaatgac tccagcactt tggatattga ctttaaattc atggaagata 
ttgagaagtc tgaagctcgc ataggcattc ccagtacaaa gtatacaaaa gaaacaccct 
ttgtttttaa attagaagat taccaagatg ccgttatcat tccaagatat cgcaattttg 
atcagcctca tcgattttat gtagctgatg tgtacactga tcttacccca ctcagtaaat 
ttccttcccc tgagtatgaa acttttgcag aatattataa aacaaagtac aaccttgacc 
taaccaatct caaccagcca ctgctggatg tggaccacac atcttcaaga cttaatcttt 
tgacacctcg acatttgaat cagaagggga aagcgcttcc tttaagcagt gctgagaaga 
ggaaagccaa atgggaaagt ctgcagaata aacagatact ggttccagaa ctctgtgcta 
tacatccaat tccagcatca ctgtggagaa aagctgtttg tctccccagc atactttatc 
gccttcactg ccttttgact gcagaggagc taagagccca gactgccagc gatgctggcg 
tgggagtcag atcacttcct gcggatttta gataccctaa cttagacttc gggtggaaaa 
aatctattga cagcaaatct ttcatctcaa tttctaactc ctcttcagct gaaaatgata 
attactgtaa gcacagcaca attgtccctg aaaatgctgc acatcaaggt gctaatagaa 
cctcctctct agaaaatcat gaccaaatgt ctgtgaactg cagaacgttg ctcagcgagt 
cccctggtaa gctccacgtt gaagtttcag cagatcttac agcaattaat ggtctttctt 
acaatcaaaa tctcgccaat ggcagttatg atttagctaa cagagacttt tgccaaggaa 
atcagctaaa ttactacaag caggaaatac ccgtgcaacc aactacctca tattccattc 
agaatttata cagttacgag aaccagcccc agcccagcga tgaatgtact ctcctgagta 
ataaatacct tgatggaaat gctaacaaat ctacctcaga tggaagtcct gtgatggccg 
taatgcctgg tacgacagac actattcaag tgctcaaggg caggatggat tctgagcaga 
gcccttctat tgggtactcc tcaaggactc ttggccccaa tcctggactt attcttcagg 
ctttgactct gtcaaacgct agtgatggat ttaacctgga gcggcttgaa atgcttggcg 
actccttttt aaagcatgcc atcaccacat atctattttg cacttaccct gatgcgcatg 
agggccgcct ttcatatatg agaagcaaaa aggtcagcaa ctgtaatctg tatcgccttg 
gaaaaaagaa gggactaccc agccgcatgg tggtgtcaat atttgatccc cctgtgaatt 
ggcttcctcc tggttatgta gtaaatcaag acaaaagcaa cacagataaa tgggaaaaag 
atgaaatgac aaaagactgc atgctggcga atggcaaact ggatgaggat tacgaggagg 
aggatgagga ggaggagagc ctgatgtgga gggctccgaa ggaagaggct gactatgaag 
atgatttcct ggagtatgat caggaacata tcagatttat agataatatg ttaatggggt 
caggagcttt tgtaaagaaa atctctcttt ctcctttttc aaccactgat tctgcatatg 
aatggaaaat gcccaaaaaa tcctccttag gtagtatgcc attttcatca gattttgagg 
attttgacta cagctcttgg gatgcaatgt gctatctgga tcctagcaaa gctgttgaag 
aagatgactt tgtggtgggg ttctggaatc catcagaaga aaactgtggt gttgacacgg 
gaaagcagtc catttcttac gacttgcaca ctgagcagtg tattgctgac aaaagcatag 
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agcttttcct ctgttcactg gggctgaagg tgctcccggt aattaaaagg actgatcggg 
aaaaggccct gtgccctact cgggagaatt tcaacagcca acaaaagaac ctttcagtga 
gctgtgctgc tgcttctgtg gccagttcac gctcttctgt attgaaagac tcggaatatg 
gttgtttgaa gattccacca agatgtatgt ttgatcatcc agatgcagat aaaacactga 
atcaccttat atcggggttt gaaaattttg aaaagaaaat caactacaga ttcaagaata 
aggcttacct tctccaggct tttacacatg cctcctacca ctacaatact atcactgatt 
gttaccagcg cttagaattc ctgggagatg cgattttgga ctacctcata accaagcacc 
tttatgaaga cccgcggcag cactccccgg gggtcctgac agacctgcgg tctgccctgg 
tcaacaacac catctttgca tcgctggctg taaagtacga ctaccacaag tacttcaaag 
ctgtctctcc tgagctcttc catgtcattg atgactttgt gcagtttcag cttgagaaga 
atgaaatgca aggaatggat tctgagctta ggagatctga ggaggatgaa gagaaagaag 
aggatattga agttccaaag gccatggggg atatttttga gtcgcttgct ggtgccattt 
acatggatag tgggatgtca ctggagacag tctggcaggt gtactatccc atgatgcggc 
cactaataga aaagttttct gcaaatgtac cccgttcccc tgtgcgagaa ttgcttgaaa 
tggaaccaga aactgccaaa tttagcccgg ctgagagaac ttacgacggg aaggtcagag 
tcactgtgga agtagtagga aaggggaaat ttaaaggtgt tggtcgaagt tacaggattg 
ccaaatctgc agcagcaaga agagccctcc gaagcctcaa agctaatcaa cctcaggttc 
ccaatagctg aaaccgcttt ttaaaattca aaacaagaaa caaaacaaaa aaaattaagg 
ggaaaattat ttaaatcgga aaggaagact taaagttgtt agtgagtgga atgaattgaa 
ggcagaattt aaagtttggt tgataacagg atagataaca gaataaaaca tttaacatat 
gtataaaatt ttggaactaa ttgtagtttt agttttttgc gcaaacacaa tcttatcttc 
tttcctcact tctgctttgt ttaaatcaca agagtgcttt aatgatgaca tttagcaagt 
gctcaaaata attgacaggt tttgtttttt tttttttgag tttatgtcag ctttgcttag 
tgttagaagg ccatggagct taaacctcca gcagtcccta ggatgatgta gattcttctc 
catctctccg tgtgtgcagt agtgccagtc ctgcagtagt tgataagctg aatagaaaga 
taaggttttc gagaggagaa gtgcgccaat gttgtctttt ctttccacgt tatactgtgt 
aaggtgatgt tcccggtcgc tgttgcacct gatagtaagg gacagatttt taatgaacat 
tggctggcat gttggtgaat cacattttag ttttctgatg ccacatagtc ttgcataaaa 
aagggttctt gccttaaaag tgaaaccttc atggatagtc tttaatctct gatctttttg 
gaacaaactg ttttacattc ctttcatttt attatgcatt agacgttgag acagcgtgat 
acttacaact cactagtata gttgtaactt attacaggat catactaaaa tttctgtcat 
atgtatactg aagacatttt aaaaaccaga atatgtagtc tacggatatt ttttatcata 
aaaatgatct ttggctaaac accccatttt actaaagtcc tcctgccagg tagttcccac 
tgatggaaat gtttatggca aataattttg ccttctaggc tgttgctcta acaaaataaa 
ccttagacat atcacaccta aaatatgctg cagattttat aattgattgg ttacttattt 
aagaagcaaa acacagcacc tttaccctta gtctcctcac ataaatttct tactatactt 
ttcataatgt tgcatgcata tttcacctac caaagctgtg ctgttaatgc cgtgaaagtt 
taacgtttgc gataaactgc cgtaattttg atacatctgt gatttaggtc attaatttag 
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tttgcctaag tttctttaat tagacttgta ggcactcttc acttaaatac ctcagttctt 
cttttctttt gcatgcattt ttcccctgtt tggtgctatg tttatgtatt atgcttgaaa 
ttttaatttt tttttttttg cactgtaact ataatacctc ttaatttacc tttttaaaag 
ctgtgggtca gtcttgcact cccatcaaca taccagtaga ggtttgctgc aatttgcccc 
gttaattatg cttgaagttt aagaaagctg agcagaggtg tctcatattt cccagcacat 
gattctgaac ttgatgcttc gtggaatgct gcatttatat gtaagtgaca tttgaatact 
gtccttcctg ctttatctgc atcatccacc cacagagaaa tgcctctgtg cgagtgcacc 
gacagaaaac tgtcagctct gctttctaag gaaccctgag tgaggggggt attaagcttc 
tccagtgttt tttgttgtct ccaatcttaa acttaaattg agatctaaat tattaaacga 
gtttttgagc aaattaggtg acttgtttta aaaatattta attccgattt ggaaccttag 
atgtctattt gattttttaa aaaaccttaa tgtaagatat gaccagttaa aacaaagcaa 
ttcttgaatt atataactgt aaaagtgtgc agttaacaag gctggatgtg aattttattc 
tgagggtgat ttgtgatcaa gtttaatcac aaatctctta atatttataa actacctgat 
gccaggagct tagggctttg cattgtgtct aatacattga tcccagtgtt acgggattct 
cttgattcct ggcaccaaaa tcagattgtt ttcacagtta tgattcccag tgggagaaaa 
atgcctcaat atatttgtaa ccttaagaag agtatttttt tgttaatact aagatgttca 
aacttagaca tgattaggtc atacattctc aggggttcaa atttccttct accattcaaa 
tgttttatca acagcaaact tcagccgttt cactttttgt tggagaaaaa tagtagattt 
taatttgact cacagtttga agcattctgt gatcccctgg ttactgagtt aaaaaataaa 
aaagtacgag ttagacatat gaaatggtta tgaacgcttt tgtgctgctg atttttaatg 
ctgtaaagtt ttcctgtgtt tagcttgttg aaatgttttg catctgtcaa ttaaggaaaa 
aaaaaatcac tctatgttgc cccactttag agccctgtgt gccaccctgt gttcctgtga 
ttgcaatgtg agaccgaatg taatatggaa aacctaccag tggggtgtgg ttgtgccctg 
agcacgtgtg taaaggactg gggaggcgtg tcttgaaaaa gcaactgcag aaattcctta 
tgatgattgt gtgcaagtta gttaacatga accttcattt gtaaattttt taaaatttct 
tttataatat gctttccgca gtcctaacta tgctgcgttt tataatagct ttttcccttc 
tgttctgttc atgtagcaca gataagcatt gcacttggta ccatgcttta cctcatttca 
agaaaatatg cttaacagag aggaaaaaaa tgtggtttgg ccttgctgct gttttgattt 
atggaatttg aaaaagataa ttataatgcc tgcaatgtgt catatactcg cacaacttaa 
ataggtcatt tttgtctgtg gcatttttac tgtttgtgaa agtatgaaac agatttgtta 
actgaactct taattatgtt tttaaaatgt ttgttatatt tcttttcttt tttcttttat 
attacgtgaa gtgatgaaat ttagaatgac ctctaacact cctgtaattg tcttttaaaa 
tactgatatt tttatttgtt aataatactt tgccctcaga aagattctga taccctgcct 
tgacaacatg aaacttgagg ctgctttggt tcatgaatcc aggtgttccc ccggcagtcg 
gcttcttcag tcgctccctg gaggcaggtg ggcactgcag aggatcactg gaatccagat 
cgagcgcagt tcatgcacaa ggccccgttg atttaaaata ttggatcttg ctctgttagg 
gtgtctaatc cctttacaca agattgaagc caccaaactg agaccttgat accttttttt 
aactgcatct gaaattatgt taagagtctt taacccattt gcattatctg cagaagagaa 
actcatgtca tgtttattac ctatatggtt gttttaatta catttgaata attatatttt 
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attgtacatg aaaagtttta aagatatgtt taagaccaag actattaaaa tgatttttaa 9720 
agttgttgga gacgccaata gcaatatcta ggaaatttgc attgagacca ttgtattttc 9780 
cactagcagt gaaaatgatt tttcacaact aacttgtaaa tatattttaa tcattacttc 9840 
tttttttcta gtccattttt atttggacat caaccacaga caatttaaat tttatagatg 9900 
cactaagaat tcactgcagc agcaggttac atagcaaaaa tgcaaaggtg aacaggaagt 9960 
aaatttctgg cttttctgct gtaaatagtg aaggaaaatt actaaaatca agtaaaacta 10020 
atgcatatta tttgattgac aataaaatat ttaccatcac atgctgcagc tgttttttaa 10080 
ggaacatgat gtcattcatt catacagtaa tcatgctgca gaaatttgca gtctgcacct 10140 
tatggatcac aattaccttt agttgttttt tttgtaataa ttgtagccaa gtaaatctcc 10200 
aataaagtta tcgtctgttc 10220 
<210> SEQ ID NO 9 
<211> LENGTH, 1922 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 9 
Met Lys Ser Pro Ala Leu Gln Pro Leu Ser Met Ala Gly Leu Gln Leu 
1 5 10 15 
Met Thr Pro Ala Ser Ser Pro Met Gly Pro Phe Phe Gly Leu Pro Trp 
20 25 30 
Gln Gln Glu Ala Ile His Asp Asn Ile Tyr Thr Pro Arg Lys Tyr Gln 
35 40 45 
Val Glu Leu Leu Glu Ala Ala Leu Asp His Asn Thr Ile Val Cys Leu 
50 55 60 
Asn Thr Gly Ser Gly Lys Thr Phe Ile Ala Val Leu Leu Thr Lys Glu 
65 70 75 80 
Leu Ser Tyr Gln Ile Arg Gly Asp Phe Ser Arg Asn Gly Lys Arg Thr 
85 90 95 
Val Phe Leu Val Asn Ser Ala Asn Gln Val Ala Gln Gln Val Ser Ala 
100 105 110 
Val Arg Thr His Ser Asp Leu Lys Val Gly Glu Tyr Ser Asn Leu Glu 
115 120 125 
Val Asn Ala Ser Trp Thr Lys Glu Arg Trp Asn Gln Glu Phe Thr Lys 
130 135 140 
His Gln Val Leu Ile Met Thr Cys Tyr Val Ala Leu Asn Val Leu Lys 
145 150 155 160 
Asn Gly Tyr Leu Ser Leu Ser Asp Ile Asn Leu Leu Val Phe Asp Glu 
165 170 175 
Cys His Leu Ala Ile Leu Asp His Pro Tyr Arg Glu Ile Met Lys Leu 
180 185 190 
Cys Glu Asn Cys Pro Ser Cys Pro Arg Ile Leu Gly Leu Thr Ala Ser 
195 200 205 
Ile Leu Asn Gly Lys Cys Asp Pro Glu Glu Leu Glu Glu Lys Ile Gln 
210 215 220 
Lys Leu Glu Lys Ile Leu Lys Ser Asn Ala Glu Thr Ala Thr Asp Leu 
225 230 235 240 
Val Val Leu Asp Arg Tyr Thr Ser Gln Pro Cys Glu Ile Val Val Asp 
245 250 255 
Cys Gly Pro Phe Thr Asp Arg Ser Gly Leu Tyr Glu Arg Leu Leu Met 
260 265 270 
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Glu Leu Glu Glu Ala Leu Asn Phe Ile Asn Asp Cys Asn Ile Ser Val 
275 280 285 
His Ser Lys Glu Arg Asp Ser Thr Leu Ile Ser Lys Gln Ile Leu Ser 
290 295 300 
Asp Cys Arg Ala Val Leu Val Val Leu Gly Pro Trp Cys Ala Asp Lys 
305 310 315 320 
Val Ala Gly Met Met Val Arg Glu Leu Gln Lys Tyr Ile Lys His Glu 
325 330 335 
Gln Glu Glu Leu His Arg Lys Phe Leu Leu Phe Thr Asp Thr Phe Leu 
340 345 350 
Arg Lys Ile His Ala Leu Cys Glu Glu His Phe Ser Pro Ala Ser Leu 
355 360 365 
Asp Leu Lys Phe Val Thr Pro Lys Val Ile Lys Leu Leu Glu Ile Leu 
370 375 380 
Arg Lys Tyr Lys Pro Tyr Glu Arg Gln Gln Phe Glu Ser Val Glu Trp 
385 390 395 400 
Tyr Asn Asn Arg Asn Gln Asp Asn Tyr Val Ser Trp Ser Asp Ser Glu 
405 410 415 
Asp Asp Asp Glu Asp Glu Glu Ile Glu Glu Lys Glu Lys Pro Glu Thr 
420 425 430 
Asn Phe Pro Ser Pro Phe Thr Asn Ile Leu Cys Gly Ile Ile Phe Val 
435 440 445 
Glu Arg Arg Tyr Thr Ala Val Val Leu Asn Arg Leu Ile Lys Glu Ala 
450 455 460 
Gly Lys Gln Asp Pro Glu Leu Ala Tyr Ile Ser Ser Asn Phe Ile Thr 
465 470 475 480 
Gly His Gly Ile Gly Lys Asn Gln Pro Arg Asn Lys Gln Met Glu Ala 
485 490 495 
Glu Phe Arg Lys Gln Glu Glu Val Leu Arg Lys Phe Arg Ala His Glu 
500 505 510 
Thr Asn Leu Leu Ile Ala Thr Ser Ile Val Glu Glu Gly Val Asp Ile 
515 520 525 
Pro Lys Cys Asn Leu Val Val Arg Phe Asp Leu Pro Thr Glu Tyr Arg 
530 535 540 
Ser Tyr Val Gln Ser Lys Gly Arg Ala Arg Ala Pro Ile Ser Asn Tyr 
545 550 555 560 
Ile Met Leu Ala Asp Thr Asp Lys Ile Lys Ser Phe Glu Glu Asp Leu 
565 570 575 
Lys Thr Tyr Lys Ala Ile Glu Lys Ile Leu Arg Asn Lys Cys Ser Lys 
580 585 590 
Ser Val Asp Thr Gly Glu Thr Asp Ile Asp Pro Val Met Asp Asp Asp 
595 600 605 
Asp Val Phe Pro Pro Tyr Val Leu Arg Pro Asp Asp Gly Gly Pro Arg 
610 615 620 
Val Thr Ile Asn Thr Ala Ile Gly His Ile Asn Arg Tyr Cys Ala Arg 
625 630 635 640 
Leu Pro Ser Asp Pro Phe Thr His Leu Ala Pro Lys Cys Arg Thr Arg 
645 650 655 
Glu Leu Pro Asp Gly Thr Phe Tyr Ser Thr Leu Tyr Leu Pro Ile Asn 
660 665 670 
Ser Pro Leu Arg Ala Ser Ile Val Gly Pro Pro Met Ser Cys Val Arg 
675 680 685 
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Leu Ala Glu Arg Val Val Ala Leu Ile Cys Cys Glu Lys Leu His Lys 
690 695 700 
Ile Gly Glu Leu Asp Asp His Leu Met Pro Val Gly Lys Glu Thr Val 
705 710 715 720 
Lys Tyr Glu Glu Glu Leu Asp Leu His Asp Glu Glu Glu Thr Ser Val 
725 730 735 
Pro Gly Arg Pro Gly Ser Thr Lys Arg Arg Gln Cys Tyr Pro Lys Ala 
740 745 750 
Ile Pro Glu Cys Leu Arg Asp Ser Tyr Pro Arg Pro Asp Gln Pro Cys 
755 760 765 
Tyr Leu Tyr Val Ile Gly Met Val Leu Thr Thr Pro Leu Pro Asp Glu 
770 775 780 
Leu Asn Phe Arg Arg Arg Lys Leu Tyr Pro Pro Glu Asp Thr Thr Arg 
785 790 795 800 
Cys Phe Gly Ile Leu Thr Ala Lys Pro Ile Pro Gln Ile Pro His Phe 
805 810 815 
Pro Val Tyr Thr Arg Ser Gly Glu Val Thr Ile Ser Ile Glu Leu Lys 
820 825 830 
Lys Ser Gly Phe Met Leu Ser Leu Gln Met Leu Glu Leu Ile Thr Arg 
835 840 845 
Leu His Gln Tyr Ile Phe Ser His Ile Leu Arg Leu Glu Lys Pro Ala 
850 855 860 
Leu Glu Phe Lys Pro Thr Asp Ala Asp Ser Ala Tyr Cys Val Leu Pro 
865 870 875 880 
Leu Asn Val Val Asn Asp Ser Ser Thr Leu Asp Ile Asp Phe Lys Phe 
885 890 895 
Met Glu Asp Ile Glu Lys Ser Glu Ala Arg Ile Gly Ile Pro Ser Thr 
900 905 910 
Lys Tyr Thr Lys Glu Thr Pro Phe Val Phe Lys Leu Glu Asp Tyr Gln 
915 920 925 
Asp Ala Val Ile Ile Pro Arg Tyr Arg Asn Phe Asp Gln Pro His Arg 
930 935 940 
Phe Tyr Val Ala Asp Val Tyr Thr Asp Leu Thr Pro Leu Ser Lys Phe 
945 950 955 960 
Pro Ser Pro Glu Tyr Glu Thr Phe Ala Glu Tyr Tyr Lys Thr Lys Tyr 
965 970 975 
Asn Leu Asp Leu Thr Asn Leu Asn Gln Pro Leu Leu Asp Val Asp His 
980 985 990 
















Ala Leu Pro Leu Ser 
1015 
Ser Leu Gln Asn Lys 
1030 
His Pro Ile Pro Ala 
1045 
Ser Ile Leu Tyr Arg 
1060 
Arg Ala Gln Thr Ala 
1075 
Pro Ala Asp Phe Arg 
1090 
Ser Ile Asp Ser Lys 
Ser Ala Glu Lys Arg 
1020 
Gln Ile Leu Val Pro 
1035 
Ser Leu Trp Arg Lys 
1050 
Leu His Cys Leu Leu 
1065 
Ser Asp Ala Gly Val 
1080 
Tyr Pro Asn Leu Asp 
1095 
Ser Phe Ile Ser Ile 
Lys Ala Lys 
Glu Leu Cys 
Ala Val Cys 
Thr Ala Glu 
Gly Val Arg 
Phe Gly Trp 
Ser Asn Ser 
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1100 1105 1110 
Ser Ser Ala Glu Asn Asp Asn Tyr Cys Lys His Ser Thr Ile Val 
1115 1120 1125 
Pro Glu Asn Ala Ala His Gln Gly Ala Asn Arg Thr Ser Ser Leu 
1130 1135 1140 
Glu Asn His Asp Gln Met Ser Val Asn Cys Arg Thr Leu Leu Ser 
1145 1150 1155 
Glu Ser Pro Gly Lys Leu His Val Glu Val Ser Ala Asp Leu Thr 
1160 1165 1170 
Ala Ile Asn Gly Leu Ser Tyr Asn Gln Asn Leu Ala Asn Gly Ser 
1175 1180 1185 
Tyr Asp Leu Ala Asn Arg Asp Phe Cys Gln Gly Asn Gln Leu Asn 
1190 1195 1200 
Tyr Tyr Lys Gln Glu Ile Pro Val Gln Pro Thr Thr Ser Tyr Ser 
1205 1210 1215 
Ile Gln Asn Leu Tyr Ser Tyr Glu Asn Gln Pro Gln Pro Ser Asp 
1220 1225 1230 
Glu Cys Thr Leu Leu Ser Asn Lys Tyr Leu Asp Gly Asn Ala Asn 
1235 1240 1245 
Lys Ser Thr Ser Asp Gly Ser Pro Val Met Ala Val Met Pro Gly 
1250 1255 1260 
Thr Thr Asp Thr Ile Gln Val Leu Lys Gly Arg Met Asp Ser Glu 
1265 1270 1275 
Gln Ser Pro Ser Ile Gly Tyr Ser Ser Arg Thr Leu Gly Pro Asn 
1280 1285 1290 
Pro Gly Leu Ile Leu Gln Ala Leu Thr Leu Ser Asn Ala Ser Asp 
1295 1300 1305 
Gly Phe Asn Leu Glu Arg Leu Glu Met Leu Gly Asp Ser Phe Leu 
1310 1315 1320 
Lys His Ala Ile Thr Thr Tyr Leu Phe Cys Thr Tyr Pro Asp Ala 
1325 1330 1335 
His Glu Gly Arg Leu Ser Tyr Met Arg Ser Lys Lys Val Ser Asn 
1340 1345 1350 
Cys Asn Leu Tyr Arg Leu Gly Lys Lys Lys Gly Leu Pro Ser Arg 
1355 1360 1365 
Met Val Val Ser Ile Phe Asp Pro Pro Val Asn Trp Leu Pro Pro 
1370 1375 1380 
Gly Tyr Val Val Asn Gln Asp Lys Ser Asn Thr Asp Lys Trp Glu 
1385 1390 1395 
Lys Asp Glu Met Thr Lys Asp Cys Met Leu Ala Asn Gly Lys Leu 
1400 1405 1410 
Asp Glu Asp Tyr Glu Glu Glu Asp Glu Glu Glu Glu Ser Leu Met 
1415 1420 1425 
Trp Arg Ala Pro Lys Glu Glu Ala Asp Tyr Glu Asp Asp Phe Leu 
1430 1435 1440 
Glu Tyr Asp Gln Glu His Ile Arg Phe Ile Asp Asn Met Leu Met 
1445 1450 1455 
Gly Ser Gly Ala Phe Val Lys Lys Ile Ser Leu Ser Pro Phe Ser 
1460 1465 1470 
Thr Thr Asp Ser Ala Tyr Glu Trp Lys Met Pro Lys Lys Ser Ser 
1475 1480 1485 
Leu Gly Ser Met Pro Phe Ser Ser Asp Phe Glu Asp Phe Asp Tyr 
1490 1495 1500 
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Ser Ser Trp Asp Ala Met Cys Tyr Leu Asp Pro Ser Lys Ala Val 
1505 1510 1515 
Glu Glu Asp Asp Phe Val Val Gly Phe Trp Asn Pro Ser Glu Glu 
1520 1525 1530 
Asn Cys Gly Val Asp Thr Gly Lys Gln Ser Ile Ser Tyr Asp Leu 
1535 1540 1545 
His Thr Glu Gln Cys Ile Ala Asp Lys Ser Ile Ala Asp Cys Val 
1550 1555 1560 
Glu Ala Leu Leu Gly Cys Tyr Leu Thr Ser Cys Gly Glu Arg Ala 
1565 1570 1575 
Ala Gln Leu Phe Leu Cys Ser Leu Gly Leu Lys Val Leu Pro Val 
1580 1585 1590 
Ile Lys Arg Thr Asp Arg Glu Lys Ala Leu Cys Pro Thr Arg Glu 
1595 1600 1605 
Asn Phe Asn Ser Gln Gln Lys Asn Leu Ser Val Ser Cys Ala Ala 
1610 1615 1620 
Ala Ser Val Ala Ser Ser Arg Ser Ser Val Leu Lys Asp Ser Glu 
1625 1630 1635 
Tyr Gly Cys Leu Lys Ile Pro Pro Arg Cys Met Phe Asp His Pro 
1640 1645 1650 
Asp Ala Asp Lys Thr Leu Asn His Leu Ile Ser Gly Phe Glu Asn 
1655 1660 1665 
Phe Glu Lys Lys Ile Asn Tyr Arg Phe Lys Asn Lys Ala Tyr Leu 
1670 1675 1680 
Leu Gln Ala Phe Thr His Ala Ser Tyr His Tyr Asn Thr Ile Thr 
1685 1690 1695 
Asp Cys Tyr Gln Arg Leu Glu Phe Leu Gly Asp Ala Ile Leu Asp 
1700 1705 1710 
Tyr Leu Ile Thr Lys His Leu Tyr Glu Asp Pro Arg Gln His Ser 
1715 1720 1725 
Pro Gly Val Leu Thr Asp Leu Arg Ser Ala Leu Val Asn Asn Thr 
1730 1735 1740 
Ile Phe Ala Ser Leu Ala Val Lys Tyr Asp Tyr His Lys Tyr Phe 
1745 1750 1755 
Lys Ala Val Ser Pro Glu Leu Phe His Val Ile Asp Asp Phe Val 
1760 1765 1770 
Gln Phe Gln Leu Glu Lys Asn Glu Met Gln Gly Met Asp Ser Glu 
1775 1780 1785 
Leu Arg Arg Ser Glu Glu Asp Glu Glu Lys Glu Glu Asp Ile Glu 
1790 1795 1800 
Val Pro Lys Ala Met Gly Asp Ile Phe Glu Ser Leu Ala Gly Ala 
1805 1810 1815 
Ile Tyr Met Asp Ser Gly Met Ser Leu Glu Thr Val Trp Gln Val 
1820 1825 1830 
Tyr Tyr Pro Met Met Arg Pro Leu Ile Glu Lys Phe Ser Ala Asn 
1835 1840 1845 
Val Pro Arg Ser Pro Val Arg Glu Leu Leu Glu Met Glu Pro Glu 
1850 1855 1860 
Thr Ala Lys Phe Ser Pro Ala Glu Arg Thr Tyr Asp Gly Lys Val 
1865 1870 1875 
Arg Val Thr Val Glu Val Val Gly Lys Gly Lys Phe Lys Gly Val 






Ser Tyr Arg Ile Ala 
1900 
Ser Leu Lys Ala Asn 
1915 
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Lys Ser Ala Ala Ala Arg Arg Ala 
1905 
Gln Pro Gln Val Pro Asn Ser 
1920 
<210> SEQ ID NO 10 
<211> LENGTH, 647 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 10 
Asp Ser Glu Gln Ser Pro Ser Ile Gly Tyr Ser Ser Arg Thr Leu Gly 
1 5 10 15 
Pro Asn Pro Gly Leu Ile Leu Gln Ala Leu Thr Leu Ser Asn Ala Ser 
20 25 30 
Asp Gly Phe Asn Leu Glu Arg Leu Glu Met Leu Gly Asp Ser Phe Leu 
35 40 45 
Lys His Ala Ile Thr Thr Tyr Leu Phe Cys Thr Tyr Pro Asp Ala His 
50 55 60 
Glu Gly Arg Leu Ser Tyr Met Arg Ser Lys Lys Val Ser Asn Cys Asn 
65 70 75 80 
Leu Tyr Arg Leu Gly Lys Lys Lys Gly Leu Pro Ser Arg Met Val Val 
85 90 95 
Ser Ile Phe Asp Pro Pro Val Asn Trp Leu Pro Pro Gly Tyr Val Val 
100 105 110 
Asn Gln Asp Lys Ser Asn Thr Asp Lys Trp Glu Lys Asp Glu Met Thr 
115 120 125 
Lys Asp Cys Met Leu Ala Asn Gly Lys Leu Asp Glu Asp Tyr Glu Glu 
130 135 140 
Glu Asp Glu Glu Glu Glu Ser Leu Met Trp Arg Ala Pro Lys Glu Glu 
145 150 155 160 
Ala Asp Tyr Glu Asp Asp Phe Leu Glu Tyr Asp Gln Glu His Ile Arg 
165 170 175 
Phe Ile Asp Asn Met Leu Met Gly Ser Gly Ala Phe Val Lys Lys Ile 
180 185 190 
Ser Leu Ser Pro Phe Ser Thr Thr Asp Ser Ala Tyr Glu Trp Lys Met 
195 200 205 
Pro Lys Lys Ser Ser Leu Gly Ser Met Pro Phe Ser Ser Asp Phe Glu 
210 215 220 
Asp Phe Asp Tyr Ser Ser Trp Asp Ala Met Cys Tyr Leu Asp Pro Ser 
225 230 235 240 
Lys Ala Val Glu Glu Asp Asp Phe Val Val Gly Phe Trp Asn Pro Ser 
245 250 255 
Glu Glu Asn Cys Gly Val Asp Thr Gly Lys Gln Ser Ile Ser Tyr Asp 
260 265 270 
Leu His Thr Glu Gln Cys Ile Ala Asp Lys Ser Ile Ala Asp Cys Val 
275 280 285 
Glu Ala Leu Leu Gly Cys Tyr Leu Thr Ser Cys Gly Glu Arg Ala Ala 
290 295 300 
Gln Leu Phe Leu Cys Ser Leu Gly Leu Lys Val Leu Pro Val Ile Lys 
305 310 315 320 
Arg Thr Asp Arg Glu Lys Ala Leu Cys Pro Thr Arg Glu Asn Phe Asn 
325 330 335 
Ser Gln Gln Lys Asn Leu Ser Val Ser Cys Ala Ala Ala Ser Val Ala 
340 345 350 
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Ser Ser Arg Ser Ser Val Leu Lys Asp Ser Glu Tyr Gly Cys Leu Lys 
355 360 365 
Ile Pro Pro Arg Cys Met Phe Asp His Pro Asp Ala Asp Lys Thr Leu 
370 375 380 
Asn His Leu Ile Ser Gly Phe Glu Asn Phe Glu Lys Lys Ile Asn Tyr 
385 390 395 400 
Arg Phe Lys Asn Lys Ala Tyr Leu Leu Gln Ala Phe Thr His Ala Ser 
405 410 415 
Tyr His Tyr Asn Thr Ile Thr Asp Cys Tyr Gln Arg Leu Glu Phe Leu 
420 425 430 
Gly Asp Ala Ile Leu Asp Tyr Leu Ile Thr Lys His Leu Tyr Glu Asp 
435 440 445 
Pro Arg Gln His Ser Pro Gly Val Leu Thr Asp Leu Arg Ser Ala Leu 
450 455 460 
Val Asn Asn Thr Ile Phe Ala Ser Leu Ala Val Lys Tyr Asp Tyr His 
465 470 475 480 
Lys Tyr Phe Lys Ala Val Ser Pro Glu Leu Phe His Val Ile Asp Asp 
485 490 495 
Phe Val Gln Phe Gln Leu Glu Lys Asn Glu Met Gln Gly Met Asp Ser 
500 505 510 
Glu Leu Arg Arg Ser Glu Glu Asp Glu Glu Lys Glu Glu Asp Ile Glu 
515 520 525 
Val Pro Lys Ala Met Gly Asp Ile Phe Glu Ser Leu Ala Gly Ala Ile 
530 535 540 
Tyr Met Asp Ser Gly Met Ser Leu Glu Thr Val Trp Gln Val Tyr Tyr 
545 550 555 560 
Pro Met Met Arg Pro Leu Ile Glu Lys Phe Ser Ala Asn Val Pro Arg 
565 570 575 
Ser Pro Val Arg Glu Leu Leu Glu Met Glu Pro Glu Thr Ala Lys Phe 
580 585 590 
Ser Pro Ala Glu Arg Thr Tyr Asp Gly Lys Val Arg Val Thr Val Glu 
595 600 605 
Val Val Gly Lys Gly Lys Phe Lys Gly Val Gly Arg Ser Tyr Arg Ile 
610 615 
Ala Lys Ser Ala Ala Ala Arg 
625 630 
Gln Pro Gln Val Pro Asn Ser 
645 
<210> SEQ ID NO 11 
<211> LENGTH, 1318 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 11 
620 
Arg Ala Leu Arg Ser Leu Lys Ala Asn 
635 640 
Met Asp Asp Asp Asp Val Phe Pro Pro Tyr Val Leu Arg Pro Asp Asp 
1 5 10 15 
Gly Gly Pro Arg Val Thr Ile Asn Thr Ala Ile Gly His Ile Asn Arg 
20 25 30 
Tyr Cys Ala Arg Leu Pro Ser Asp Pro Phe Thr His Leu Ala Pro Lys 
35 40 45 
Cys Arg Thr Arg Glu Leu Pro Asp Gly Thr Phe Tyr Ser Thr Leu Tyr 
50 55 60 
Leu Pro Ile Asn Ser Pro Leu Arg Ala Ser Ile Val Gly Pro Pro Met 
66 
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65 70 75 80 
Ser Cys Val Arg Leu Ala Glu Arg Val Val Ala Leu Ile Cys Cys Glu 
85 90 95 
Lys Leu His Lys Ile Gly Glu Leu Asp Asp His Leu Met Pro Val Gly 
100 105 110 
Lys Glu Thr Val Lys Tyr Glu Glu Glu Leu Asp Leu His Asp Glu Glu 
115 120 125 
Glu Thr Ser Val Pro Gly Arg Pro Gly Ser Thr Lys Arg Arg Gln Cys 
130 135 140 
Tyr Pro Lys Ala Ile Pro Glu Cys Leu Arg Asp Ser Tyr Pro Arg Pro 
145 150 155 160 
Asp Gln Pro Cys Tyr Leu Tyr Val Ile Gly Met Val Leu Thr Thr Pro 
165 170 175 
Leu Pro Asp Glu Leu Asn Phe Arg Arg Arg Lys Leu Tyr Pro Pro Glu 
180 185 190 
Asp Thr Thr Arg Cys Phe Gly Ile Leu Thr Ala Lys Pro Ile Pro Gln 
195 200 205 
Ile Pro His Phe Pro Val Tyr Thr Arg Ser Gly Glu Val Thr Ile Ser 
210 215 220 
Ile Glu Leu Lys Lys Ser Gly Phe Met Leu Ser Leu Gln Met Leu Glu 
225 230 235 240 
Leu Ile Thr Arg Leu His Gln Tyr Ile Phe Ser His Ile Leu Arg Leu 
245 250 255 
Glu Lys Pro Ala Leu Glu Phe Lys Pro Thr Asp Ala Asp Ser Ala Tyr 
260 265 270 
Cys Val Leu Pro Leu Asn Val Val Asn Asp Ser Ser Thr Leu Asp Ile 
275 280 285 
Asp Phe Lys Phe Met Glu Asp Ile Glu Lys Ser Glu Ala Arg Ile Gly 
290 295 300 
Ile Pro Ser Thr Lys Tyr Thr Lys Glu Thr Pro Phe Val Phe Lys Leu 
305 310 315 320 
Glu Asp Tyr Gln Asp Ala Val Ile Ile Pro Arg Tyr Arg Asn Phe Asp 
325 330 335 
Gln Pro His Arg Phe Tyr Val Ala Asp Val Tyr Thr Asp Leu Thr Pro 
340 345 350 
Leu Ser Lys Phe Pro Ser Pro Glu Tyr Glu Thr Phe Ala Glu Tyr Tyr 
355 360 365 
Lys Thr Lys Tyr Asn Leu Asp Leu Thr Asn Leu Asn Gln Pro Leu Leu 
370 375 380 
Asp Val Asp His Thr Ser Ser Arg Leu Asn Leu Leu Thr Pro Arg His 
385 390 395 400 
Leu Asn Gln Lys Gly Lys Ala Leu Pro Leu Ser Ser Ala Glu Lys Arg 
405 410 415 
Lys Ala Lys Trp Glu Ser Leu Gln Asn Lys Gln Ile Leu Val Pro Glu 
420 425 430 
Leu Cys Ala Ile His Pro Ile Pro Ala Ser Leu Trp Arg Lys Ala Val 
435 440 445 
Cys Leu Pro Ser Ile Leu Tyr Arg Leu His Cys Leu Leu Thr Ala Glu 
450 455 460 
Glu Leu Arg Ala Gln Thr Ala Ser Asp Ala Gly Val Gly Val Arg Ser 
465 470 475 480 
Leu Pro Ala Asp Phe Arg Tyr Pro Asn Leu Asp Phe Gly Trp Lys Lys 
485 490 495 
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Ser Ile Asp Ser Lys Ser Phe Ile Ser Ile Ser Asn Ser Ser Ser Ala 
500 505 510 
Glu Asn Asp Asn Tyr Cys Lys His Ser Thr Ile Val Pro Glu Asn Ala 
515 520 525 
Ala His Gln Gly Ala Asn Arg Thr Ser Ser Leu Glu Asn His Asp Gln 
530 535 540 
Met Ser Val Asn Cys Arg Thr Leu Leu Ser Glu Ser Pro Gly Lys Leu 
545 550 555 560 
His Val Glu Val Ser Ala Asp Leu Thr Ala Ile Asn Gly Leu Ser Tyr 
565 570 575 
Asn Gln Asn Leu Ala Asn Gly Ser Tyr Asp Leu Ala Asn Arg Asp Phe 
580 585 590 
Cys Gln Gly Asn Gln Leu Asn Tyr Tyr Lys Gln Glu Ile Pro Val Gln 
595 600 605 
Pro Thr Thr Ser Tyr Ser Ile Gln Asn Leu Tyr Ser Tyr Glu Asn Gln 
610 615 620 
Pro Gln Pro Ser Asp Glu Cys Thr Leu Leu Ser Asn Lys Tyr Leu Asp 
625 630 635 640 
Gly Asn Ala Asn Lys Ser Thr Ser Asp Gly Ser Pro Val Met Ala Val 
645 650 655 
Met Pro Gly Thr Thr Asp Thr Ile Gln Val Leu Lys Gly Arg Met Asp 
660 665 670 
Ser Glu Gln Ser Pro Ser Ile Gly Tyr Ser Ser Arg Thr Leu Gly Pro 
675 680 685 
Asn Pro Gly Leu Ile Leu Gln Ala Leu Thr Leu Ser Asn Ala Ser Asp 
690 695 700 
Gly Phe Asn Leu Glu Arg Leu Glu Met Leu Gly Asp Ser Phe Leu Lys 
705 710 715 720 
His Ala Ile Thr Thr Tyr Leu Phe Cys Thr Tyr Pro Asp Ala His Glu 
725 730 735 
Gly Arg Leu Ser Tyr Met Arg Ser Lys Lys Val Ser Asn Cys Asn Leu 
740 745 750 
Tyr Arg Leu Gly Lys Lys Lys Gly Leu Pro Ser Arg Met Val Val Ser 
755 760 765 
Ile Phe Asp Pro Pro Val Asn Trp Leu Pro Pro Gly Tyr Val Val Asn 
770 775 780 
Gln Asp Lys Ser Asn Thr Asp Lys Trp Glu Lys Asp Glu Met Thr Lys 
785 790 795 800 
Asp Cys Met Leu Ala Asn Gly Lys Leu Asp Glu Asp Tyr Glu Glu Glu 
805 810 815 
Asp Glu Glu Glu Glu Ser Leu Met Trp Arg Ala Pro Lys Glu Glu Ala 
820 825 830 
Asp Tyr Glu Asp Asp Phe Leu Glu Tyr Asp Gln Glu His Ile Arg Phe 
835 840 845 
Ile Asp Asn Met Leu Met Gly Ser Gly Ala Phe Val Lys Lys Ile Ser 
850 855 860 
Leu Ser Pro Phe Ser Thr Thr Asp Ser Ala Tyr Glu Trp Lys Met Pro 
865 870 875 880 
Lys Lys Ser Ser Leu Gly Ser Met Pro Phe Ser Ser Asp Phe Glu Asp 
885 890 895 
Phe Asp Tyr Ser Ser Trp Asp Ala Met Cys Tyr Leu Asp Pro Ser Lys 
900 905 910 
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Ala Val Glu Glu Asp Asp Phe Val Val Gly Phe Trp Asn Pro Ser Glu 
915 920 925 
Glu Asn Cys Gly Val Asp Thr Gly Lys Gln Ser Ile Ser Tyr Asp Leu 
930 935 940 
His Thr Glu Gln Cys Ile Ala Asp Lys Ser Ile Ala Asp Cys Val Glu 
945 950 955 960 
Ala Leu Leu Gly Cys Tyr Leu Thr Ser Cys Gly Glu Arg Ala Ala Gln 
965 970 975 
Leu Phe Leu Cys Ser Leu Gly Leu Lys Val Leu Pro Val Ile Lys Arg 
980 985 990 
Thr Asp Arg Glu Lys Ala Leu Cys Pro Thr Arg Glu Asn 
1005 










































Lys Asn Leu Ser Val 
1015 
Arg Ser Ser Val Leu 
1030 
Pro Pro Arg Cys Met 
1045 
Asn His Leu Ile Ser 
1060 
Tyr Arg Phe Lys Asn 
1075 
Ala Ser Tyr His Tyr 
1090 
Glu Phe Leu Gly Asp 
1105 
Leu Tyr Glu Asp Pro 
1120 
Leu Arg Ser Ala Leu 
1135 
Val Lys Tyr Asp Tyr 
1150 
Leu Phe His Val Ile 
1165 
Asn Glu Met Gln Gly 
1180 
Asp Glu Glu Lys Glu 
1195 
Asp Ile Phe Glu Ser 
1210 
Met Ser Leu Glu Thr 
1225 
Pro Leu Ile Glu Lys 
1240 
Arg Glu Leu Leu Glu 
1255 
Ala Glu Arg Thr Tyr 
1270 
Val Gly Lys Gly Lys 
1285 
Ala Lys Ser Ala Ala 
1300 
Ser Cys Ala Ala Ala 
1020 
Lys Asp Ser Glu Tyr 
1035 
Phe Asp His Pro Asp 
1050 
Gly Phe Glu Asn Phe 
1065 
Lys Ala Tyr Leu Leu 
1080 
Asn Thr Ile Thr Asp 
1095 
Ala Ile Leu Asp Tyr 
1110 
Arg Gln His Ser Pro 
1125 
Val Asn Asn Thr Ile 
1140 
His Lys Tyr Phe Lys 
1155 
Asp Asp Phe Val Gln 
1170 
Met Asp Ser Glu Leu 
1185 
Glu Asp Ile Glu Val 
1200 
Leu Ala Gly Ala Ile 
1215 
Val Trp Gln Val Tyr 
1230 
Phe Ser Ala Asn Val 
1245 
Met Glu Pro Glu Thr 
1260 
Asp Gly Lys Val Arg 
1275 
Phe Lys Gly Val Gly 
1290 
Ala Arg Arg Ala Leu 
1305 
Lys Ala Asn Gln Pro Gln Val Pro Asn Ser 
Ser Val Ala 
Gly Cys Leu 
Ala Asp Lys 
Glu Lys Lys 
Gln Ala Phe 
Cys Tyr Gln 
Leu Ile Thr 
Gly Val Leu 
Phe Ala Ser 
Ala Val Ser 
Phe Gln Leu 
Arg Arg Ser 
Pro Lys Ala 
Tyr Met Asp 
Tyr Pro Met 
Pro Arg Ser 
Ala Lys Phe 
Val Thr Val 
Arg Ser Tyr 
Arg Ser Leu 
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<210> SEQ ID NO 12 
<211> LENGTH, 257 
<212> TYPE, PRT 
73 
1315 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 12 
-continued 
Phe Glu Asn Phe Glu Lys Lys Ile Asn Tyr Arg Phe Lys Asn Lys Ala 
1 5 10 15 
Tyr Leu Leu Gln Ala Phe Thr His Ala Ser Tyr His Tyr Asn Thr Ile 
20 25 30 
Thr Asp Cys Tyr Gln Arg Leu Glu Phe Leu Gly Asp Ala Ile Leu Asp 
35 40 45 
Tyr Leu Ile Thr Lys His Leu Tyr Glu Asp Pro Arg Gln His Ser Pro 
50 55 60 
Gly Val Leu Thr Asp Leu Arg Ser Ala Leu Val Asn Asn Thr Ile Phe 
65 70 75 80 
Ala Ser Leu Ala Val Lys Tyr Asp Tyr His Lys Tyr Phe Lys Ala Val 
85 90 95 
Ser Pro Glu Leu Phe His Val Ile Asp Asp Phe Val Gln Phe Gln Leu 
100 105 110 
Glu Lys Asn Glu Met Gln Gly Met Asp Ser Glu Leu Arg Arg Ser Glu 
115 120 125 
Glu Asp Glu Glu Lys Glu Glu Asp Ile Glu Val Pro Lys Ala Met Gly 
130 135 140 
Asp Ile Phe Glu Ser Leu Ala Gly Ala Ile Tyr Met Asp Ser Gly Met 
145 150 155 160 
Ser Leu Glu Thr Val Trp Gln Val Tyr Tyr Pro Met Met Arg Pro Leu 
165 170 175 
Ile Glu Lys Phe Ser Ala Asn Val Pro Arg Ser Pro Val Arg Glu Leu 
180 185 190 
Leu Glu Met Glu Pro Glu Thr Ala Lys Phe Ser Pro Ala Glu Arg Thr 
195 200 205 
Tyr Asp Gly Lys Val Arg Val Thr Val Glu Val Val Gly Lys Gly Lys 
210 215 220 
Phe Lys Gly Val Gly Arg Ser Tyr Arg Ile Ala Lys Ser Ala Ala Ala 
225 230 235 240 
Arg Arg Ala Leu Arg Ser Leu Lys Ala Asn Gln Pro Gln Val Pro Asn 
245 250 255 
Ser 
<210> SEQ ID NO 13 
<211> LENGTH, 247 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 13 
Phe Glu Asn Phe Glu Lys Lys Ile Asn Tyr Arg Phe Lys Asn Lys Ala 
1 5 10 15 
Tyr Leu Leu Gln Ala Phe Thr His Ala Ser Tyr His Tyr Asn Thr Ile 
20 25 30 
Thr Asp Cys Tyr Gln Arg Leu Glu Phe Leu Gly Asp Ala Ile Leu Asp 
35 40 45 
Tyr Leu Ile Thr Lys His Leu Tyr Glu Asp Pro Arg Gln His Ser Pro 
50 55 60 
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Gly Val Leu Thr Asp Leu Arg Ser Ala Leu Val Asn Asn Thr Ile Phe 
65 70 75 80 
Ala Ser Leu Ala Val Lys Tyr Asp Tyr His Lys Tyr Phe Lys Ala Val 
85 90 95 
Ser Pro Glu Leu Phe His Val Ile Asp Asp Phe Val Gln Phe Gln Leu 
100 105 110 
Glu Lys Asn Glu Met Gln Gly Met Asp Ser Glu Leu Arg Arg Ser Glu 
115 120 125 
Glu Asp Glu Glu Lys Glu Glu Asp Ile Glu Val Pro Lys Ala Met Gly 
130 135 140 
Asp Ile Phe Glu Ser Leu Ala Gly Ala Ile Tyr Met Asp Ser Gly Met 
145 150 155 160 
Ser Leu Glu Thr Val Trp Gln Val Tyr Tyr Pro Met Met Arg Pro Leu 
165 170 175 
Ile Glu Lys Phe Ser Ala Asn Val Pro Arg Ser Pro Val Arg Glu Leu 
180 185 190 
Leu Glu Met Glu Pro Glu Thr Ala Lys Phe Ser Pro Ala Glu Arg Thr 
195 200 205 
Tyr Asp Gly Lys Val Arg Val Thr Val Glu Val Val Gly Lys Gly Lys 
210 215 220 
Phe Lys Gly Val Gly Arg Ser Tyr Arg Ile Ala Lys Ser Ala Ala Ala 
225 230 235 240 
Arg Arg Ala Leu Arg Ser Leu 
245 
<210> SEQ ID NO 14 
<211> LENGTH, 234 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 14 
Phe Glu Asn Phe Glu Lys Lys Ile Asn Tyr Arg Phe Lys Asn Lys Ala 
1 5 10 15 
Tyr Leu Leu Gln Ala Phe Thr His Ala Ser Tyr His Tyr Asn Thr Ile 
20 25 30 
Thr Asp Cys Tyr Gln Arg Leu Glu Phe Leu Gly Asp Ala Ile Leu Asp 
35 40 45 
Tyr Leu Ile Thr Lys His Leu Tyr Glu Asp Pro Arg Gln His Ser Pro 
50 55 60 
Gly Val Leu Thr Asp Leu Arg Ser Ala Leu Val Asn Asn Thr Ile Phe 
65 70 75 80 
Ala Ser Leu Ala Val Lys Tyr Asp Tyr His Lys Tyr Phe Lys Ala Val 
85 90 95 
Ser Pro Glu Leu Phe His Val Ile Asp Asp Phe Val Gln Phe Gln Leu 
100 105 110 
Glu Lys Asn Glu Met Gln Gly Met Asp Glu Asp Ile Glu Val Pro Lys 
115 120 125 
Ala Met Gly Asp Ile Phe Glu Ser Leu Ala Gly Ala Ile Tyr Met Asp 
130 135 140 
Ser Gly Met Ser Leu Glu Thr Val Trp Gln Val Tyr Tyr Pro Met Met 
145 150 155 160 
Arg Pro Leu Ile Glu Lys Phe Ser Ala Asn Val Pro Arg Ser Pro Val 
165 170 175 
Arg Glu Leu Leu Glu Met Glu Pro Glu Thr Ala Lys Phe Ser Pro Ala 
76 
US 9,464,289 B2 
77 
-continued 
180 185 190 
Glu Arg Thr Tyr Asp Gly Lys Val Arg Val Thr Val Glu Val Val Gly 
195 200 205 
Lys Gly Lys Phe Lys Gly Val Gly Arg Ser Tyr Arg Ile Ala Lys Ser 
210 215 220 
Ala Ala Ala Arg Arg Ala Leu Arg Ser Leu 
225 230 
<210> SEQ ID NO 15 
<211> LENGTH, 550 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 15 
Met Asp Ser Glu Gln Ser Pro Ser Ile Gly Tyr Ser Ser Arg Thr Leu 
1 5 10 15 
Gly Pro Asn Pro Gly Leu Ile Leu Gln Ala Leu Thr Leu Ser Asn Ala 
20 25 30 
Ser Asp Gly Phe Asn Leu Glu Arg Leu Glu Met Leu Gly Asp Ser Phe 
35 40 45 
Leu Lys His Ala Ile Thr Thr Tyr Leu Phe Cys Thr Tyr Pro Asp Ala 
50 55 60 
His Glu Gly Arg Leu Ser Tyr Met Arg Ser Lys Lys Val Ser Asn Cys 
65 70 75 80 
Asn Leu Tyr Arg Leu Gly Lys Lys Lys Gly Leu Pro Ser Arg Met Val 
85 90 95 
Val Ser Ile Phe Asp Pro Pro Val Asn Trp Leu Pro Pro Gly Tyr Val 
100 105 110 
Val Asn Gln Asp Lys Ser Asn Thr Asp Lys Trp Glu Lys Asp Glu Met 
115 120 125 
Thr Lys Asp Cys Met Leu Ala Asn Gly Lys Leu Asp Glu Asp Tyr Glu 
130 135 140 
Glu Glu Asp Glu Glu Glu Glu Ser Leu Met Trp Arg Ala Pro Lys Glu 
145 150 155 160 
Glu Ala Asp Tyr Glu Asp Asp Phe Leu Glu Tyr Asp Gln Glu His Ile 
165 170 175 
Arg Phe Ile Asp Asn Met Leu Met Gly Ser Gly Ala Phe Val Lys Lys 
180 185 190 
Ile Ser Leu Ser Pro Phe Ser Thr Thr Asp Ser Ala Tyr Glu Trp Lys 
195 200 205 
Met Pro Lys Lys Ser Ser Leu Gly Ser Met Pro Phe Ser Ser Asp Phe 
210 215 220 
Glu Asp Phe Asp Tyr Ser Ser Trp Asp Ala Met Cys Tyr Leu Asp Pro 
225 230 235 240 
Ser Lys Ala Val Glu Glu Asp Asp Phe Val Val Gly Phe Trp Asn Pro 
245 250 255 
Ser Glu Glu Asn Cys Gly Val Asp Thr Gly Lys Gln Ser Ile Ser Tyr 
260 265 270 
Asp Leu His Thr Glu Gln Cys Ile Ala Asp Lys Ser Ile Ala Asp Cys 
275 280 285 
Val Glu Ala Leu Leu Gly Cys Tyr Leu Thr Ser Cys Gly Glu Arg Ala 
290 295 300 
Ala Gln Leu Phe Leu Cys Ser Leu Gly Leu Lys Val Leu Pro Val Ile 
305 310 315 320 
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Lys Arg Thr Asp Arg Glu Lys Ala Leu Cys Pro Thr Arg Glu Asn Phe 
325 330 335 
Asn Ser Gln Gln Lys Asn Leu Ser Val Ser Cys Ala Ala Ala Ser Val 
340 345 350 
Ala Ser Ser Arg Ser Ser Val Leu Lys Asp Ser Glu Tyr Gly Cys Leu 
355 360 365 
Lys Ile Pro Pro Arg Cys Met Phe Asp His Pro Asp Ala Asp Lys Thr 
370 375 380 
Leu Asn His Leu Ile Ser Gly Phe Glu Asn Phe Glu Lys Lys Ile Asn 
385 390 395 400 
Tyr Arg Phe Lys Asn Lys Ala Tyr Leu Leu Gln Ala Phe Thr His Ala 
405 410 415 
Ser Tyr His Tyr Asn Thr Ile Thr Asp Cys Tyr Gln Arg Leu Glu Phe 
420 425 430 
Leu Gly Asp Ala Ile Leu Asp Tyr Leu Ile Thr Lys His Leu Tyr Glu 
435 440 445 
Asp Pro Arg Gln His Ser Pro Gly Val Leu Thr Asp Leu Arg Ser Ala 
450 455 460 
Leu Val Asn Asn Thr Ile Phe Ala Ser Leu Ala Val Lys Tyr Asp Tyr 
465 470 475 480 
His Lys Tyr Phe Lys Ala Val Ser Pro Glu Leu Phe His Val Ile Asp 
485 490 495 
Asp Phe Val Gln Phe Gln Leu Glu Lys Asn Glu Met Gln Gly Met Asp 
500 505 510 
Ser Glu Leu Arg Arg Ser Glu Glu Asp Glu Glu Lys Glu Glu Asp Ile 
515 520 525 
Glu Val Pro Lys Ala Met Gly Asp Ile Phe Glu Ser Leu Ala Gly Ala 
530 535 540 
Ile Tyr Met Asp Ser Gly 
545 550 
<210> SEQ ID NO 16 
<211> LENGTH, 549 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 16 
Asp Ser Glu Gln Ser Pro Ser Ile Gly Tyr Ser Ser Arg Thr Leu Gly 
1 5 10 15 
Pro Asn Pro Gly Leu Ile Leu Gln Ala Leu Thr Leu Ser Asn Ala Ser 
20 25 30 
Asp Gly Phe Asn Leu Glu Arg Leu Glu Met Leu Gly Asp Ser Phe Leu 
35 40 45 
Lys His Ala Ile Thr Thr Tyr Leu Phe Cys Thr Tyr Pro Asp Ala His 
50 55 60 
Glu Gly Arg Leu Ser Tyr Met Arg Ser Lys Lys Val Ser Asn Cys Asn 
65 70 75 80 
Leu Tyr Arg Leu Gly Lys Lys Lys Gly Leu Pro Ser Arg Met Val Val 
85 90 95 
Ser Ile Phe Asp Pro Pro Val Asn Trp Leu Pro Pro Gly Tyr Val Val 
100 105 110 
Asn Gln Asp Lys Ser Asn Thr Asp Lys Trp Glu Lys Asp Glu Met Thr 
115 120 125 
Lys Asp Cys Met Leu Ala Asn Gly Lys Leu Asp Glu Asp Tyr Glu Glu 
130 135 140 
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Glu Asp Glu Glu Glu Glu Ser Leu Met Trp Arg Ala Pro Lys Glu Glu 
145 150 155 160 
Ala Asp Tyr Glu Asp Asp Phe Leu Glu Tyr Asp Gln Glu His Ile Arg 
165 170 175 
Phe Ile Asp Asn Met Leu Met Gly Ser Gly Ala Phe Val Lys Lys Ile 
180 185 190 
Ser Leu Ser Pro Phe Ser Thr Thr Asp Ser Ala Tyr Glu Trp Lys Met 
195 200 205 
Pro Lys Lys Ser Ser Leu Gly Ser Met Pro Phe Ser Ser Asp Phe Glu 
210 215 220 
Asp Phe Asp Tyr Ser Ser Trp Asp Ala Met Cys Tyr Leu Asp Pro Ser 
225 230 235 240 
Lys Ala Val Glu Glu Asp Asp Phe Val Val Gly Phe Trp Asn Pro Ser 
245 250 255 
Glu Glu Asn Cys Gly Val Asp Thr Gly Lys Gln Ser Ile Ser Tyr Asp 
260 265 270 
Leu His Thr Glu Gln Cys Ile Ala Asp Lys Ser Ile Ala Asp Cys Val 
275 280 285 
Glu Ala Leu Leu Gly Cys Tyr Leu Thr Ser Cys Gly Glu Arg Ala Ala 
290 295 300 
Gln Leu Phe Leu Cys Ser Leu Gly Leu Lys Val Leu Pro Val Ile Lys 
305 310 315 320 
Arg Thr Asp Arg Glu Lys Ala Leu Cys Pro Thr Arg Glu Asn Phe Asn 
325 330 335 
Ser Gln Gln Lys Asn Leu Ser Val Ser Cys Ala Ala Ala Ser Val Ala 
340 345 350 
Ser Ser Arg Ser Ser Val Leu Lys Asp Ser Glu Tyr Gly Cys Leu Lys 
355 360 365 
Ile Pro Pro Arg Cys Met Phe Asp His Pro Asp Ala Asp Lys Thr Leu 
370 375 380 
Asn His Leu Ile Ser Gly Phe Glu Asn Phe Glu Lys Lys Ile Asn Tyr 
385 390 395 400 
Arg Phe Lys Asn Lys Ala Tyr Leu Leu Gln Ala Phe Thr His Ala Ser 
405 410 415 
Tyr His Tyr Asn Thr Ile Thr Asp Cys Tyr Gln Arg Leu Glu Phe Leu 
420 425 430 
Gly Asp Ala Ile Leu Asp Tyr Leu Ile Thr Lys His Leu Tyr Glu Asp 
435 440 445 
Pro Arg Gln His Ser Pro Gly Val Leu Thr Asp Leu Arg Ser Ala Leu 
450 455 460 
Val Asn Asn Thr Ile Phe Ala Ser Leu Ala Val Lys Tyr Asp Tyr His 
465 470 475 480 
Lys Tyr Phe Lys Ala Val Ser Pro Glu Leu Phe His Val Ile Asp Asp 
485 490 495 
Phe Val Gln Phe Gln Leu Glu Lys Asn Glu Met Gln Gly Met Asp Ser 
500 505 510 
Glu Leu Arg Arg Ser Glu Glu Asp Glu Glu Lys Glu Glu Asp Ile Glu 
515 520 525 
Val Pro Lys Ala Met Gly Asp Ile Phe Glu Ser Leu Ala Gly Ala Ile 
530 535 540 
Tyr Met Asp Ser Gly 
545 
82 
<210> SEQ ID NO 17 
<211> LENGTH, 10323 
<212> TYPE, DNA 
83 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 17 
US 9,464,289 B2 
-continued 
cggaggcgcg gcgcaggctg ctgcaggccc aggtgaatgg agtaacctga cagcggggac 
gaggcgacgg cgagcgcgag gaaatggcgg cgggggcggc ggcgccgggc ggctccggga 
ggcctgggct gtgacgcgcg cgccggagcg gggtccgatg gttctcgaag gcccgcggcg 
ccccgtgctg cagtaagctg tgctagaaca aaaatgcaat gaaagaaaca ctggatgaat 
gaaaagccct gctttgcaac ccctcagcat ggcaggcctg cagctcatga cccctgcttc 
ctcaccaatg ggtcctttct ttggactgcc atggcaacaa gaagcaattc atgataacat 
ttatacgcca agaaaatatc aggttgaact gcttgaagca gctctggatc ataataccat 
cgtctgttta aacactggct cagggaagac atttattgca gtactactca ctaaagagct 
gtcctatcag atcaggggag acttcagcag aaatggaaaa aggacggtgt tcttggtcaa 
ctctgcaaac caggttgctc aacaagtgtc agctgtcaga actcattcag atctcaaggt 
tggggaatac tcaaacctag aagtaaatgc atcttggaca aaagagagat ggaaccaaga 
gtttactaag caccaggttc tcattatgac ttgctatgtc gccttgaatg ttttgaaaaa 
tggttactta tcactgtcag acattaacct tttggtgttt gatgagtgtc atcttgcaat 
cctagaccac ccctatcgag aaattatgaa gctctgtgaa aattgtccat catgtcctcg 
cattttggga ctaactgctt ccattttaaa tgggaaatgt gatccagagg aattggaaga 
aaagattcag aaactagaga aaattcttaa gagtaatgct gaaactgcaa ctgacctggt 
ggtcttagac aggtatactt ctcagccatg tgagattgtg gtggattgtg gaccatttac 
tgacagaagt gggctttatg aaagactgct gatggaatta gaagaagcac ttaattttat 
caatgattgt aatatatctg tacattcaaa agaaagagat tctactttaa tttcgaaaca 
gatactatca gactgtcgtg ccgtattggt agttctggga ccctggtgtg cagataaagt 
agctggaatg atggtaagag aactacagaa atacatcaaa catgagcaag aggagctgca 
caggaaattt ttattgttta cagacacttt cctaaggaaa atacatgcac tatgtgaaga 
gcacttctca cctgcctcac ttgacctgaa atttgtaact cctaaagtaa tcaaactgct 
cgaaatctta cgcaaatata aaccatatga gcgacagcag tttgaaagcg ttgagtggta 
taataataga aatcaggata attatgtgtc atggagtgat tctgaggatg atgatgagga 
tgaagaaatt gaagaaaaag agaagccaga gacaaatttt ccttctcctt ttaccaacat 
tttgtgcgga attatttttg tggaaagaag atacacagca gttgtcttaa acagattgat 
aaaggaagct ggcaaacaag atccagagct ggcttatatc agtagcaatt tcataactgg 
acatggcatt gggaagaatc agcctcgcaa caaacagatg gaagcagaat tcagaaaaca 
ggaagaggta cttaggaaat ttcgagcaca tgagaccaac ctgcttattg caacaagtat 
tgtagaagag ggtgttgata taccaaaatg caacttggtg gttcgttttg atttgcccac 
agaatatcga tcctatgttc aatctaaagg aagagcaagg gcacccatct ctaattatat 
aatgttagcg gatacagaca aaataaaaag ttttgaagaa gaccttaaaa cctacaaagc 
tattgaaaag atcttgagaa acaagtgttc caagtcggtt gatactggtg agactgacat 
tgatcctgtc atggatgatg atgacgtttt cccaccatat gtgttgaggc ctgacgatgg 
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accaagtgat ccgtttactc atctagctcc taaatgcaga acccgagagt tgcctgatgg 
tacattttat tcaactcttt atctgccaat taactcacct cttcgagcct ccattgttgg 
tccaccaatg agctgtgtac gattggctga aagagttgta gctctcattt gctgtgagaa 
actgcacaaa attggcgaac tggatgacca tttgatgcca gttgggaaag agactgttaa 
atatgaagag gagcttgatt tgcatgatga agaagagacc agtgttccag gaagaccagg 
ttccacgaaa cgaaggcagt gctacccaaa agcaattcca gagtgtttga gggatagtta 
tcccagacct gatcagccct gttacctgta tgtgatagga atggttttaa ctacaccttt 
acctgatgaa ctcaacttta gaaggcggaa gctctatcct cctgaagata ccacaagatg 
ctttggaata ctgacggcca aacccatacc tcagattcca cactttcctg tgtacacacg 
ctctggagag gttaccatat ccattgagtt gaagaagtct ggtttcatgt tgtctctaca 
aatgcttgag ttgattacaa gacttcacca gtatatattc tcacatattc ttcggcttga 
aaaacctgca ctagaattta aacctacaga cgctgattca gcatactgtg ttctacctct 
taatgttgtt aatgactcca gcactttgga tattgacttt aaattcatgg aagatattga 
gaagtctgaa gctcgcatag gcattcccag tacaaagtat acaaaagaaa caccctttgt 
ttttaaatta gaagattacc aagatgccgt tatcattcca agatatcgca attttgatca 
gcctcatcga ttttatgtag ctgatgtgta cactgatctt accccactca gtaaatttcc 
ttcccctgag tatgaaactt ttgcagaata ttataaaaca aagtacaacc ttgacctaac 
caatctcaac cagccactgc tggatgtgga ccacacatct tcaagactta atcttttgac 
acctcgacat ttgaatcaga aggggaaagc gcttccttta agcagtgctg agaagaggaa 
agccaaatgg gaaagtctgc agaataaaca gatactggtt ccagaactct gtgctataca 
tccaattcca gcatcactgt ggagaaaagc tgtttgtctc cccagcatac tttatcgcct 
tcactgcctt ttgactgcag aggagctaag agcccagact gccagcgatg ctggcgtggg 
agtcagatca cttcctgcgg attttagata ccctaactta gacttcgggt ggaaaaaatc 
tattgacagc aaatctttca tctcaatttc taactcctct tcagctgaaa atgataatta 
ctgtaagcac agcacaattg tccctgaaaa tgctgcacat caaggtgcta atagaacctc 
ctctctagaa aatcatgacc aaatgtctgt gaactgcaga acgttgctca gcgagtcccc 
tggtaagctc cacgttgaag tttcagcaga tcttacagca attaatggtc tttcttacaa 
tcaaaatctc gccaatggca gttatgattt agctaacaga gacttttgcc aaggaaatca 
gctaaattac tacaagcagg aaatacccgt gcaaccaact acctcatatt ccattcagaa 
tttatacagt tacgagaacc agccccagcc cagcgatgaa tgtactctcc tgagtaataa 
ataccttgat ggaaatgcta acaaatctac ctcagatgga agtcctgtga tggccgtaat 
gcctggtacg acagacacta ttcaagtgct caagggcagg atggattctg agcagagccc 
ttctattggg tactcctcaa ggactcttgg ccccaatcct ggacttattc ttcaggcttt 
gactctgtca aacgctagtg atggatttaa cctggagcgg cttgaaatgc ttggcgactc 
ctttttaaag catgccatca ccacatatct attttgcact taccctgatg cgcatgaggg 
ccgcctttca tatatgagaa gcaaaaaggt cagcaactgt aatctgtatc gccttggaaa 
aaagaaggga ctacccagcc gcatggtggt gtcaatattt gatccccctg tgaattggct 
tcctcctggt tatgtagtaa atcaagacaa aagcaacaca gataaatggg aaaaagatga 
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tgaggaggag gagagcctga tgtggagggc tccgaaggaa gaggctgact atgaagatga 
tttcctggag tatgatcagg aacatatcag atttatagat aatatgttaa tggggtcagg 
agcttttgta aagaaaatct ctctttctcc tttttcaacc actgattctg catatgaatg 
gaaaatgccc aaaaaatcct ccttaggtag tatgccattt tcatcagatt ttgaggattt 
tgactacagc tcttgggatg caatgtgcta tctggatcct agcaaagctg ttgaagaaga 
tgactttgtg gtggggttct ggaatccatc agaagaaaac tgtggtgttg acacgggaaa 
gcagtccatt tcttacgact tgcacactga gcagtgtatt gctgacaaaa gcatagcgga 
ctgtgtggaa gccctgctgg gctgctattt aaccagctgt ggggagaggg ctgctcagct 
tttcctctgt tcactggggc tgaaggtgct cccggtaatt aaaaggactg atcgggaaaa 
ggccctgtgc cctactcggg agaatttcaa cagccaacaa aagaaccttt cagtgagctg 
tgctgctgct tctgtggcca gttcacgctc ttctgtattg aaagactcgg aatatggttg 
tttgaagatt ccaccaagat gtatgtttga tcatccagat gcagataaaa cactgaatca 
ccttatatcg gggtttgaaa attttgaaaa gaaaatcaac tacagattca agaataaggc 
ttaccttctc caggctttta cacatgcctc ctaccactac aatactatca ctgattgtta 
ccagcgctta gaattcctgg gagatgcgat tttggactac ctcataacca agcaccttta 
tgaagacccg cggcagcact ccccgggggt cctgacagac ctgcggtctg ccctggtcaa 
caacaccatc tttgcatcgc tggctgtaaa gtacgactac cacaagtact tcaaagctgt 
ctctcctgag ctcttccatg tcattgatga ctttgtgcag tttcagcttg agaagaatga 
aatgcaagga atggattctg agcttaggag atctgaggag gatgaagaga aagaagagga 
tattgaagtt ccaaaggcca tgggggatat ttttgagtcg cttgctggtg ccatttacat 
ggatagtggg atgtcactgg agacagtctg gcaggtgtac tatcccatga tgcggccact 
aatagaaaag ttttctgcaa atgtaccccg ttcccctgtg cgagaattgc ttgaaatgga 
accagaaact gccaaattta gcccggctga gagaacttac gacgggaagg tcagagtcac 
tgtggaagta gtaggaaagg ggaaatttaa aggtgttggt cgaagttaca ggattgccaa 
atctgcagca gcaagaagag ccctccgaag cctcaaagct aatcaacctc aggttcccaa 
tagctgaaac cgctttttaa aattcaaaac aagaaacaaa acaaaaaaaa ttaaggggaa 
aattatttaa atcggaaagg aagacttaaa gttgttagtg agtggaatga attgaaggca 
gaatttaaag tttggttgat aacaggatag ataacagaat aaaacattta acatatgtat 
aaaattttgg aactaattgt agttttagtt ttttgcgcaa acacaatctt atcttctttc 
ctcacttctg ctttgtttaa atcacaagag tgctttaatg atgacattta gcaagtgctc 
aaaataattg acaggttttg tttttttttt tttgagttta tgtcagcttt gcttagtgtt 
agaaggccat ggagcttaaa cctccagcag tccctaggat gatgtagatt cttctccatc 
tctccgtgtg tgcagtagtg ccagtcctgc agtagttgat aagctgaata gaaagataag 
gttttcgaga ggagaagtgc gccaatgttg tcttttcttt ccacgttata ctgtgtaagg 
tgatgttccc ggtcgctgtt gcacctgata gtaagggaca gatttttaat gaacattggc 
tggcatgttg gtgaatcaca ttttagtttt ctgatgccac atagtcttgc ataaaaaagg 
gttcttgcct taaaagtgaa accttcatgg atagtcttta atctctgatc tttttggaac 
aaactgtttt acattccttt cattttatta tgcattagac gttgagacag cgtgatactt 
acaactcact agtatagttg taacttatta caggatcata ctaaaatttc tgtcatatgt 
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tgatctttgg ctaaacaccc cattttacta aagtcctcct gccaggtagt tcccactgat 
ggaaatgttt atggcaaata attttgcctt ctaggctgtt gctctaacaa aataaacctt 
agacatatca cacctaaaat atgctgcaga ttttataatt gattggttac ttatttaaga 
agcaaaacac agcaccttta cccttagtct cctcacataa atttcttact atacttttca 
taatgttgca tgcatatttc acctaccaaa gctgtgctgt taatgccgtg aaagtttaac 
gtttgcgata aactgccgta attttgatac atctgtgatt taggtcatta atttagataa 
actagctcat tatttccatc tttggaaaag gaaaaaaaaa aaaacttctt taggcatttg 
cctaagtttc tttaattaga cttgtaggca ctcttcactt aaatacctca gttcttcttt 
tcttttgcat gcatttttcc cctgtttggt gctatgttta tgtattatgc ttgaaatttt 
aatttttttt tttttgcact gtaactataa tacctcttaa tttacctttt taaaagctgt 
gggtcagtct tgcactccca tcaacatacc agtagaggtt tgctgcaatt tgccccgtta 
attatgcttg aagtttaaga aagctgagca gaggtgtctc atatttccca gcacatgatt 
ctgaacttga tgcttcgtgg aatgctgcat ttatatgtaa gtgacatttg aatactgtcc 
ttcctgcttt atctgcatca tccacccaca gagaaatgcc tctgtgcgag tgcaccgaca 
gaaaactgtc agctctgctt tctaaggaac cctgagtgag gggggtatta agcttctcca 
gtgttttttg ttgtctccaa tcttaaactt aaattgagat ctaaattatt aaacgagttt 
ttgagcaaat taggtgactt gttttaaaaa tatttaattc cgatttggaa ccttagatgt 
ctatttgatt ttttaaaaaa ccttaatgta agatatgacc agttaaaaca aagcaattct 
tgaattatat aactgtaaaa gtgtgcagtt aacaaggctg gatgtgaatt ttattctgag 
ggtgatttgt gatcaagttt aatcacaaat ctcttaatat ttataaacta cctgatgcca 
ggagcttagg gctttgcatt gtgtctaata cattgatccc agtgttacgg gattctcttg 
attcctggca ccaaaatcag attgttttca cagttatgat tcccagtggg agaaaaatgc 
ctcaatatat ttgtaacctt aagaagagta tttttttgtt aatactaaga tgttcaaact 
tagacatgat taggtcatac attctcaggg gttcaaattt ccttctacca ttcaaatgtt 
ttatcaacag caaacttcag ccgtttcact ttttgttgga gaaaaatagt agattttaat 
ttgactcaca gtttgaagca ttctgtgatc ccctggttac tgagttaaaa aataaaaaag 
tacgagttag acatatgaaa tggttatgaa cgcttttgtg ctgctgattt ttaatgctgt 
aaagttttcc tgtgtttagc ttgttgaaat gttttgcatc tgtcaattaa ggaaaaaaaa 
aatcactcta tgttgcccca ctttagagcc ctgtgtgcca ccctgtgttc ctgtgattgc 
aatgtgagac cgaatgtaat atggaaaacc taccagtggg gtgtggttgt gccctgagca 
cgtgtgtaaa ggactgggga ggcgtgtctt gaaaaagcaa ctgcagaaat tccttatgat 
gattgtgtgc aagttagtta acatgaacct tcatttgtaa attttttaaa atttctttta 
taatatgctt tccgcagtcc taactatgct gcgttttata atagcttttt cccttctgtt 
ctgttcatgt agcacagata agcattgcac ttggtaccat gctttacctc atttcaagaa 
aatatgctta acagagagga aaaaaatgtg gtttggcctt gctgctgttt tgatttatgg 
aatttgaaaa agataattat aatgcctgca atgtgtcata tactcgcaca acttaaatag 
gtcatttttg tctgtggcat ttttactgtt tgtgaaagta tgaaacagat ttgttaactg 
aactcttaat tatgttttta aaatgtttgt tatatttctt ttcttttttc ttttatatta 
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gatattttta tttgttaata atactttgcc ctcagaaaga ttctgatacc ctgccttgac 9300 
aacatgaaac ttgaggctgc tttggttcat gaatccaggt gttcccccgg cagtcggctt 9360 
cttcagtcgc tccctggagg caggtgggca ctgcagagga tcactggaat ccagatcgag 9420 
cgcagttcat gcacaaggcc ccgttgattt aaaatattgg atcttgctct gttagggtgt 9480 
ctaatccctt tacacaagat tgaagccacc aaactgagac cttgatacct ttttttaact 9540 
gcatctgaaa ttatgttaag agtctttaac ccatttgcat tatctgcaga agagaaactc 9600 
atgtcatgtt tattacctat atggttgttt taattacatt tgaataatta tatttttcca 9660 
accactgatt acttttcagg aatttaatta tttccagata aatttcttta ttttatattg 9720 
tacatgaaaa gttttaaaga tatgtttaag accaagacta ttaaaatgat ttttaaagtt 9780 
gttggagacg ccaatagcaa tatctaggaa atttgcattg agaccattgt attttccact 9840 
agcagtgaaa atgatttttc acaactaact tgtaaatata ttttaatcat tacttctttt 9900 
tttctagtcc atttttattt ggacatcaac cacagacaat ttaaatttta tagatgcact 9960 
aagaattcac tgcagcagca ggttacatag caaaaatgca aaggtgaaca ggaagtaaat 10020 
ttctggcttt tctgctgtaa atagtgaagg aaaattacta aaatcaagta aaactaatgc 10080 
atattatttg attgacaata aaatatttac catcacatgc tgcagctgtt ttttaaggaa 10140 
catgatgtca ttcattcata cagtaatcat gctgcagaaa tttgcagtct gcaccttatg 10200 
gatcacaatt acctttagtt gttttttttg taataattgt agccaagtaa atctccaata 10260 
aagttatcgt ctgttcaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 10320 
aaa 10323 
<210> SEQ ID NO 18 
<211> LENGTH, 1374 
<212> TYPE, PRT 
<213> ORGANISM: Schizosaccharomyces pombe 
<400> SEQUENCE, 18 
Met Asp Ile Ser Ser Phe Leu Leu Pro Gln Leu Leu Arg Lys Tyr Gln 
1 5 10 15 
Gln Asp Val Tyr Asn Ile Ala Ser Lys Gln Asn Thr Leu Leu Val Met 
20 25 30 
Arg Thr Gly Ala Gly Lys Thr Leu Leu Ala Val Lys Leu Ile Lys Gln 
35 40 45 
Lys Leu Glu Glu Gln Ile Leu Ile Gln Glu Ser Asn Leu Glu His Lys 
50 55 60 
Lys Ile Ser Val Phe Leu Val Asn Lys Val Pro Leu Val Phe Gln Gln 
65 70 75 80 
Ala Glu Tyr Ile Arg Ser Gln Leu Pro Ala Lys Val Gly Met Phe Tyr 
85 90 95 
Gly Glu Leu Ser Ile Glu Met Ser Glu Gln Leu Leu Thr Asn Ile Ile 
100 105 110 
Leu Lys Tyr Asn Val Ile Val Ile Thr Ala Asp Leu Phe Tyr Leu Phe 
115 120 125 
Leu Ala Arg Gly Phe Leu Ser Ile Asn Asp Leu Asn Leu Ile Ile Phe 
130 135 140 
Asp Glu Cys His His Ala Ile Gly Asn Asp Ala Tyr Ala Arg Ile Met 
145 150 155 160 
Asn Asp Phe Tyr His Arg Ala Lys Ala Val Leu Ser Lys Lys His Phe 
165 170 175 
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Thr Leu Pro Arg Ile Phe Gly Met Thr Ala Ser Pro Phe Thr Gly Lys 
180 185 190 
Lys Gly Asn Leu Tyr His Arg Leu Tyr Gln Trp Glu Gln Leu Phe Asp 
195 200 205 
Ser Lys Ala His Val Val Ser Glu Asn Glu Leu Ala Asp Tyr Phe Cys 
210 215 220 
Leu Pro Glu Glu Ser Tyr Val Met Tyr Ser Asn Lys Leu Val Val Pro 
225 230 235 240 
Pro Ser Asp Ser Ile Ile Lys Lys Cys Glu Glu Thr Leu Gln Gly Cys 
245 250 255 
Lys Leu Ile Ser Arg Ala Val Lys Thr Ala Leu Ala Glu Thr Ile Asp 
260 265 270 
Met Gly Leu Trp Phe Gly Glu Gln Val Trp Leu Tyr Leu Val Asp Phe 
275 280 285 
Val Glu Thr Lys Arg Leu Lys Lys Lys Ala Leu Gly Lys Gln Leu Ser 
290 295 300 
Asp Asp Glu Glu Leu Ala Ile Asp Arg Leu Lys Ile Phe Val Glu Asp 
305 310 315 320 
Trp Lys Asn Asn Lys Tyr Ser Asp Asn Gly Pro Arg Ile Pro Val Phe 
325 330 335 
Asp Ser Thr Asp Val Thr Asp Lys Val Phe Lys Leu Leu Glu Leu Leu 
340 345 350 
Lys Ala Thr Tyr Arg Lys Ser Asp Ser Val Arg Thr Val Ile Phe Val 
355 360 365 
Glu Arg Lys Ala Thr Ala Phe Thr Leu Ser Leu Phe Met Lys Thr Leu 
370 375 380 
Asn Leu Pro Asn Ile Arg Ala His Ser Phe Ile Gly His Gly Pro Ser 
385 390 395 400 
Asp Gln Gly Glu Phe Ser Met Thr Phe Arg Arg Gln Lys Asp Thr Leu 
405 410 415 
His Lys Phe Lys Thr Gly Lys Tyr Asn Val Leu Ile Ala Thr Ala Val 
420 425 430 
Ala Glu Glu Gly Ile Asp Val Pro Ser Cys Asn Leu Val Ile Arg Phe 
435 440 445 
Asn Ile Cys Arg Thr Val Thr Gln Tyr Val Gln Ser Arg Gly Arg Ala 
450 455 460 
Arg Ala Met Ala Ser Lys Phe Leu Ile Phe Leu Asn Thr Glu Glu Leu 
465 470 475 480 
Leu Ile His Glu Arg Ile Leu His Glu Glu Lys Asn Leu Lys Phe Ala 
485 490 495 
Leu Ser Glu Leu Ser Asn Ser Asn Ile Phe Asp Ser Leu Val Cys Glu 
500 505 510 
Glu Arg Glu Arg Val Thr Asp Asp Ile Val Tyr Glu Val Gly Glu Thr 
515 520 525 
Gly Ala Leu Leu Thr Gly Leu Tyr Ala Val Ser Leu Leu Tyr Asn Phe 
530 535 540 
Cys Asn Thr Leu Ser Arg Asp Val Tyr Thr Arg Tyr Tyr Pro Thr Phe 
545 550 555 560 
Thr Ala Gln Pro Cys Leu Ser Gly Trp Tyr Cys Phe Glu Val Glu Leu 
565 570 575 
Pro Lys Ala Cys Lys Val Pro Ala Ala Gln Gly Ser Pro Ala Lys Ser 
580 585 590 
Ile Arg Lys Ala Lys Gln Asn Ala Ala Phe Ile Met Cys Leu Asp Leu 
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595 600 605 
Ile Arg Met Gly Leu Ile Asp Lys His Leu Lys Pro Leu Asp Phe Arg 
610 615 620 
Arg Lys Ile Ala Asp Leu Glu Thr Leu Glu Glu Asp Glu Leu Lys Asp 
625 630 635 640 
Glu Gly Tyr Ile Glu Thr Tyr Glu Arg Tyr Val Pro Lys Ser Trp Met 
645 650 655 
Lys Val Pro Glu Asp Ile Thr Arg Cys Phe Val Ser Leu Leu Tyr Thr 
660 665 670 
Asp Ala Asn Glu Gly Asp Asn His Ile Phe His Pro Leu Val Phe Val 
675 680 685 
Gln Ala His Ser Phe Pro Lys Ile Asp Ser Phe Ile Leu Asn Ser Thr 
690 695 700 
Val Gly Pro Arg Val Lys Ile Val Leu Glu Thr Ile Glu Asp Ser Phe 
705 710 715 720 
Lys Ile Asp Ser His Leu Leu Glu Leu Leu Lys Lys Ser Thr Arg Tyr 
725 730 735 
Leu Leu Gln Phe Gly Leu Ser Thr Ser Leu Glu Gln Gln Ile Pro Thr 
740 745 750 
Pro Tyr Trp Leu Ala Pro Leu Asn Leu Ser Cys Thr Asp Tyr Arg Phe 
755 760 765 
Leu Glu Asn Leu Ile Asp Val Asp Thr Ile Gln Asn Phe Phe Lys Leu 
770 775 780 
Pro Glu Pro Val Gln Asn Val Thr Asp Leu Gln Ser Asp Thr Val Leu 
785 790 795 800 
Leu Val Asn Pro Gln Ser Ile Tyr Glu Gln Tyr Ala Phe Glu Gly Phe 
805 810 815 
Val Asn Ser Glu Phe Met Ile Pro Ala Lys Lys Lys Asp Lys Ala Pro 
820 825 830 
Ser Ala Leu Cys Lys Lys Leu Pro Leu Arg Leu Asn Tyr Ser Leu Trp 
835 840 845 
Gly Asn Arg Ala Lys Ser Ile Pro Lys Ser Gln Gln Val Arg Ser Phe 
850 855 860 
Tyr Ile Asn Asp Leu Tyr Ile Leu Pro Val Ser Arg His Leu Lys Asn 
865 870 875 880 
Ser Ala Leu Leu Ile Pro Ser Ile Leu Tyr His Ile Glu Asn Leu Leu 
885 890 895 
Val Ala Ser Ser Phe Ile Glu His Phe Arg Leu Asp Cys Lys Ile Asp 
900 905 910 
Thr Ala Cys Gln Ala Leu Thr Ser Ala Glu Ser Gln Leu Asn Phe Asp 
915 920 925 
Tyr Asp Arg Leu Glu Phe Tyr Gly Asp Cys Phe Leu Lys Leu Gly Ala 
930 935 940 
Ser Ile Thr Val Phe Leu Lys Phe Pro Asp Thr Gln Glu Tyr Gln Leu 
945 950 955 960 
His Phe Asn Arg Lys Lys Ile Ile Ser Asn Cys Asn Leu Tyr Lys Val 
965 970 975 
Ala Ile Asp Cys Glu Leu Pro Lys Tyr Ala Leu Ser Thr Pro Leu Glu 
980 985 990 
Ile Arg His Trp Cys Pro Tyr Gly Phe Gln Lys Ser Thr 
1005 




Tyr Ala Val Leu Gln 
1015 


















































Val Glu Ala Ser Ile 
1030 
Ser Ala Leu Lys Ile 
1045 
Ile Ser Asn Trp Asp 
1060 
Tyr Ala Asp Ser Leu 
1075 
Ile Glu Glu Thr Ile 
1090 
His Leu Ala Phe Ile 
1105 
Tyr Glu Asn Tyr Gln 
1120 
Asp Tyr Ile Ile Val 
1135 
Thr Ser Gly Glu Leu 
1150 
Lys Ser Leu Ser Tyr 
1165 
Ile Gln His Glu Ser 
1180 
Gln Glu Leu Ile Glu 
1195 
Trp Phe Trp Phe Glu 
1210 
Leu Glu Ala Met Ile 
1225 
Leu Gln Ser Leu Gln 
1240 
Gly Asp Ala Thr His 
1255 
Val Tyr Gln Leu Leu 
1270 
Lys Cys Val Ile Glu 
1285 
Asn Thr Glu Leu His 
1300 
Arg His Gly Asn Ile 
1315 
Asn Ala Lys Tyr Ile 
1330 
Asp Lys Ser Asn Leu 
1345 
Lys Lys Lys Pro Ser 
1360 
Lys Val Lys Ser Leu Thr 
1370 
<210> SEQ ID NO 19 
<211> LENGTH, 4125 
<212> TYPE, DNA 
US 9,464,289 B2 
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Gly Ala Cys Leu Leu 
1035 
Cys Lys Ser Leu Ser 
1050 
Glu Trp Asn Asn Tyr 
1065 
Arg Asn Val Gln Phe 
1080 
Gly Tyr Ser Phe Lys 
1095 
His Pro Ser Met Met 
1110 
Gln Leu Glu Phe Leu 
1125 
Gln Tyr Leu Tyr Lys 
1140 
Thr Asp Tyr Lys Ser 
1155 
Ile Gly Phe Val Leu 
1170 
Ala Ala Met Cys Asp 
1185 
Ala Phe Arg Glu Thr 
1200 
Ile Asp Ser Pro Lys 
1215 
Cys Ala Ile Phe Leu 
1230 
Phe Val Leu Pro Leu 
1245 
Thr Lys Ala Lys Gly 
1260 
Lys Asp Gln Gly Cys 
1275 
Glu Val Lys Ser Ser 
1290 
Leu Thr Lys Tyr Tyr 
1305 
Val Ala Tyr Gly Lys 
1320 
Met Lys Gln Arg Leu 
1335 
Leu Leu Tyr Ser Cys 
1350 
Asp Glu Gln Ile Lys 
1365 
Asp Ser Gly 
Val Gly Leu 
Phe Asp Leu 
Pro Tyr Ser 
Asn Lys Lys 
Ser Gln Gln 
Gly Asp Ala 
Lys Tyr Pro 
Phe Tyr Val 
Asn Leu His 
Ala Ile Phe 
Ala Ser Glu 
Phe Ile Ser 
Asp Ser Gly 
Phe Leu Asn 
Asp Ile Glu 
Glu Asp Phe 
His Lys Thr 
Gly Phe Ser 
Ser Arg Lys 
Leu Lys Leu 
Asn Cys Lys 
Gly Asp Gly 
<213> ORGANISM: Schizosaccharomyces pombe 
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<400> SEQUENCE, 19 
atggatattt caagttttct acttcctcaa cttttacgta aatatcaaca agatgtgtat 
aatatcgcga gcaagcaaaa tactttactt gttatgagaa cgggcgctgg taagacatta 
cttgctgtga agttgataaa acaaaagctc gaggagcaaa ttttaatcca agaatcaaat 
cttgaacata aaaaaatatc agtttttctc gtcaacaaag tccctttggt atttcaacaa 
gcggaataca ttcgatctca actaccggct aaggttggca tgttttatgg cgaattatct 
atagaaatga gcgagcagtt gttgactaat attatattga agtataatgt gattgttatt 
actgcagatt tgttctattt gtttcttgca agaggttttc tttcaataaa tgatttgaat 
ttaattatat tcgacgaatg tcatcatgca attggaaatg atgcgtatgc tcgcatcatg 
aatgattttt atcacagagc caaagcagta ttgtcaaaaa aacatttcac cctaccaaga 
atttttggta tgactgcttc accattcact ggaaaaaaag gaaacttata ccatcgactg 
tatcaatggg agcaattatt tgattctaaa gcacacgtgg tttcggaaaa cgagctagcc 
gattacttct gtcttcccga agaaagctat gtaatgtatt ccaataagtt ggttgtgcca 
ccctcggatt ctattatcaa gaaatgcgag gaaactcttc aaggatgcaa gttaatttct 
cgggctgtta agactgcttt agcagaaacc atagatatgg gtctttggtt tggggagcaa 
gtttggttat atttggttga ttttgtggaa acgaaaagat taaaaaaaaa ggctttaggg 
aagcagttgt cagatgacga ggaactggca attgaccggt taaaaatatt tgttgaagat 
tggaaaaata acaaatattc agacaatggc cctagaatcc ctgtttttga ttccactgat 
gttactgata aagtctttaa actcttagaa ttgttaaagg ctacttaccg caaaagtgat 
agcgttcgta cggttatttt cgttgaaaga aaagctacgg cgtttacttt aagtttgttt 
atgaaaactc ttaatctgcc taacatccgc gctcattctt ttataggaca tggaccgtcc 
gatcagggtg aattttctat gacattcagg aggcaaaaag atacccttca taagtttaag 
actggaaaat ataatgtttt aattgctact gcagttgcag aagaaggtat cgatgtacca 
tcatgtaact tagttatacg cttcaatatt tgtcggactg tcacccagta tgtccaatct 
cgaggtagag cgagagcaat ggcttcaaag tttctaattt ttttaaacac agaagagttg 
ttaattcatg aacgcattct acacgaagaa aaaaatctta aatttgccct ttcagagctc 
agcaattcga atatttttga ttcattggta tgtgaggaaa gagaacgtgt gactgatgat 
atcgtctatg aagttggcga gactggtgct ttactcacag ggttgtatgc agttagtctg 
ctttataact tttgtaacac actttcaaga gacgtataca caagatatta tcccactttt 
acagctcaac cctgtctttc aggttggtat tgttttgagg tagaattgcc aaaagcctgc 
aaagttccag cggctcaagg atctcccgct aaatcaatta ggaaagccaa acagaatgct 
gcgttcatca tgtgtttgga tctgattcgt atgggtctta tagacaaaca tttaaaaccc 
ctagatttta gaagaaaaat tgccgacctt gaaactcttg aggaagacga gctaaaagat 
gaaggttata tcgagacata tgagcgctat gtaccaaaaa gttggatgaa agttcctgaa 
gatattacac gttgcttcgt ctctttactt tatactgatg ctaatgaagg agacaatcat 
atattccatc ccttagtgtt tgtacaagct cattcattcc ccaaaattga tagctttatt 
cttaattcga ctgttggccc ccgagttaaa attgttttag aaacgattga ggatagtttt 
aagatcgatt ctcatctgct tgagttgtta aaaaaatcaa ctcgttatct acttcaattc 
ggtttatcta cttctcttga gcaacaaata cctactcctt actggcttgc gcctttaaat 









































US 9,464,289 B2 
101 
-continued 
ttttttaaat taccggaacc tgttcaaaat gttactgatt tgcaatccga tactgtatta 
ttagtaaatc cacagtcaat atatgaacag tatgcttttg agggatttgt caattctgaa 
tttatgattc ctgctaaaaa gaaagataag gccccttctg ccttatgtaa gaaacttcct 
ttacgattaa attattcact ttggggcaat agagctaaat ccattcccaa atcacagcaa 
gtgcgcagtt tttatatcaa tgacctctat attctcccag tctctagaca tttgaaaaac 
agcgccttgc taataccctc catactgtac catattgaaa acttattggt cgcctcttct 
tttatcgaac actttcgact tgattgtaaa attgacactg cttgtcaggc tttaacatct 
gcggaatcac aattgaattt tgattacgat cgtctagagt tttacggaga ctgctttcta 
aaattgggtg cttctattac agtttttttg aaatttcctg atactcaaga gtaccaactg 
cattttaatc gaaagaaaat tattagcaac tgtaatttgt ataaagtagc aatagattgt 
gagttgccga agtatgctct ctcgactccc ttggaaatcc gtcattggtg tccatatggt 
tttcagaaaa gcacatcgga taagtgccgc tacgccgttt tacagaaatt atcggttaag 
aggatagcag atatggtcga agctagtatc ggtgcatgtc ttttagacag tggacttgac 
tcagcactca agatctgtaa atctttaagc gttggtctgc tggatatcag caattgggat 
gagtggaaca attattttga tttaaataca tatgcggatt cactgagaaa tgttcaattc 
ccttactcct cgtatataga ggaaactatt ggatattcat ttaaaaacaa gaaactactc 
catttggcat ttattcatcc ttccatgatg tctcagcaag gtatttacga aaactatcaa 
cagttggagt ttttgggtga tgctgtattg gattacatta tcgtacaata cctttataaa 
aagtatccta acgcaacttc tggcgaatta actgattaca aatcttttta tgtgtgtaac 
aagagtctat catacattgg ctttgttttg aatttgcaca aatatatcca acatgaaagc 
gcagcaatgt gtgatgcaat atttgaatat caagaattaa ttgaagcgtt cagggagact 
gcttcagaga atccgtggtt ctggtttgaa attgattcac caaagttcat ttcagatact 
ttagaagcta tgatatgtgc catttttttg gattctgggt ttagtttaca atctctacaa 
ttcgttttac ctctttttct taattcgtta ggggatgcga cacatactaa ggctaaagga 
gatattgaac acaaggtata ccaattactg aaagatcagg gatgtgaaga cttcggaaca 
aagtgtgtca tcgaggaggt gaaatccagt cacaaaacat tgttaaatac tgaactccat 
ttaacaaagt attatgggtt ttcattcttc cgccacggga atattgttgc ttacggcaaa 
tcccgtaaag ttgccaatgc aaagtatatt atgaaacaaa gacttctcaa attgttagag 
gataagtcta acttactttt gtattcttgt aattgcaaat ttagtaagaa aaagccatca 
gatgagcaaa taaaaggaga tggaaaagtt aaaagtttga cttga 
<210> SEQ ID NO 20 
<211> LENGTH, 754 
<212> TYPE, PRT 
<213> ORGANISM: Giardia lamblia virus 
<400> SEQUENCE, 20 
Met His Ala Leu Gly His Cys Cys Thr Val Val Thr Thr Arg Gly Pro 
1 5 10 15 
Ser His Trp Leu Leu Leu Leu Asp Thr His Leu Gly Thr Leu Pro Gly 
20 25 30 
Phe Lys Val Ser Ala Gly Arg Gly Leu Pro Ala Ala Glu Val Tyr Phe 
35 40 45 
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50 55 60 
Ala Val Tyr Gln Ser Ile Leu Phe Gln Leu Leu Gly Pro Thr Phe Pro 
65 70 75 80 
Ala Ser Trp Thr Glu Ile Gly Ala Thr Met Pro His Asn Glu Tyr Thr 
85 90 95 
Phe Pro Arg Phe Ile Ser Asn Pro Pro Gln Phe Ala Thr Leu Ala Phe 
100 105 110 
Leu Pro Leu Leu Ser Pro Thr Ser Pro Leu Asp Leu Arg Ala Leu Met 
115 120 125 
Val Thr Ala Gln Leu Met Cys Asp Ala Lys Arg Leu Ser Asp Glu Tyr 
130 135 140 
Thr Asp Tyr Ser Thr Leu Ser Ala Ser Leu His Gly Arg Met Val Ala 
145 150 155 160 
Thr Pro Glu Ile Ser Trp Ser Leu Tyr Val Val Leu Gly Ile Asp Ser 
165 170 175 
Thr Gln Thr Ser Leu Ser Tyr Phe Thr Arg Ala Asn Glu Ser Ile Thr 
180 185 190 
Tyr Met Arg Tyr Tyr Ala Thr Ala His Asn Ile His Leu Arg Ala Ala 
195 200 205 
Asp Leu Pro Leu Val Ala Ala Val Arg Leu Asp Asp Leu Lys Asp His 
210 215 220 
Gln Ile Pro Ala Pro Gly Ser Trp Asp Asp Leu Ala Pro Lys Leu Arg 
225 230 235 240 
Phe Leu Pro Pro Glu Leu Cys Leu Leu Leu Pro Asp Glu Phe Asp Leu 
245 250 255 
Ile Arg Val Gln Ala Leu Gln Phe Leu Pro Glu Ile Ala Lys His Ile 
260 265 270 
Cys Asp Ile Gln Asn Thr Ile Cys Ala Leu Asp Lys Ser Phe Pro Asp 
275 280 285 
Cys Gly Arg Ile Gly Gly Glu Arg Tyr Phe Ala Ile Thr Ala Gly Leu 
290 295 300 
Arg Leu Asp Gln Gly Arg Gly Arg Gly Leu Ala Gly Trp Arg Thr Pro 
305 310 315 320 
Phe Gly Pro Phe Gly Val Ser His Thr Asp Val Phe Gln Arg Leu Glu 
325 330 335 
Leu Leu Gly Asp Ala Val Leu Gly Phe Ile Val Thr Ala Arg Leu Leu 
340 345 350 
Cys Leu Phe Pro Asp Ala Ser Val Gly Thr Leu Val Glu Leu Lys Met 
355 360 365 
Glu Leu Val Arg Asn Glu Ala Leu Asn Tyr Leu Val Gln Thr Leu Gly 
370 375 380 
Leu Pro Gln Leu Ala Glu Phe Ser Asn Asn Leu Val Ala Lys Ser Lys 
385 390 395 400 
Thr Trp Ala Asp Met Tyr Glu Glu Ile Val Gly Ser Ile Phe Thr Gly 
405 410 415 
Pro Asn Gly Ile Tyr Gly Cys Glu Glu Phe Leu Ala Lys Thr Leu Met 
420 425 430 
Ser Pro Glu His Ser Lys Thr Val Gly Ser Ala Cys Pro Asp Ala Val 
435 440 445 
Thr Lys Ala Ser Lys Arg Val Cys Met Gly Glu Ala Gly Ala His Glu 
450 455 460 
Phe Arg Ser Leu Val Asp Tyr Ala Cys Glu Gln Gly Ile Ser Val Phe 
465 470 475 480 
104 
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Cys Ser Ser Arg Val Ser Thr Met Phe Leu Glu Arg Leu Arg Asp Ile 
485 490 495 
Pro Ala Glu Asp Met Leu Asp Trp Tyr Arg Leu Gly Ile Gln Phe Ser 
500 505 510 
His Arg Ser Gly Leu Ser Gly Pro Gly Gly Val Val Ser Val Ile Asp 
515 520 525 
Ile Met Thr His Leu Ala Arg Gly Leu Trp Leu Gly Ser Pro Gly Phe 
530 535 540 
Tyr Val Glu Gln Gln Thr Asp Lys Asn Glu Ser Ala Cys Pro Pro Thr 
545 550 555 560 
Ile Pro Val Leu Tyr Ile Tyr His Arg Ser Val Gln Cys Pro Val Leu 
565 570 575 
Tyr Gly Ser Leu Thr Glu Thr Pro Thr Gly Pro Val Ala Ser Lys Val 
580 585 590 
Leu Ala Leu Tyr Glu Lys Ile Leu Ala Tyr Glu Ser Ser Gly Gly Ser 
595 600 605 
Lys His Ile Ala Ala Gln Thr Val Ser Arg Ser Leu Ala Val Pro Ile 
610 615 620 
Pro Ser Gly Thr Ile Pro Phe Leu Ile Arg Leu Leu Gln Ile Ala Leu 
625 630 635 640 
Thr Pro His Val Tyr Gln Lys Leu Glu Leu Leu Gly Asp Ala Phe Leu 
645 650 655 
Lys Cys Ser Leu Ala Leu His Leu His Ala Leu His Pro Thr Leu Thr 
660 665 670 
Glu Gly Ala Leu Thr Arg Met Arg Gln Ser Ala Glu Thr Asn Ser Val 
675 680 685 
Leu Gly Arg Leu Thr Lys Arg Phe Pro Ser Val Val Ser Glu Val Ile 
690 695 700 
Ile Glu Ser His Pro Lys Ile Gln Pro Asp Ser Lys Val Tyr Gly Asp 
705 710 715 720 
Thr Phe Glu Ala Ile Leu Ala Ala Ile Leu Leu Ala Cys Gly Glu Glu 
725 730 735 
Ala Ala Gly Ala Phe Val Arg Glu His Val Leu Pro Gln Val Val Ala 
740 745 750 
Asp Ala 
<210> SEQ ID NO 21 
<211> LENGTH, 2265 
<212> TYPE, DNA 
<213> ORGANISM, Giardia lamblia virus 
<400> SEQUENCE, 21 
atgcatgctt tgggacactg ttgcacagtt gtgactacta gaggaccatc ccactggttg 
ctacttctag acactcacct gggcaccttg ccagggttta aggttagtgc aggccgaggg 
cttcccgccg cagaggtgta ctttgaagcg ggtccgaggg tgtctctctc tcgaactgat 
gcaactatag tagccgtgta tcagtccatt ctctttcagc tgctgggacc cacatttcct 
gcttcatgga ctgagattgg agcaacaatg cctcacaatg aatacacttt ccctcgattt 
atatccaatc caccacaatt cgccaccctg gcatttttac ccttactatc tcctaccagc 
cctctggact tgcgtgcatt aatggtcact gcacaactca tgtgtgatgc aaagcgcttg 
tcagatgaat atacagacta ttccacttta tctgcatccc tccatgggcg tatggttgca 
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ctttcttact ttaccagagc aaatgaatca ataacataca tgagatacta tgcaacagcc 
cacaatattc acctgcgtgc tgcagatctt ccgcttgtgg cagcagtcag attagacgat 
ctaaaagacc accagattcc cgcgcctgga tcctgggatg atttggctcc caagcttcgc 
ttcctgccgc ctgagctctg cctactgctg ccagatgaat ttgatctaat cagggtccag 
gcgcttcaat ttctaccaga gattgctaag cacatatgtg acatacagaa tacaatctgt 
gccctggata aaagctttcc tgactgtggg cggatcggtg gcgagcgata ctttgcaatc 
actgccggac ttcggctcga tcaggggcgt ggacgagggc ttgccggttg gagaacaccc 
tttgggcctt ttggtgtaag tcacaccgat gttttccagc gactcgaatt gctaggagat 
gctgtgttag gctttatcgt gactgcccgc ctcctttgcc tttttccaga tgcgtctgtg 
ggaacacttg ttgagctaaa gatggagctt gttcgcaatg aggctctaaa ctatcttgta 
caaacgcttg gacttcctca gttggcggag ttttccaaca accttgtggc gaagagcaaa 
acatgggcag atatgtatga ggagatcgtt ggatcaatct ttacgggacc taatggaatc 
tatggctgtg aggaatttct tgcgaagacg cttatgagtc ccgaacactc caagacagta 
ggatctgcct gtccagatgc agtcaccaag gcatcaaagc gtgtttgcat gggagaagcg 
ggggcgcatg aattcagaag ccttgtggac tatgcttgtg agcaaggcat tagtgtcttc 
tgttcttcgc gggtgtcaac tatgtttctc gagcgtctca gagacattcc agcagaggac 
atgctagatt ggtaccgact tggtatccag ttttcgcatc gttcaggcct atcaggacct 
ggcggcgtcg tatcagttat agacataatg acacatttgg ctcgaggcct atggctgggc 
tctccaggct tctatgttga acagcaaact gataagaatg agtcggcttg tccgcccact 
atacctgttt tatatatcta tcatcgctct gtgcagtgtc ctgttttata tgggtcgctc 
acagaaaccc ctacagggcc cgttgcttct aaggttctcg ctctctatga gaagattctg 
gcatatgagt catcaggagg tagtaagcat atagcagctc agacagttag cagatctctg 
gccgtaccca ttcctagtgg cactatcccc ttcctgattc ggttattgca aatagcacta 
actcctcacg tgtaccaaaa acttgagctt cttggagacg cattcctgaa gtgcagcctt 
gctctccatc tccacgctct ccaccccacg ctcacagagg gcgctcttac acgcatgcgg 
caatctgcag aaacaaattc tgtactggga agattgacaa aaaggtttcc ttctgtagtt 
tctgaggtta ttatagaatc ccatccgaaa atacagcctg acagcaaggt ttatggcgat 
acatttgaag ccattttggc agcaattctt cttgcgtgcg gggaagaggc agcaggtgct 
tttgttcgag agcatgttct cccacaagta gtagctgatg cgtag 
<210> SEQ ID NO 22 
<211> LENGTH, 91 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, oligonucleotide 






























cccgggttca cgccattctc ctgcctcagc ctcacgagta gctgggacta caggcgcccg 60 
acaccactcc cggctaattt tttgtatttt t 91 
<210> SEQ ID NO 23 
<211> LENGTH, 29 
<212> TYPE, DNA 




<223> OTHER INFORMATION, Oligonucleotide 
<400> SEQUENCE, 23 
tgaggtcagg agatcgagac catcccggc 
<210> SEQ ID NO 24 
<211> LENGTH, 29 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, oligonucleotide 
<400> SEQUENCE, 24 
tgaggtcagg agatcgaaac catcccggc 
<210> SEQ ID NO 25 
<211> LENGTH, 29 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, oligonucleotide 
<400> SEQUENCE, 25 
tgaggtcagg agttcgaaac catcccggc 
<210> SEQ ID NO 26 
<211> LENGTH, 29 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, oligonucleotide 
<400> SEQUENCE, 26 
tgaggtcagg agttcgagac catcccggc 
<210> SEQ ID NO 27 
<211> LENGTH, 291 
<212> TYPE, DNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 27 
ggccgggcgc ggtggctcac ggctgtaatc ccagcacttt 
tcacctgagg tcaggagttc gagagcagcc tggccaacat 
aaaaatacaa aaattagccg grcgtggtgg cgggcgcctg 
gctgaggcag gagaatcgct tgaacccggg aggccgagct 
ccactgcact ccagcctggg caacaagagc gaaactccgt 
<210> SEQ ID NO 28 
<211> LENGTH, 302 
<212> TYPE, DNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 28 
ggccgggcgc aatggctcag acctctaatc ccgacacttt 
tcacctgagg tcaggagttc gaaaccatcc tggctgacat 
aaaaatacaa aaaattagcc gggcgtggtg gtgggtgcct 
ggagaatggc gtgaaccctg gaggcggagg ttacggtgag 
tccagcctgg gctacagagc gcgacttggt ctcaaaaaac 
a a 







gggaggccga ggcgggtgga 60 
ggtgaaaccc cgtctctact 120 
taatcccacc tactcgggag 180 
tgcagtgagc cgagatcgcg 240 
ctcaaaaaaa a 291 
gcgaggctga ggcgggcaga 60 
ggtgaaaccc cgtctctact 120 
gtagtcccag ctactcggca 180 
ccgaggtcgc gccactgcac 240 
aaacaggcaa aaagaaaaaa 300 
302 
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<210> SEQ ID NO 29 
<211> LENGTH, 221 
<212> TYPE, DNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 29 
atcccagcac tctggcaggc cgaggcgggt ggatcatgag gtcaggagat cgagaccatc 60 
ccggccaaca cagcgaaacc ccatctctac taaaaaatac aaaaagaaaa aattagccag 120 
gtgtggtggt gggcgcctgt agtctcagct gctcgggagg ctgaggcggg agagttgctt 180 
gggcccggga ggcggaggtt gcagtgagcc gggatcacgc c 221 
What is claimed is: 
1. An isolated nucleotide molecule selected from: 
a double-stranded RNA molecule that inhibits expression 
of Alu RNA, wherein a first strand of the double-
20 
stranded RNA comprises a sequence selected from 
SEQ ID NO: 1, 2, 3, 4, 5, and 6 and including about 19 
to 25 nucleotides; and 
a vector comprising an oligonucleotide that inhibits the 
expression of Alu RNA, comprising a sequence 
selected from SEQ ID NO: 22, 23, 24, and 25 and 
including about 29 to 100 nucleotides; and a vector 
comprising an oligonucleotide that inhibits the expres-
sion of Alu RNA, consisting of the sequence of SEQ ID 
NO: 26. 
2. A method of protecting an RPE cell, comprising 
administering a nucleotide molecule of claim 1. 
* * * * * 
